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Chapter 1 
General introduction 

Although medication is the cornerstone of the treatment of rheumatoid arthritis 
(RA), patients do not always take their medication as recommended by the 
rheumatologist. Medication non-adherence can have serious consequences for the 
patient's health and for societal costs. Therefore, effective interventions to improve 
adherence are warranted . As beliefs about medication seem to play an important 
role in predicting non-adherence in RA patients, they could be promising 
intervention targets. This thesis is about exploring and intervening on generic and 
RA-specific medication beliefs. 
Living with rheumatoid arthritis 
Rheumatoid arthritis is a chronic, progressive and systemic autoimmune disease. It 
is characterized by joint inflammation that (if untreated) leads to irreversible joint 
damage, fatigue and decreased physical abilities [1,2]. RA can occur at any age but is 
most common among those aged 40-70 years [3] . The disease affects approximately 
0.5-1% of the European and North American adults, with the prevalence being 
higher among women than among men (overall gender rat io 3:1) [3-5] . Distal joints 
in hands and feet are most often affected, and inflammation in the joints is 
associated with (morning) stiffness, swelling, and pain. RA can also affect organs 
such as periarticular tissue, skin, eyes, and lungs [3,4]. 
Having RA has major effects on a patient's health-related quality of life in both 
physical and mental domains of well-being [6,7], because RA limits activities in daily 
living, household management, social participation and work [1,2,8-10]. The death 
incidence from cardiovascular disease, infection and malignancies is also 
significantly higher for patients with RA compared to the general population 
[11-13]. 
Treatment of rheumatoid arthritis 
Patients receive non-pharmacological and pharmacological treatment for RA. Non-
pharmacological treatment includes, amongst others, exercise therapy and manual 
therapy, provision of aids and devices (e.g., special jar openers, customized beds), 
orthoses, self-management interventions, psychological support and patient 
education [14]. However, the key to minimize joint damage and functional decline is 
early pharmacological treatment with disease-modifying antirheumatic drugs 
(DMARDs) [15-17]. 
Traditionally, RA has been treated with non-steroidal anti-inflammatory drugs 
(NSAIDs) like diclofenac, ibuprofen and naproxen, and synthet ic DMARDs like 
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methotrexate (MTX), sulfasalazine and hydroxychloroquine [18]. Whereas NSAIDs 
provide symptomatic relief, they do not alter the course of the disease. In contrast 
to NSAIDs, DMARDs do modify the underlying systemic inflammatory process of RA 
by their impact on synovitis and bone and joint destruction [19]. The newest class of 
DMARDs (biological DMARDs like etanercept, adalimumab or infliximab) target pro-
inflammatory cytokines and immune-cellular targets (B-and T-cells) [18]. 
(lnter)national guidelines recommend to start DMARD therapy very early in the 
treatment of RA, because it slows joint destruction more effectively than a delayed 
start of DMARD therapy, and because joint damage and irreversible disability are a 
consequence of time exposed to high disease activity [16,18] (Figure 1). 
Figure 1 
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Especially synthetic DMARDs do not have an immediate effect on reducing disease 
activity. It may take several weeks or even months before patients experience 
symptom reductions. Still, patients must closely follow treatment regimens to fully 
benefit from DMARD therapy [20]. Some patients, as a consequence, have to take 
multiple medicines during the day which might conflict with other activities like food 
consumption, social life and work [1] . So, effective medication use requires 
continuous personal investment of time and effort of RA patients [21]. 
10 I Chapter 1 
Ambivalence about taking medication 
It is well-known that RA patients (like other chronic patients) perceive taking 
medication not only as beneficial but also as a burden [21,22]. Apart from the 
patient's investment of time and effort to use medication effectively, 
pharmacological treatment can also initiate side effects [21]. Amongst others, 
DMARD use is associated with an increased risk of toxicity like gastro-intestinal 
complaints, infections, hypertension and abnormal liver function tests [1,3,23]. 
The benefits and harm of RA medication can promote tension, ambivalence and 
sometimes dissatisfaction in RA patients [21,22]. Participants of focus groups 
expressed ambivalence most clearly about taking DMARDs: most RA patients 
described side effects which could, at times, be severe and could outweigh the 
(perceived) benefits of taking the medication [21]. 
The ambivalence and challenges that RA patients face in taking medication may 
evoke insufficient use or even non-use of medication (i.e ., non-adherence). Before 
we discuss the consequences of non-adherence in RA patients, we first present 
some definitions and measurements of (non)-adherence. 
Medication (non-)adherence 
The term 'adherence' comprises three different components, each referring to 
different phases in medication intake behavior [24]: the initiation phase (when a 
patient takes the first dose of prescribed medication), the implementation phase 
(the extent to which a patient's actual dosing corresponds to the prescribed dosing 
regimen: from initiation to the last dose taken) and the discontinuation phase (when 
the next do~ to be taken is omitted and no more doses are taken thereafter). The 
empirical studies in this thesis are focusing on the implementation phase (Figure 2) . 
Within the implementation phase, many types of aberrations in taking 
medication can be identified. Over a defined period of time, patients, for instance, 
might take a suboptimal proportion of prescribed tablets, might take a proportion of 
prescribed tablets at the wrong time of the day, or might take drug holidays (the 
deliberate interruption of pharmacotherapy for a defined period) [24,25]. 
Patients are most often defined as 'medication adherent' if they take ~ 80% of 
prescribed doses, and non-adherent if they take <80% of prescribed doses [26-29]. 
This arbitrary 80% cut-off point is also commonly used in studies assessing 
adherence to DMARDs in RA patients [29-31] and is used in two empirical studies 
within this thesis (chapters 4 and 6 [32,33]). 
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Adherence measurement in this thesis 
Because a gold standard to measure adherence is still lacking and every 
measurement method has advantages and disadvantages [34], it is important to 
triangulate different measures to assess robustness of study findings [35]. 
Therefore, we used multiple adherence measures within two empirical studies of 
this thesis (chapters 4 and 6 [32,33]) . 
In these studies, the Compliance Questionnaire Rheumatology (CQR) is the main 
outcome measure for adherence. The CQR has 19 items which reflect statements 
about drug-taking behavior (e.g., "If the rheumatologist tells me to take the 
medicines, I do so") and is able to detect whether a patient takes s 80% of 
prescribed medication with a sensitivity of 62% and a specificity of 95%. The CQR is 
validated against an objective adherence measure: electronic monitoring 
(Medication Event Monitoring System (MEMS) [30,36]). 
In addition to the CQR, we used the five item Medication Adherence Report 
Scale [37] . The MARS has been widely used in a range of long term conditions, 
including RA, asthma/COPD, cardiovascular diseases, diabetes, inflammatory bowel 
disease and depression [38-46], and a 9-item version of the MARS was recently 
(partly) validated in a sample of RA patients [45] . In addition, we used pharmacy 
refill data [47] as an objective adherence measure by calculating the medication 
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possession ratio: days of DMARD supply divided by the number of days within an 
observation period [31]. 
Consequences of non-adherence in RA patients 
As stated, medication adherence in RA patients is suboptimal and varies from 22% 
(underuse) to 107% (overuse) [48-52] . DMARD non-adherence results in more 
disease activity/radiological damage, loss of function and a lower quality of life 
[20,29,53-55] . Pascual-Ramos et al. demonstrated that 83% of RA patients who 
continued DMARD/corticosteroid therapy had a sustained remission of the disease 
over six months follow-up compared with 47% of patients who discontinued 
therapy. Patients continuing therapy also had a better functional status according to 
the Health Assessment Questionnaire during a two-year period [54]. Moreover, 
Waimann et al. demonstrated that RA patients non-adherent to oral DMARD and 
steroid therapy had higher disease activity scores across 2 years follow-up, with an 
additional trend towards increased radiographic damage (see Figures 3 and 4) [29] . 
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Non-adherence also has negative consequences for the economy. Of all medication-
related hospital admissions in the United States, 33-69% are due to poor medication 
adherence with a resultant cost of approximately $100 billion a year [56-59] . In the 
Netherlands, it is estimated that improving medication adherence (in general) can 
save up to 4 billion euro each year [60]. In view of the negative implications of 
medication non-adherence, effective interventions targeting the determinants of 
non-adherence are warranted . 
Beliefs about medication 
According to the World Health Organization (WHO), factors associated with non-
adherence can be divided into five domains: the socio-economic domain (e.g., age, 
gender), the healthcare system domain (e.g., patient-provider relationship, type of 
insurance), the condition-related domain (e.g., disease duration, disease activity), 
the therapy-related domain (e.g., regimen complexity), and the patient-related 
domain (e.g., self-efficacy, coping style, beliefs about medication). Non-adherence 
appears to be a multidimensional phenomenon, with determinants in these domains 
not consistently associated with non-adherent behavior [34,61,62]. 
A relevant distinction between a patient's reasons for non-adherence is the 
distinction between 'unintentional' and 'intentional' non-adherence [34,63-70]. 
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Unintentional non-adherence occurs when the patient is prevented from 
implementing their intention to take the medication as prescribed by factors beyond 
their control, such as forgetting, poor manual dexterity, losing medicines, or not 
being able to afford them [66]. 
Intentional non-adherence, in contrast, is driven by a decision not to take 
medicines as prescribed. According to the Necessity-Concerns framework (NC-
framework) of Horne et al. (Figure 5 [66]), it is assumed that intentional adherence 
decisions are influenced by a cost-benefit assessment. Herein, personal beliefs 
about the necessity of taking medication for maintaining or improving health are 
balanced against concerns about the potential adverse effects of taking the 
medication [65,66]. 
Figure 5 
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Patient adherence to medication is influenced by a number of factors relating to how the 
patient judges the necessity of their treatment relative to their concerns [66] 
In turn, these beliefs could be influenced by illness perceptions, background beliefs 
about medication, and contextual factors like past experiences with medication and 
views of other people. 
Illness perceptions comprise beliefs about, amongst others, symptoms, causes, 
personal consequences of, and the potential to control or cure the disease. They 
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help patients to make sense of the illness and are believed to be directly related to 
beliefs about the necessity of taking medication [41] . RA patients who perceive their 
illness as having minimal personal consequences may be less likely to perceive the 
need for regular use of DMARDs, for instance. 
Background beliefs about medication in general are supposed to influence 
specific concerns about prescribed medication [41,64]. Even before illness occurs, a 
significant proportion of individuals have strong, general, negative beliefs about 
medication: that they are harmful, chemical, and could better be avoided. Many 
individuals also believe that doctors are far too willing to prescribe medications. 
These ideas make some patients turn towards natural remedies that are perceived 
to be a safer option [66]. 
Many earlier and recent (empirical) studies underline the importance of 
addressing necessity and concern beliefs about medication to improve adherence, 
in- and outside the field of RA [1,46,63,65,71-80]. Necessity beliefs and concern 
beliefs about medication can be measured using the Beliefs about Medicines 
Questionnaire (BMQ), a validated instrument in patients with somatic chronic 
illnesses [74] and with sufficient to good psychometric properties in RA samples 
[33, 79,80]. 
In a recent meta-analysis with studies using the BMQ, both stronger perceptions 
of necessity of treatment and fewer concerns about treatment were associated with 
better medication adherence (ORnecessitv = 1.7, 95% Cl: 1.6-1.9, ORconcerns = 0.5, 95% 
Cl: 0.5-0.6) [73] . In RA patients, necessity beliefs about medication were found to be 
among the most relevant determinants of non-adherence according to a recent 
systematic review (78]. Thus, beliefs about medication might be a promising 
intervention target to improve medication adherence in RA patients. Therefore, this 
thesis is focusing on the patient-related domain of the WHO classification of 
determinants of adherence. 
Existing interventions to improve adherence in RA patients 
Existing interventions to improve medication adherence in chronic diseases are 
mostly complex and have limited effect [81,82] . Moreover, although beliefs about 
medication have been identified as a promising intervention to improve medication 
in chronically ill patients, most interventions did not (systematically) address such 
beliefs. Only one study suggested that a short, individual, patient-centered 
telephone advice in chronically ill patients resulted in more positive beliefs about 
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medication and higher levels of adherence than a control condition. However, these 
findings should be interpreted with caution as baseline data were not reported [71]. 
So far, three studies have assessed the effectiveness of a medication adherence 
intervention in RA [83-85]. Only one of these studies demonstrated a slight 
improvement in adherence to D-penicillamine following a patient education 
program [85]. However, this program was (time) intensive as 51 individual patients 
were provided seven education sessions of 30 minutes each, and was intended for 
both adherent and non-adherent patients. So far, interventions targeting the 
medication beliefs in non-adherent RA patients have not been developed. 
Aim and outline of this thesis 
Given the central role of beliefs about medication in adherence literature and the 
absence of time-efficient interventions to improve adherence in RA patients, the 
main aim of this thesis is to explore and to intervene on beliefs about medication to 
improve medication adherence in RA patients. 
In part one, relevant targets for improving medication adherence in RA patients are 
identified. Subsequently, a short intervention is developed and tested for its 
effectiveness in changing medication beliefs and improving adherence. 
Chapter 2 
Chapter 3 
Chapter4 
comprises a narrative review of adherence literature. Herein, some 
elements of this general introduction are further elaborated: non-
adherence terminology and measurements, the extent of non-
adherence in RA patients, risk factors for non-adherence, 
interventions to improve adherence among RA patients, and what is 
needed to develop those interventions are being discussed. 
describes the development of a short, group-based intervention to 
improve adherence to DMARDs in adult, non-adherent RA patients. It 
aims to improve adherence by changing the balance between 
necessity and concern beliefs about medication and by resolving 
practical barriers to take medication. 
describes the effectiveness of the intervention, which is tested using a 
randomized clinical trial design. 123 non-adherent patients are 
randomly assigned to the intervention arm (two group sessions + 
brochure about DMARDs) or control arm (only brochures about 
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DMARDs) . The primary outcome measures are the BMQ and CQR 
questionnaires. 
To further explore beliefs about medication as possible intervention target, different 
aspects of medication beliefs in relation to medication non-adherence are examined 
in part two. 
Chapter 5 
Chapter 6 
Chapter 7 
comprises a systematic review about longitudinal associations 
between beliefs about medication, other psychosocial predictors and 
non-adherence to chronic medication. 
reports a cross-sectional study, which examines if beliefs about 
medication are independent associates of non-adherence to DMARDs 
when controlling for potential important demographical, clinical and 
psychological confounders (anxiety/depression, self-efficacy and 
illness cognitions) . 
describes rheumatologists' beliefs about medication and compares 
them with beliefs about medication of RA patients. 
Finally, the results of the thesis are summarized and discussed within a broader 
perspective in chapter 8. Recommendations for future research and clinical practice 
are also provided . 
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SUMMARY 
Adherence to medication in patients with rheumatoid arthritis is low, varying from 
30 to 80%. Improving adherence to therapy could therefore dramatically improve 
the efficacy of drug therapy. Although indicators for suboptimal adherence can be 
useful to identify nonadherent patients, and could function as targets for 
adherence-improving interventions, no indicators are yet found to be consistently 
and strongly related to nonadherence. Despite this, nonadherence behavior could 
conceptually be categorized into two subtypes: unintentional (due to forgetfulness, 
regimen complexity or physical problems) and intentional (based on the patient's 
decision to take no/less medication). In case of intentional nonadherence, patients 
seem to make a benefit- risk analysis weighing the perceived risks of the treatment 
against the perceived benefits. This weighing process may be influenced by the 
patient's beliefs about medication, the patient's self-efficacy and the patient's 
knowledge of the disease. This implicates that besides tackling practical barriers, 
clinicians should be sensitive to patient's personal beliefs that may impact 
medication adherence. 
INTRODUCTION 
The prescription of a medicine is one of the most common interventions in the 
healthcare system. However, the full benefit of pharmacological interventions can 
only be achieved if patients follow drug regimens closely. Adherence is, however, 
low in chronic medical conditions: approximately 50% of all people with chronic 
medical conditions do not adhere to their prescribed medication regimens [1,2). The 
implications of nonadherence are far reaching, as nonadherence may severely 
compromise the effectiveness of treatment and increase healthcare costs; for 
example, the cost of nonadherence in the USA has been estimated to reach US$100 
billion annually [3). The reduction of nonadherence is therefore thought likely to 
have a greater effect in health than further improvements in traditional biomedical 
treatment [4). 
Medication nonadherence has negative consequences on the pharmacological 
treatment of rheumatoid arthritis (RA), as disease-modifying antirheumatic drugs 
(DMARDs) reduce disease activity and radiological progression and improve long-
term functional outcome in patients with RA [5). Nonadherence is associated with 
disease flares and increased disability, for example [6,7). Despite this, adherence 
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rates to prescribed medicine regimes in people with RA are low, varying from 30 to 
80% [7-22]. Improving adherence to therapy could therefore dramatically improve 
the efficacy of medical treatments and reduce costs associated with RA. 
The purpose of this critical narrative appraisal of the literature is to give a broad 
overview of the existing literature on medication nonadherence and adherence to 
disease-modifying drugs in RA, by addressing adherence terminology, measuring 
nonadherence, the extent of the problem and risk factors for nonadherence, and by 
providing a short overview of interventions to improve medication adherence 
among people with RA. Available studies published until July 2011 on medication 
adherence in RA were searched for using an electronic literature search in PubMed. 
The search strategy is described in Table 1. 
Table 1 
B9olean 
operator 
Search strategy in PubMed for retrieving studies on medication adherence in rheumatoid 
arthritis 
Text words and Meditallndex Subject Headings 
Arthnt1s, rheumatoid [mesh terms] or rheumatoid arthrit is[tw] 
AND Medication adherence [mesh terms] or patient compliance [mesh terms]-or-
(medication[tw] or med1c1ne[tw] or medic1nes[tw] or med1cal[tw] or therapy[tw] or 
therapie[tw] or drug[tw] or drugs[tw]) and (complian* or non-complian* or non compl ian* 
or noncomplian* or adher* or nonadher* or non ad her* or nonadher~ or persist* or non-
persist* or non persist* or nonpers1st*) 
AND adult[mesh terms] or mature [tw] or adult [tw] 
Adherence terminology: adherence, compliance & concordance 
The terminology used in the area of medicine-taking reflects the changing 
understanding of medicine-taking behavior and the changing relationships between 
healthcare professionals and patients. In the medical literature of the 1950s, the 
term 'compliance' was used. This term, strongly led by a physician- based approach, 
was defined as the extent to which patient's behavior coincides with medical advice 
[23]. However, the word 'compliance' became quickly unpopular for its judgmental 
overtones. Therefore, the term 'adherence' was introduced as an alternative to 
compliance. It comes closer to describing and emphasizing patient and clinician 
collaboration in decisions, rather than conveying the idea of obedience to a medical 
prescription [24-26]. 'Medication adherence' can be defined as the extent to which 
a patient's behavior, with respect to taking medication, corresponds with agreed 
recommendations from a healthcare provider [101]. 
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Medication adherence can be divided into three major components: persistence 
(defined as the length of time a patient fills his/her prescriptions); initiation 
adherence (does the patient start with the indented pharmacotherapy); and 
execution adherence (the comparison between the prescribed drug dosing regimen 
and the real patient's drug-taking behavior). Execution adherence includes dose 
omissions (missed doses) and the so-called 'drug holidays' (3 or more days without 
drug intake) . In the mid 1990s, the concept of 'concordance' was born. The term 
'concordance' relates to a process of the consultation in which prescribing is based 
on partnership. In this process, healthcare professionals recognize the primacy of 
the patient's decision about taking the recommended medication, and the patient's 
expertise and beliefs are fully valued. The term 'concordance' overtly recognizes 
that for optimal medication use, the patient's opinion on medication should be 
taken into account and discussed throughout the therapy. This discussion will help 
to foster a patient-physician relationship in which the patient is able to 
communicate as a partner in the selection of treatment and the subsequent review 
of its effect. Therefore, compliance focuses on the behavior of one person (the 
patient), whereas concordance requires the participation of at least two people. 
Measuring nonadherence 
The validity of adherence assessment is based on the method of measurement. The 
minimum requirements of a gold standard for adherence measurement include: 
• Validity: proving ingestion of the medication and giving a detailed overview 
about timing and ingestion; 
• Reliability and sensitivity to change: stable results under stable adherence and 
differential results under variable adherence; 
• Feasibility: the patient should not be aware of adherence measurement and 
should not be able to censor the result. 
Although it is ethically desirable that patients know that his/her medication use is 
being followed, the consciousness of being monitored may increase a patient's 
adherence. Moreover, the assessment should be easy to use and the method should 
be noninvasive. Unfortunately, a single instrument fulfilling these properties is 
currently unavailable [27). Despite the absence of a gold standard, adherence can be 
measured in a variety of ways, as depicted in Table 2 [9,10,28,29). 
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Table2 Methods to assess adherence 
Method of assessment 
Subjective 
Self-report 
Physicians' estimation 
Direct 
Biomarkers (drug 
concentration/metabol ites) 
Indirect 
Pharmacy ref1ll 
Tablet counts 
Electronic monitors 
Questionnaires 
Subjective measurement 
Advantage 
Easy to use 
Readily available 
Noninvasive 
Sensit ive for nonadherence 
Inexpensive 
Easy to use 
Inexpensive 
Noninvasive 
Objectively proves ingestion of 
the medication 
Accurate 
Inexpensive 
Nonin"asive 
Patient is not aware that they 
are being monitored 
Easy to use 
Inexpensive 
Noninvasive 
Noninvasive 
Objective 
Provides additional information 
about dosmg mterval 
Easy to use 
Noninvasive 
Validation possible 
Disadvantage 
No evidence that the drug is 
actually mgested 
Nat accurate 
Patient aware ofthe 
measurement 
Not accurate 
Sensit ive for white coat 
adherence 
Invasive 
Expensive 
Varies with individual difference 
in metabolism 
No evidence that the drug is 
actually ingested once f1lled 
No evidence that the drug is 
actually ingested once f11led 
Pat1ent is aware of the 
measurement 
Patient is aware ofthe 
measurement 
The simplest assessment of medication adherence is frequently used, and involves 
asking the patient whether he or she is taking the medications as prescribed. 
Although patient self-report may be 100% specific for being nonadherent, this 
method is relatively insensitive for the detection of nonadherence (which is 
confirmed in several studies showing that the answers of the patient are not always 
accurate). In fact, patients claiming to be adherent may under-report their 
nonadherence to avoid caregiver disapproval [30]. Furthermore, self-report is time-
dependent, since patients have the best recall for adherence in the last 24-h period. 
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Studies have consistently shown that third-party assessments (e.g., assessment 
by healthcare providers) are unreliable and tend to overestimate patient adherence 
[30]. Physician's estimate of patient's adherence correlated poorly with objective pill 
counts [31]. In more detail, physicians seem to detect good adherence well 
(specificity ~90%), but were not good at predicting poor or partial adherence [32]. 
Direct objective measurement 
Direct methods prove directly that the medication has been taken by the patient. 
Examples of direct methods include direct observation and measurement of serum 
drug/metabolite levels or biological markers. Although no method is 100% reliable, 
direct measurements have low bias, although these methods may be expensive and 
inconvenient for patients. 
Furthermore, the use of biological markers only reflects short-term adherence, 
and can overestimate patients' long-term adherence due to the tooth-brush 
effect/white coat adherence. This phenomenon takes its name from the fact that 
dentists often see patients beginning to brush their teeth only a few days before the 
appointment. This can also be the case for drug taking, implicating that only 
drug/metabolites with long elimination half-lives are fair predictors for 
nonadherence. lnterindividual differences in drug absorption and metabolism can 
also lead to inaccurate conclusions regarding medication adherence. 
Indirect measurement 
Indirect methods are the most common approach to measuring medication 
adherence. Commonly used indirect measures include: pharmacy refills; electronic 
monitoring; tablet counts; and questionnaires. 
Pharmacy refills 
Pharmacy refills provide a convenient, noninvasive, objective and inexpensive 
method for estimating medication adherence and persistence. Calculation of a 
patient's refill adherence is especially suited for large populations of (chronic) 
medication users. However, the extent of adherence obtained from pharmacy refill 
data does not provide the patient's medication consumption information, but rather 
provides the acquisition of the medication. Pharmacy refill data are therefore 
especially specific for identifying nonadherent patients [33]. However, a number of 
different measures and definitions of adherence and persistence have been 
reported in the published literature. The appropriateness and choice of the specific 
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measure employed should be determined by the overall goals of the study, as well 
as the relative advantages and limitations of the measures. A commonly used 
method is the medication possession ratio, often defined as the proportion of days 
supply obtained during a specified time period or over a period of refill intervals. 
However, it is important to notice that various methods of calculation of the 
medication possession ratio exist. Therefore, it is important to evaluate how the 
medication possession ratio was calculated when interpreting literature regarding 
patient adherence [34]. 
Electronic monitoring devices 
Electronic monitoring devices, such as the Medication Event Monitoring System 
(MEMS) can be used to provide accurate and detailed information on medication-
taking behavior [35,36]. These devices compile the dosing histories of patients' 
prescribed medication, registering the number of pills missed, as well as deviations 
from the dosing schedule. The availability and costs of MEMS devices could limit the 
feasibility of its use [28,37,38]. Another disadvantage of electronic monitoring 
devices is the fact that an electronic device may increase the patient's awareness 
about the fact that his/her adherence will be monitored. Although the boxes can be 
opened without medication being taken, MEMS devices have been shown to have 
superior sensitivity compared with other methods for the assessment of medication 
adherence. 
Tablet counts 
Tablet counts are frequently used in clinical trials and adherence research, but are 
notoriously unreliable and usually provide overestimates [17,27]. Although using 
tablet counts offers advantages such as low costs, and relatively simple data 
collection and calculation, the accuracy of the assessment relies on the patient's 
willingness to return unused medication [39]. As a consequence, adherence may be 
overestimated, as patients can manipulate the tablet count by dumping the 
medication prior to the scheduled visits, leading to an overestimation of adherence. 
Furthermore, the reliability of the pill count is also dependent on the correct 
number of drugs being dispensed and counted. 
Questionnaires 
Although a number of self-report medication adherence questionnaires have been 
described in the literature, no gold standard questionnaire for the assessment of 
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nonadherence and adherence in RA exists. Three adherence questionnaires are 
most widely used in RA: the Morisky questionnaire [40]; the Medication Adherence 
Report Scale {MARS) [41]; and the Compliance Questionnaire on Rheumatology 
[42,43]. The Morisky scale is a commonly used questionnaire that consists of four 
questions on reasons for nonadherence, which are answered with a yes/no 
response. The measure has been found to have adequate internal consistency 
{Cronbach's a= 0.61), a good sensitivity {0.81) and moderate specificity (0.44) when 
validated to non-RA clinical parameters such as blood pressure [40,44]. The Morisky 
scale is not yet validated in RA. The MARS has been used in a variety of patients 
(e.g., patients with asthma, chronic obstructive pulmonary disease, high cholesterol, 
RA and diabetes) [41]. Four of the five items in the MARS are related to intentional 
nonadherence, such as the tendency to avoid, forget, adjust and stop taking 
medication, whereas one MARS item focuses on forgetting medication [16,45]. 
However, both the Morisky scale and the MARS did not perform well compared with 
an electronic MEMS in transplant recipients taking oral steroids and 
immunosuppressants [45]. 
Currently, there is only one rheumatology-specific adherence measure: the 19-
item Compliance Questionnaire on Rheumatology. This questionnaire has been 
validated in patients with inflammatory rheumatic diseases against a MEMS device 
[13]. The 19-item Compliance Questionnaire on Rheumatology compares well with 
electronic monitoring over 6 months, with a sensitivity of 0.98, a specificity of 0.67 
and an estimated k of 0.78 to detect nonadherence [13,42,43]. 
In conclusion, although a wide variety of methods have been used to assess 
nonadherence and adherence, a gold standard for adherence assessment is lacking. 
Although objective methods (e.g., blood or urine samples, pharmacy refill data, 
electronic pill monitoring or pill counts) are considered to be more reliable than 
subjective methods, they are in general more expensive and more complicated than 
subjective methods. Urine and serum samples are constrained by interindividual 
variations, whereas pill counts and electronic devices assume that patients really 
take their medication when they pick up the drug in the pharmacy and/or open the 
bottle of pills. Although subjective measures are cheap and relatively easy to use, 
the psychometric properties of these instruments are often poor; patient self-
reported adherence is often poorly associated with adherence rates assessed with a 
MEMS device and pill count [46-49]. It has been suggested that adherence may be 
underestimated by MEMS and overestimated by patient self-report and pill count 
[49]. 
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EXTENT OF THE PROBLEM: ADHERENCE TO TRADITIONAL & 
BIOLOGICAL DMARDS 
Studies reporting adherence rates on both traditional and biological DMARDs are 
listed in Table 3. Despite the varied extent of nonadherence found in these studies, 
they all confirm that adherence in RA is still suboptima I. Nine studies exclusively 
targeted nonadherence to DMARDs. These studies were published between 1988 
and 2010, with sample sizes ranging from 26 to 14,586. The authors used several 
methods for capturing DMARD medication adherence, including subjective (patient 
interview and physician's estimation), direct (chemical markers) and indirect (MEMS, 
refill data and pill count questionnaires) methods. Estimates of the extent to which 
patients adhere to DMARD therapy varied between 22 (underuse) and 107% 
(overuse). This variation relates to differences in the study groups, the duration of 
follow-up {1 day-1 year), the type of drugs included, the definition of adherence 
(e.g., used cutoff points), the duration of the disease (in order to separate initiation 
and execution adherence) and methods of assessment. As seen in Table 3, 
adherence rates in studies using MEMS devices ranged from 72 to 107%, adherence 
rates obtained with refill dates ranged from 22 to 73% and with self report from 50 
to 99%. Besides studies only focusing on DMARDs, several studies included both 
NSAID and DMARD users. These studies may overestimate the extent of adherence, 
as adherence to pain relievers (with an almost immediate pain relief) could 
theoretically be higher, compared with slow-acting drugs (with often a delayed 
onset to retard disease progression). 
An important point to consider is that medication adherence is a dynamic 
feature that is not stable over time [41,50,51]. This is confirmed in two longitudinal 
studies in this population suggesting that 12-24% of the patients with RA are 
consistently nonadherent, whereas only 3Q-35% of the patients are consistently 
adherent. Furthermore, in contrast to cross-sectional studies, it is important to 
notice that longitudinal studies including patients from the start of therapy will also 
measure initiation nonadherence. Recognition of the dynamic nature of medication 
adherence (both during initiation and execution of the pharmacotherapy) is 
therefore important when considering ways in which poor medication-taking 
behavior could be improved. 
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w Table3 Studies assessing the extent of nonadherence to medication in rheumatoid arthritis en 
n Study (year) Type of medication Patients ( n) study characteristics Measure Results(%} Ref 
:::,-
OJ 
""0 
..... 
~ Studies measuring DMARD adherence 
N 
de Klerk eta/. Traditional DMARDs RA, 6 months longitudinal MEMS In RAgroup : [11] 
2003 (SASA and MTX) polymyalgia NSAIDs· 76-82 
and gout (127) MTX 107 
SASA 72 
Grijalva eta/. 2010 Trad1t1onal and RA (14,586) Longitudinal Refill data Etanercept 73 [12] 
biological DMARDs Leflunomide : 69 
MTX 59 
Hydroxychloquine : 49 
Sulfasalazine 33 
Borah et a/. Etanercept or RA (3829) 12 months longitudinal Ref1ll data Adallmumab 63 (na·ive users), [13] 
2009 adallmumab 70 (existing users) 
Etanercept. 65 (naive users), 
73 (existing users) 
Curkendall eta/. Etanercept or RA (2285) 12 months longitudinal Ref1ll data 22-56 (depending on co-payment) [14] 
2008 adalimumab 
Contreras-Yanez DMARDs RA(93) 6 months long1tud1nal Interview 51 [6] 
eta/ 2010 
van den Bemt DMARDs RA (228) Cross-sectional Interview 99 [15] 
eta/. 2009 Questionnaires 66-67 
(CQR/MARS) 
- Table 3 -continues -
-Table 3 -continued-
Study (yeer) Type of medication Patients (n) Study characteristics lVIeasure Results(%) Ref 
Studies measuring DMARD adherence 
Doyle eta/ DMARDs RA(59) Cross-sectional Chemical marker 39 [16] 
1993 (penicillamine) 
s:: Pullar eta/. DMARDs RA(26) Cross-sect1onal Patient interview 96 [17] 
f1) 1988 (penic1llamme) Pill count 77 a. 
r;· Chemical marker 58 
llJ 
d'. Estimation 42 0 
:::J physician 
llJ 
a. 
::::,-
f1) Brus etal. DMARDs RA(SS) 6 months random1zed Pill count 82-91 (no difference bet ween [18] n; 
:::J 1999 (sulfasalazine) climcal trial Intervention and control) 
n 
f1) 
llJ 
q Studil!s studying both NSAID and DMARD adherence 
a: 
n V1ller eta/ NSAIDs, DMARDs or RA (592) 36 months longitudinal Pat1ent interview Baseline adherence : 59-6.5 [7] ~ 
llJ 1999 corticostero ids Cons istent adherent 35.7 
"'0 
"'0 Consistent non-adherent: 23.8 iil 
v;· 
~ 
0 Tun cay eta/. NSAIDs, DMARDs or RA (100) 12 months long1tudmal Interview Baseline adherence · 52,3 [19] ...., 
rt 2007 corticosteroids Consistent adherent: 30.2 ::::,-
f1) Consistent non-adherent: 11.6 f1) 
":". 
V1 
d'. 
:::J Owen eta/. NSAIDs and DMARDs RA (178) Cross-sectional Patient interview 63.5 [20] OQ 
;:;: 1985 
f1) 
iil -Table 3 -continues-
rt 
c 
n; 
IJJ 
-...J 
()..) 
00 
n 
::,-
OJ 
"0 
rt 
~ 
N 
-Table 3 -continued -
Study {year) 
Deyo eta/. 
1981 
Garcia-Gonzalez 
eta/ 2008 
Park et al. 
1999 
Taal eta/ 
1993 
Type of medication 
NSAIDs or DMARDs 
Not described 
Not described 
Not described 
Patients {n) Study characteristics 
RA, OA, gout 6 months longitudinal 
and AS (171) 
RA(70) Cross-sectional 
RA (121) 1 month longitudinal 
RA(96) Cross-sectional 
Measure Results(%) Ref 
Refill rates NSAID 58-73 [21] 
Penicillamine : 84 (n=9) 
Interview 50 [22] 
MEMS Perfect adherence m 38% ofthe [53] 
patients 
Patient interview 93 [79] 
-.--.-- - ··-- - · ··-- -- ····- -···---- ------- .. ...... ........ . ··-····--- ----·-----------·······-·· - ·--····- ··-···- ··--····--·-·--·····-· 
AS: Ankolysing spondylitis; CQR: Compliance Questionnaire on Rheumatology; DMARD: Disease-modifying antirheumatic drug; MARS: Medication Adherence Report 
Scale; MEMS: Medication Event Monitoring System; MTX: Methotrexate; OA: Osteoarthritis; RA: Rheumatoid arthritis; SASA: Sulfasalazine. 
RISK FACTORS FOR NONADHERENCE 
Knowledge of factors associated with medication adherence in RA could help 
healthcare professionals to identify patients who would benefit from an intervention 
in this regard, and could provide possible targets for treatment of nonadherence. 
Studies examining associates to adherence with DMARDs in RA are listed in Table 4. 
According to the WHO, factors associated with nonadherence can be divided into 
five domains [101]: socioeconomic factors; healthcare system factors; condition-
related factors; therapy-related factors; and patient-related factors. 
Socioeconomic factors 
In RA, many sociodemographic factors have been studied as potential risk factors for 
nonadherence. Factors such as age, gender, education, tobacco use, social-
economic status, living situation, marital status and presence of children were not 
unequivocally related to adherence. Age, for example, is not consistently associated 
with medication nonadherence. While some investigators have found older patients 
to have better adherence, others have shown younger patients to be more 
successful adherers [6,7,15,18,19,52,53]. 
However, the association between age and nonadherence and adherence may also 
be influenced by confounding factors such as multiple comorbidities and complex 
medical regimens (which are both often associated with an increased age). Although 
studies in other conditions suggested that ethnical/cultural aspects could predict 
nonadherence, evidence in RA is lacking. Only one study demonstrated that RA and 
systemic lupus erythematosus patients of south Asian origin have higher levels of 
concerns regarding DMARDs and are generally more worried about prescribed 
medicines. Concerns about medication may have an impact on adherence in this 
group of patients [54]. 
Healthcare system factors 
Whereas a good patient-provider relationship seems to improve adherence 
[7,52,55], poorly developed health services with inadequate or nonexistent 
reimbursement by health insurance plans negatively affect adherence [14]. 
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Condition-related factors 
A number of condition-related risk factors have been studied, such as disease 
activity, erythrocyte sedimentation rates, morning stiffness, overall (perceived) 
health, functioning, disease duration and quality of life. However, none of these 
factors were consistently related to nonadherence. Only perceived effect was poorly 
associated with nonadherence and adherence. In other chronic diseases, however, 
comorbidities such as depression [56] (in diabetes or HIV/AIDS), and drug and 
alcohol abuse are important modifiers of adherence behavior. 
Therapy-related factors 
Although there are many therapy-related factors that could potentially affect 
adherence, none of these factors (class of medication, drug load, the immediacy of 
beneficial effects and side effects) were adequate predictors for nonadherence in 
RA [11,20,22,57]. Despite this, a review of studies in non-RA patients confirmed that 
the prescribed number of doses per day and the complexity of the regimen was 
inversely related to compliance. Simpler, less frequent dosing regimens resulted in 
better compliance across a variety of therapeutic classes [58]. 
Patient-related factors 
Patients seem to adhere better when the treatment regimen makes sense to them: 
when the treatment seems effective, when the benefits seem to exceed the 
risks/costs (both financial, emotional and physical), and when they feel they have 
the ability to succeed at the regimen. Therefore, patient knowledge, self-efficacy, 
and beliefs about the disease and its treatment indeed seem to influence adherence 
behavior [7,11,15,18,20,52,53]. 
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Table 4 Factors associated and not associated with nonadherence in studies targeting disease-modifying antirheumatic drug adherence 
study, (year) Type of Patients (n) Study Factors associated with adherence --:F:-a--:ct-or_s_n_o-:-t -assoa--a~te-d-:-Wit7.,' =-h ---=R-ef:---
-~-- -----· de Klerk eta/. 
(2003) 
Borah eta/. 
2009 
Curkendall et a/. 
2008 
Contreras-Yanez 
eta/.2010 
medication characteristics adherence 
- ·------·-·-·--
Traditional 
DMARDs 
(sulfasalzine 
and 
methotrexate) 
Etanercept or 
adallmumab 
Etanercept or 
adallmumab 
DMARDs 
··· ·-· ·-------~ -
RA, polymyalgia 
and gout {127) 
Assessed w1th 
MEMS 
RA(3829) 
Assessed w1th refill 
data 
RA {2285) 
Assessed with refill 
data 
RA{93) 
Assessed with 
mterv1ew 
6 months 
longitudinal 
12 months 
long1tudmal 
12 months 
long1tud1nal 
6 months 
longitudinal 
condi~~-related f~~t~ --- --··condlti 'on-related factors~· 
perceived health, and functioning, and quality of l1fe 
subcategones of overall health Patient-related factors : coping 
Patient-related factors self- Therapy-related factors : side 
efficacy effects 
Therapy-related factors : naive vs 
existing users 
Socioeconomic factors : gender, 
and residence 
Healthcare system: HMO 
Insurance, and out-of-pocket 
payments 
Therapy-related factors : prior 
DMARDs 
Condition-related factors: disease 
act1v1ty, and erythrocyte 
sed1mentat1on rate 
Socioeconomic factors : gender, 
age, education, socioeconomic 
status, and manta I status 
Condition-related factors : 
functiomng, comorbid1ty, and 
drug load 
[11] 
[13] 
[14] 
[6] 
- Table 4 continues -
- Table 4 continued-
Patients (n) Study 
charactenstics 
Factors associated with 
adherence 
Factors not associated with 
adherence 
Ref 
--·- ·- · - --- ------- -- ·-···-··-·--·- ··- ··----·---·-···- ··---- ---·- ··----- -- -· - --- ---·--------· 
van den Bemt DMARDs RA (228) Cross-sectional Therapy-related factors : number 
eta/. 2009 Assessed with of side effects 
Brus et a/.1999 DMARDs 
(sulfasalazine) 
Hill et a/. 2001 Penicillamine 
interview and Condition-related factors 
questionnaires disease activity 
Patient-related factors : BMQ 
necessity 
RA (n=55) Randomized Patient-related factors : self-
Assessed with pill clinical trial efficacy 
count (education vs 
standard care) 6 
months follow-
up 
RA (100) Randomized Socioeconomic factors : 
Assessed with cllmcal tnal12 education 
pharmacological weeks 
marker 
Socioeconomic factors age, 
gender, marital status, education, 
and tobacco use Condition-related 
factors funct1on1ng, and number 
of medication 
Patient-related factors : BMQ 
concerns, and satisfaction with 
information 
Socioeconomic factors · education, 
age, and gender Patient-related 
factors : outcome expectation, and 
perceived social attitude/support 
Condition-related factors pain, 
functioning, disease activity, and 
perceived barriers 
[15] 
[18] 
[74] 
- Table 4 continues -
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- Table 4 continued -
Study, (year) Type of 
medication 
Patients (n} 
- Treharne e-t a--:1---:-N:-::S-:-A:-::ID-s, .. DMA~ RA (85) 
2004 
Lorish eta/. 1989 
or 
corticostero ids 
Not described 
Assessed with 
questionnaires 
RA (200) 
Study 
characteriStics 
Cross-sectional 
Cross-sectional 
--Factors associated with 
adherence 
Factors not associated with 
adherence 
Socioeconomic factors presence--Soci; economlc factors : gender, 
of children age, socioeconomic status, 
Therapy-related factors 5tero1d marital status, employment, livmg 
use, and drug load alone, and number of children 
Healthcare system : satisfaction Condition-related factors : disease 
consultation duration, comorbidity, class of 
Pat1ent-related factors BMQ med1cat1on, and d1sease activity 
necessity, beliefs about harm Patient-related factors : 
and overuse of medication satisfaction, soc1al support, 
extent support, and opt1m1sm 
Socioeconomic factors : live 
alone. divorced, employed, years 
of education, financ1al status, 
and expense 
Therapy-related factors side 
effects, and scheduled routines 
Socioeconomic factors family 
against tak1ng med1cat1on . 
Therapy-related factors ran out 
of med1cat1on, interruption 
before taking, unclear dosing 
directiOn, price ofthe drugs, and 
med1cat1on stopped working 
Cond1t1on-related factors : 
physical funct1omng, and 
improvement oft he disease. 
Patient-related factors · 
stress/hurry, forgetfulness, and 
wornes about long-term 
resistance 
Ref 
[52] 
[57] 
- Table 4 continues-
.j>. 
- Table 4 continued-
.j>. 
------·- - ~-·---
n Study, (year) 
::::r 
ru 
"0 
..... 
~ Viller eta/. 1999 
N 
Tun cay eta/. 2007 
Type of 
medication 
NSAIDs, 
DMARDsor 
cort1costero1ds 
NSAIDs, 
DMARDs or 
corticosteroids 
Patients (n) 
RA (592) 
RA (100) 
Study 
characteristics 
36 months 
long1tudrnal 
12 months 
longitudinal 
Factors associated with 
adherenoe 
Socioeconomic factors : age, and 
gender Healthcare system: 
satisfactory contacts with 
healthcare provider. Patient-
related factors: knowledge 
about disease and treatment. 
Condition-related factors : 
decreased disability 
Socioeconomic 
factors : age 
Factors not associated with 
adherenoe 
Soc1oeconom1c factors : education 
Socioeconomic factors: gender 
Condition-related factors disease 
duration, number of medication, 
HAQ disease act ivity, morning 
stiffness, erythrocyte 
sedimentation rate, CRP, and 
decreased disability 
Healthcare system : regularity 
insurance 
Ref 
[7] 
[19] 
- Table 4 continues-
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- Table 4 continued -
SWdY;(yaail __ .Type of 
medication 
Owen eta/. 1985 NSAIDs and 
DMARDs 
Garcia-Gonzalez Not described 
eta/. 2008 
Park eta/. 1999 Not described 
Patients (n) 
RA (178) 
Adherence 
measured by 
Inter-view 
RA(70) 
RA (121) 
Study 
characteristiCS 
Cross-sectional 
Cross-sectional 
1 month 
longitudinal 
Factors associated with adherence 
Condition-related factors 
erythrocyte sedimentation rate. 
and duration of mornmg stiffness 
Patient-related factors cited 
reason for tak1ng drugs, and 
attitude towards med1cat1on 
Socioeconomic factors: education, 
and ethnic1ty 
Therapy-related factors severity of 
side effects 
Socioeconomic factors : age 
Patient-related factors · busy life 
style, cognitive deficits, and copmg 
w1th arthritis -elated moods 
Factors not associated with 
adherence 
·----- -·· Socioeconomic factors : gender, 
education, socio-economic status, 
and residential location . Condition-
related factors : disability score, 
and number of medication 
Therapy-related factors : type of 
medication, current/previous s1de 
effects, and number of dally doses 
Patient-related factors : perce1ved 
effectiveness of the medication, 
and level of pain 
Condition-related factors : d1sease 
duration, health status, and activity 
Condition-related factors : illness 
seventy, medication load, and 
physical function 
Ref 
[20] 
[22] 
[53] 
BMQ: Beliefs about Medication Questionnaire; CRP: C-reactive protein; DMARD: Disease-modifying antirheumatic drug; HAQ: Health Assessment Questionnaire; HMO: 
Health Maintenance Organization; MEMS: Medication Event Monitoring System; RA: Rheumatoid arthritis. 
However, caution should be exercized by synthesizing the findings about possible 
associates to adherence to DMARDs [59]. Inconsistent findings could be explained 
by the differences among studies in methods of assessing {non)adherence and its 
possible determinants. Furthermore, heterogeneity of characteristics of the study 
populations may have affected the validity of the synthesis of the results. 
Unintentional & intentional adherence 
Nonadherent RA patients seem hard to characterize by their {social) demographic, 
therapy-related and condition-related factors . These findings are confirmed in 
studies in other chronic diseases. Although more than 200 variables have been 
identified by researchers as influencing medication adherence [60], no clear risk 
profiles could be constructed. Characteristics were often inconsistently correlated 
with nonadherence, were sometimes contradictory, and correlations were often 
weak. Furthermore, it is important to recognize that a person may have multiple risk 
factors for medication nonadherence. In addition, factors that can influence a 
person's medication-taking behavior may change over time. 
A valuable conceptual distinction that brings together the findings of different 
types of research and explanations of patients' medication use is the distinction 
between 'unintentional' and 'intentional' nonadherence [57,61-64]. Unintentional 
nonadherence reflects a person's ability and skill at medicine-taking, including 
forgetting, poor manual dexterity, losing medicines or not being able to afford them. 
Intentional nonadherence is a behavior driven by a decision not to take 
medicines. The drivers of this decision are complex but have been suggested to be 
based on beliefs about a patient's illness and its {pharmacological) treatment. These 
beliefs can be categorized into perceived concerns and perceived benefits. 
Perceived concerns include side effects and dependence on mediation. Perceived 
benefits include a decrease in symptoms {pain, fatigue and wellbeing), prevention of 
functional loss and cure of the disease. Existing evidence suggests that beliefs about 
medicines are more predictive of intentional nonadherence than of unintentional 
nonadherence. In a sample of 173 patients with asthma, intentional nonadherence 
was most strongly predicted by a patients' balance of the pros and cons of taking 
the medication [63-65] . Conversely, unintentional nonadherence was not predicted 
by this balance of beliefs. The same association was found in a study of 117 patients 
who were taking antiretroviral medication [66]. Intentional nonadherent patients 
seem to make a risk-benefit analysis, in which beliefs about the necessity of taking 
prescribed medications are weighed-up against concerns about possible negative 
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effects [52]. This balance of perceptions of necessity and concerns is consistent with 
the concepts of benefits and barriers in Rosenstock's health belief model [63,67]. 
This widely used model can be outlined using four constructs that represent the 
perceived threat and net benefits. According to this model, individuals will adhere 
with health regimens if they perceive themselves as being susceptible for getting a 
certain condition, if the condition has serious consequences, if the therapy would be 
beneficial, and if they feel that barriers to action are outweighed by the benefits 
[68]. 
Only a few studies have addressed patients' beliefs about medication as a 
possible predictor for adherence, although patients' beliefs about medication can be 
easily assessed by the Beliefs about Medicines Questionnaire [63]. The scale is 
comprised of ten items: five items about the necessity of the medication and 
another five items on the concerns about medication. The Beliefs about Medicines 
Questionnaire has been validated in various patient groups with chronic illnesses 
(asthma, diabetes, and renal and cardiovascular disease) and predicted adherence 
to treatment among various groups of patients with chronic conditions (e.g., people 
with asthma) [15,69]. 
In studies with the Beliefs about Medicines Questionnaire in patients with RA, it 
was found that most people with RA report positive beliefs about the necessity of 
their medication. More pain, fatigue, helplessness, the number of DMARDs along 
with physical disability increased the belief in the necessity of the medication. Levels 
of concern are, nonetheless, high, as 91% of the nonadherent patients had one or 
more concerns about potential adverse effects, particularly over the long term. 
Despite the positive association between adherence and factors such as necessity, 
degree of pain, fatigue, physical disability, perceived helplessness and the number of 
DMARDs prescribed, these factors were, on the other hand, also found to be 
positively related to concerns/barriers to taking medications [69]. 
Based on Rosenstock's 'health belief' model, and considering the conceptual 
distinction between intentional and unintentional behavior, we developed a 
simplified model to explain adherent behavior. This model suggests that once a 
patient receives a prescription, he/she will weigh up the necessity of the treatment 
(based on the patient's perceived threat of the illness and his/ her outcome 
expectancy) with the concerns for the treatment (expected disadvantages) [69]. 
Therefore, patients make a risk-benefit analysis considering whether their beliefs 
about the necessity of the medication outweigh their concerns. When the necessity 
is stronger than the concerns, patients will intend to take their medication, and will 
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take this medication unless practical unintentional barriers hinder the patient in 
taking their medication (Figure 1). 
Presctiption 
Disadvantages 
medication 
{C~ma} 
Advantages 
medication 
(I\I»Q;SiJ!iyj 
Willingness 
Practical 
barners 
Adherent 
behaviour 
Figure 1 Simplified model to concordantly discuss patient's main barriers for medication 
adherence (intentional due to a imbalance between perceived benefits and concerns and 
unintentional due to practical barriers. During this discussion, the patient's expertise and 
beliefs are fully valued) 
INTERVENTIONS TO IMPROVE ADHERENCE 
Interventions in chronic diseases 
Although clinicians and researchers have carried out a variety of interventions 
(diverse in approach and intensity) to improve adherence in chronic diseases, the 
effectiveness of these interventions was generally modest [1,4,70,71]. 
Comprehensive interventions that combined approaches were typically more 
effective than interventions focusing on single causes of nonadherence; although 
the effect size was still small [72,102]. However, few interventions really 
individualized the approach to match patients' needs and preferences, in order to 
target a patient's individual feelings on the necessity of the drug, his/her concerns 
and possible practical barriers for medication taking. Furthermore, only a few 
interventions have been systematically developed, with a theoretical model as a 
stepping stone and a structured identification of the targets of the intervention 
followed by a pilot session before the final randomized trial. 
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Interventions in RA 
The modest effectiveness of adherence-improving interventions in chronic diseases 
is in line with the scarce results from research into medication adherence 
interventions in RA. Although education about medication and medication use, as 
well as self-management interventions, are often part of the treatment in RA, 
adherence is seldom reported as an outcome measure in studies into the effect of 
these interventions [73]. Only three studies assessed the effect of a medication 
adherence intervention in RA using adherence as an outcome measure [74-76]. One 
study demonstrated an improvement in adherence to D-penicillamine following a 
patient education program, including seven one-to-one visits of 30 min each [14]. 
However, the second intervention study was not successful in increasing adherence 
to sulfasalazine among patients with active, recent-onset RA. Adherence to 
medication in participants of the patient education intervention (six group meetings) 
was already high at baseline. Both adherence intervention programs were intensive, 
with inconsistent results and limited effect at best. Finally, our group demonstrated 
that supplying written information about patients' nonadherence and adherence to 
the rheumatologist was insufficient to increase patients' adherence on drug therapy 
[76]. 
Therefore, simple, easy to implement and effective interventions to improve 
adherence are needed in clinical practice [103,77]. Some researchers suggest that 
adherence interventions can be improved by identifying and focusing the 
intervention on nonadherent patients only [77]. Most existing interventions target 
all patients with a drug prescription, thus limiting the efficiency of the intervention. 
However, it is hard to identify nonadherent patients. Besides, adherence fluctuates 
and changes over time: adherent patients may become nonadherent ones. 
A second promising strategy to improve the efficiency of adherence interventions is 
to tailor the content of the intervention to the individual patient's cause(s) of 
nonadherence [103, 77]. 
Expert commentary 
In conclusion, the effectiveness of RA therapy may be limited by inadequate 
adherence to medication and by discrepancies between the physician-prescribed 
regimen and the regimen actually used by the patient. Failure to take medication 
has important consequences; it not only reduces the efficacy of the treatment, but 
also wastes healthcare resources [6,7]. Although knowledge of factors associated 
with medication adherence in RA could help health professionals to identify patients 
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who would benefit from adherence-improving interventions, adherence seems to be 
influenced by patient characteristics that are less visible and more subtle, such as 
patient's beliefs about their medication. These factors are more difficult to detect 
and need more time and attention from prescribers. Besides tackling practical 
barriers, such as forgetfulness, clinicians should therefore be sensitive to a patient's 
personal beliefs that may impact medication adherence, and should discuss with 
their patient any concerns that they raise about prescribed medications. 
Five-year view 
Today, and in the future, patients receive more information about their health 
problems through accessing the internet, television and other media, where a 
myriad of (pharmacological) treatment options are regularly discussed. The wider 
availability of information empowers patients and will influence patients' beliefs 
about the necessity of the drugs and their potential disadvantages. As it is ultimately 
the patient who decides on a daily basis whether or not to take their medication as 
prescribed, clinicians should take the empowered patient's opinion into account to 
enable optimal medication use [78]. 
Clinicians should discuss the patient's perception of the need for the proposed 
treatment and consider the individual's concerns about taking it throughout the 
course of therapy. This discussion will help to foster a patient-physician relationship 
in which the patient is able to communicate as a partner in the selection of 
treatment and the subsequent review of its effect. To achieve this shared decision-
making, clinicians and patients need to be able to discuss concerns about treatment 
regimens. The aim of this discussion is concordance between patient and healthcare 
provider about diagnosis and prognosis of the illness, the treatment required and 
the risks and benefits associated with treatment. This point of view differentiates 
adherence (the extent to which the patient's behavior matches agreed 
recommendations from the prescriber) from compliance (the extent to which a 
patient follows medical instruction). Simple interventions seem to be the most 
promising way to improve patient adherence, preferably when carried out in a 
multidisciplinary setting (physicians, psychologists and pharmacists) and, not in the 
least, by incorporating patients' perspectives. 
However, in order to measure the effectiveness of these interventions, more 
research on medication adherence in RA is necessary. Although the main priority for 
research is to develop effective and efficient interventions to facilitate a patient's 
adherence, basic research on outcome measures to reliably assess adherence is 
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necessary to adequately measure the extent of nonadherence and to objectify the 
effectiveness of medication adherence interventions. Finally, an improved 
understanding of the relationships between patients' characteristics, patients' 
cognitions, disease-related factors and patient-physician interaction should lead to 
more robust theoretical frameworks, and to more effective methods of improving 
adherence. 
Key issues 
• Adherence rates to prescribed medicine regimes m people with rheumatoid arthritis (RA) are low, 
varying from 30 to 80%. Improving adherence in RA could improve the efficacy of drug therapy in 
RA. 
• Medication adherence can be d1vided mto three major components: persistence; in1tiat1on 
adherence, and execution adherence. 
• Medical decisions should be based on concordance patients should be able to communicate as a 
partner in the selection oftreatment and 'm the evaluation of effect. 
• Currently, a gold standard for the measurement of adherence is not available. 
• The appropriateness and choice of the specific measure employed should be determmed by the 
overall goals of adherence measurement. 
• Despite the heterogeneity of the available studies on disease-modifying antirheumatic drug 
nonadherence, all studies consistently show that disease-modifying antirheumatic drug adherence 
is suboptimal, w1th adherence rates rangmg from 22 (underuse) to 107% (overuse) . 
• The vanation in these studies relates to differences in the study groups, the duration of follow-up, 
the type of drugs included, the definition of adherence. the duration of the disease and the 
methods of assessment. 
• Nonadherent RA patients seem hard to charactenze by the1r (social) demographic, therapy-related 
and condition-related factors. 
o Nonadherence behavior could conceptually be categorized into two subtypes· unintentional (due to 
forgetfulness, regimen complexity or physical problems), and intentional (based on a patient's 
decision to take no/less medication). 
o In case of intentional nonadherence, patients seem to make a benefit-risk analysis weighing the 
perceived risks of the treatment against the perceived benefits. 
• Current methods for improving med1cat1on adherence in chronic diseases are often complex and 
not very effective. 
• Most interventions that target adherence were not tailored to patients' needs and preferences. 
• Only one ofthe three studies assessing the effectiveness of a med1cat1on adherence intervention in 
RA demonstrated a slight improvement in adherence. 
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Development and content of a 
group-based intervention to improve 
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ABSTRACT 
Objective To describe the systematic development and content of a short 
intervention to improve medication adherence to disease-modifying antirheumatic 
drugs in non-adherent patients with rheumatoid arthritis (RA). 
Methods The intervention mapping (IM) framework was used to develop the 
intervention. The following IM steps were conducted: (1) a needs assessment; (2) 
formulation of specific intervention objectives; (3) inventory of methods and 
techniques needed to design the intervention and (4) production and piloting of the 
intervention. 
Results The intervention (consisting of two group sessions led by a pharmacist, a 
homework assignment, and a follow-up call) aims to improve the balance between 
necessity and concern beliefs about medication, and to resolve practical barriers in 
medication taking. The central communication method used is motivational 
interviewing. 
Conclusion By applying the IM framework, we were able to create a feasible, time-
efficient and promising intervention to improve medication adherence in non-
adherent RA patients. Intervention effects are currently being assessed in a 
randomized controlled trial. 
Practice implications This paper could serve as a guideline for other healthcare 
professionals when developing similar interventions. If the RCT demonstrates 
sufficient effectiveness ofthis intervention in reducing medication non-adherence in 
RA patients, the intervention could be embedded in clinical practice. 
Keywords 
Adherence; beliefs about medication; development; intervention mapping; non-
adherence; medication; motivational interviewing; practical barriers; rheumatoid 
arthritis 
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1. INTRODUCTION 
Adherence to disease-modifying antirheumatic drugs (DMARDs) in patients with 
rheumatoid arthritis (RA) (a chronic polyarthritis often leading to joint damage) is 
not optimal and ranges from 58% to 82% [1-3]. Taking DMARDs as prescribed can, 
however, limit or prevent disease activity, pain, joint and radiological damage, and 
can improve long term functional outcome in RA patients. DMARDs can also cause 
side effects, such as gastro-intestinal complaints, low white blood counts, and 
abnormal liver function tests [4]. These side effects, amongst other factors, may 
contribute to non-adherence to DMARDs, which can have serious consequences. 
Non-adherence reduces treatment efficacy, which in turn can result in unnecessary 
disease activity, joint I radiological damage, and loss of function [5-7]. Moreover, 
the annual costs of non-adherence for all conditions in the USA have been estimated 
to be $100 billion [8]. In view of the negative implications of medication non-
adherence, this behavior thus should be addressed. 
To date, evidence supporting the effectiveness of health interventions to 
improve medication adherence in RA and other chronic illnesses remains 
inconclusive [9,10]. The effectiveness of a medication adherence intervention in RA 
has been assessed in three studies [11-13]. Only one of these studies demonstrated 
a slight improvement in adherence to d-penicillamine after a patient education 
program [13]. This program, however, was intensive (51 individuals, 7x 30 minutes) 
and time-inefficient, as it was not group-based and it was intended for both 
adherent and non-adherent patients. Moreover, all three studies lacked a 
description of the development process and grounding of these interventions in 
empirical evidence, theory, and practice perspectives. Consequently, internal and 
external validity of these interventions is insufficiently guaranteed. 
The aim of the present paper is to transparently describe the systematic 
development and content of a short, time-efficient intervention to improve 
medication adherence to DMARDs in non-adherent RA-patients. The intervention 
consists of two motivational interviewing-guided [14] group sessions led by a 
pharmacist, aimed at improving the individual patient's balance between necessity 
and concern beliefs about medication and at resolving practical barriers in 
medication taking. We used the intervention mapping framework [15] (a common 
framework not yet used in RA interventions) to systematically apply theories, 
empirical evidence, and practice perspectives in the development of the 
intervention. 
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2. METHODS 
Intervention mapping (1M) comprises six steps, each leading to a product that guides 
the next step. Figure 1 (derived from Brug and colleagues [16]) depicts these steps 
and their operationalization during our development process. 
Step 1: Needs assessment- analysis of determinants 
Literature study, cross-sectional study and focus group 
study about determinants of medication non-adherence 
Step 2: Intervention objectives 
Formulation of specific Intervention objectives, based on 
information of the needs assessment 
Step 3: Health behavior change methods and 
techniques 
Literature study to select appropriate health behavior 
change methods and techniques in accomplishing the 
specific 1ntervent1on objectives 
Step 4: Intervention content and pilot 
Determination of intervention content (created by combining 
health behav1or methods and techniques) and pilot of 
intervention and materials 
Step 5: Implementation of intervention 
Step 6: Evaluation of intervention 
Figure 1 Model of intervention mapping used for intervention development 
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The IM framework was chosen because it (1) enhances the formulation of 
intervention objectives based on empirical evidence and/or theory; (2) covers all the 
important objectives; (3) links final materials and activities to theory; and (4) ensures 
the intervention is compatible with the target population [17]. IM has already been 
used successfully in, for example, asthma management, HIV prevention, and sun 
protection [18]. 
In the present study, the IM steps were conducted by members of a 
multidisciplinary task group, consisting of pharmacists, researchers, psychologists, 
rheumatologists, experts on motivational interviewing, and RA patients. Two task 
group members [Wvl, BvdM] were responsible for the daily coordination; final 
decisions regarding the development process and output of the IM steps were 
reached through discussion in task group meetings. 
This section describes how each IM step was ope rationalized. 
2.1. Needs assessment- analysis of determinants 
Possible targets of the intervention were identified by carrying out a literature 
study, a cross-sectional study, and a focus group study about medication non-
adherence and possible determinants among RA patients. 
The literature study [19] was based on publications about determinants of 
medication non-adherence in RA that were retrieved from Pubmed, Psychlnfo, 
Embase and Cinahl [BvdB/BvdM]. The search strategy included all possible search 
terms (MeSH and text word) for rheumatoid arthritis, medication non-adherence, 
compliance, and persistence. 
For the cross-sectional study [BvdB] [20], 228 consecutive RA patients on 
DMARD therapy treated in the St. Maartenskliniek (a clinic specialized in 
rheumatology, rehabilitation and orthopedic surgery) completed questionnaires to 
examine the prevalence and possible determinants of non-adherence, including 
demographics, coping, beliefs about medication, satisfaction about medicine 
information, and physical functioning. Non-adherence was measured with the 
Compliance Questionnaire Rheumatology (CQR [21]) and the Medication Adherence 
Report Scale (MARS [22]). 
To gain in-depth insight into possible determinants of non-adherence, two 
patient focus groups led by two psychologists [WvL/BvdM] were organized to 
discuss necessity and concern beliefs about medication, the need for education, 
experienced social support, and practical barriers as perceived by RA patients. The 
focus groups (seven patients per group) consisted of a non-selective sample of 
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fourteen non-adherent RA patients (selected according to CQR data of the cross-
sectional study, with non-adherence being defined as taking <80% of prescribed 
medications). 
2.2. Intervention objectives 
The results of the needs assessment were discussed during task group meetings. 
Subsequently, modifiable determinants of non-adherence relevant to our target 
group (adult, non-adherent RA patients taking DMARDs) were selected as targets for 
the intervention. To achieve the overall aim of the intervention (improving 
participants' medication adherence), specific intervention objectives (Section 3.2) 
were formulated for each determinant to identify exactly what needed to change 
during the intervention. 
2.3. Health behavior change methods and techniques 
Literature about established communication -and health behavior (change) models, 
- methods and - theories was studied [GB], to identify appropriate methods and 
techniques in accordance with the specific intervention objectives. Based on this 
literature study, the task group selected health behavior change methods and 
techniques to be used during the intervention. 
2.4. Intervention content and pilot 
The intervention objectives and selected methods and techniques were combined in 
a single plan [GB], namely the intervention protocol. Draft versions of this 
intervention protocol were discussed during task group meetings, resulting in the 
final version of the intervention protocol. Based on this final intervention protocol, 
materials were developed, such as a participant workbook with homework 
assignments (Section 3.4). 
The feasibility of the intervention (consisting of two consecutive group sessions, 
see Section 3.4) was examined by piloting the intervention twice. A non-selective 
sample of twelve adult, non-adherent RA patients (based on CQR data of the cross-
sectional study) was recruited for the pilot. The pilot was attended by an expert 
panel, consisting of two psychologists, and a patient panel (independent advisory 
board comprising two RA patients familiar with scientific research). A global 
checklist and a patient satisfaction questionnaire were developed [BvdM) to assess 
the communication style of the intervention, transparency of information, and 
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satisfaction about general intervention characteristics, such as session duration and 
group size. 
2.5. Implementation and evaluation of the intervention 
Implementation of the intervention was facilitated by (1) the pilot of the 
intervention (Section 2.4) and (2) the task group participation of rheumatologists 
and pharmacists responsible for carrying out the intervention in clinical practice. 
Furthermore, a practical workbook for use during the intervention was written for 
these rheumatologists and pharmacists (Section 3.4). To check treatment integrity, 
audio-taped intervention sessions will be analyzed. 
To objectify intervention effects on treatment outcomes, a research proposal 
was drafted for a randomized controlled trial (Section 3.5). 
3. RESULTS 
3.1. Needs assessment- analysis of determinants 
3.1.1. Literature study 
The literature study into the empirical determinants of medication non-adherence in 
RA revealed that non-adherence is a multidimensional phenomenon, with 
determinants not consistently associated with non-adherence across studies [19]. 
Although regimen complexity, a poor patient-provider relationship, costs of drugs, 
lack of social support, a low level of self efficacy, and beliefs about medication 
(including perceived (side) effects of medication) tend to be associated with 
medication non-adherence, these associations are often weak. 
Recently, determinants of medication non-adherence have been conceptualized 
as 'unintentional' or 'intentional' factors of non-adherence [19]. Unintentional non-
adherence reflects a person's lack of ability and skills to take medicines, including 
forgetting or poor manual dexterity [23], while intentional non-adherence is driven 
by a decision not to take medicines as prescribed. It is assumed that adherence 
decisions are influenced by a cost-benefit assessment in which personal beliefs 
(assumptions and convictions that are believed to be true by an individual) about 
the necessity of the medication for maintaining or improving health are balanced 
against concerns about the potential adverse effects of taking the medication [24]. It 
should be noted, however, that this cost-benefit assessment may be implicit rather 
than explicit and unconscious rather than conscious [25,26]. Nevertheless, targeting 
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intentional non-adherence (beliefs about medication) as well as unintentional non-
adherence (e.g., practical barriers) might improve medication adherence [27,28]. 
3.1.2. Cross-sectional study 
In the cross-sectional study, an association between beliefs about medication and 
non-adherence was confirmed for necessity beliefs about medication [20]. Adherent 
patients had higher mean necessity scores than non-adherent patients (20.3 versus 
19.1; p=0.02). Moreover, patients with recent onset RA were more adherent than 
patients with a longer RA duration (76% and 62%, respectively; p=O.OS). 
Furthermore, adherent patients (according to the CQR) reported fewer adverse 
medication effects than non-adherent patients. 
Although > 90% of patients had one or more concerns about their medication, 
concern beliefs about medication were not associated with non-adherence. This 
also applied to satisfaction about information, coping, physical functioning, and 
demographics. 
3.1.3. Focus groups 
The focus groups revealed that all participants had necessity beliefs and concern 
beliefs about medication. Although the nature of beliefs varied highly between 
individuals, almost all patients perceived medications as a 'necessary evil ' and as 
'chemical junk' . Almost half of the participants appeared to experiment with their 
medication to find a balance between taking it (because of the inevitable necessity) 
and not taking it (because of (possible) adverse effects). 
Participants reported that they preferred receiving oral information about RA 
and medications from peers and rheumatologists rather than receiving written 
information. Add itionally, participants stressed the importance of practical support 
from their spouses in overcoming practical barriers such as forgetfulness, difficulties 
in opening pill strips and bottles, difficulties with cooling medication on hol idays, 
and difficulties with injecting medicines. 
3.2. Intervention objectives 
Based on the needs assessment, the task group selected determinants as targets of 
the intervention. These determinants are shown in Table 1, along with their 
corresponding intervention objectives. 
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Table 1 Determinants and specific intervention objectives 
-------------------Overall aim: after the intervention, participants are more adherent in taking their medtcatlons as 
prescnbed by their rheumatologist 
Central determinants 
Intentional non-adherence: 
beliefs about medication 
Unintentional non-
adherence practical barriers 
Enabling determinants 
Knowledge 
Social influence: modeling 
Self-efficacy 
Afterthe mterventron, partrapants ... 
.. have an improved balance between necessity and concern beliefs. 
That is, participants have stronger necessity beliefs about medication 
and less unrealistic concern beliefs about medication 
... are able to overcome their own practical barners in using medication 
... have adequate knowledge about RA and RA-medications 
... understand that beliefs about medication and practical barriers 
contribute to non-adherent behavior 
... have a clear picture oftherr own beliefs about medication and 
practical barriers, by listening and talking to their 'peer participants' 
... discussed and obtained skills to overcome their own practical barriers 
in using medication, so self efficacy is enhanced 
The task group chose only to target modifiable determinants or resolvable practical 
barriers in medication taking, and therefore non-adherence determinants like a poor 
patient-provider relationship or costs of drugs were not selected as intervention 
targets. However, the task group found beliefs about medication to be a promising 
intervention target, since most published interventions failed to systematically 
target such beliefs and since beliefs about medication played a significant role in all 
three sub-studies of our needs assessment. Furthermore, since our focus groups 
revealed that most RA patients experience practical barriers in medication taking, 
several task group members suggested that effectiveness of adherence 
interventions could be increased by targeting both intentional non-adherence (i.e., 
beliefs about medication) and unintentional non-adherence (i.e., practical barriers). 
To accomplish the central intervention objectives, three prerequisites (defined 
as 'enabling determinants') should be met. Two out of three prerequisites were 
derived from the needs assessment by the task group: (1) 'social influence' had to 
be incorporated into the intervention, because our focus groups revealed that RA 
patients prefer receiving oral information about RA and medications from peers and 
rheumatologists rather than receiving written information; (2) self-efficacy in taking 
medication should be enhanced. According to the literature study, poor self-efficacy 
correlates with non-adherence, and the task group therefore assumed that 
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enhancing self-efficacy may help patients to overcome their practical barriers. The 
last prerequisite, which is unrelated to the outcome of the needs assessment ('RA 
patients should have adequate knowledge about RA, RA medication, and non-
adherence') was suggested by the task group because they felt that adequate 
medication knowledge in patients is important in changing beliefs about medication 
[16]. 
The task group decided to focus the intervention on adults (as treatment of 
children with RA in the St. Maartenskliniek was scarce at the time of intervention 
development) and on patients with a disease duration of longer than one year (as 
we assumed medication-taking behavior would be more stable). The intervention 
was not further tailored to subgroups, as the needs assessment found that 
demographic factors were no strong predictors of non-adherence. 
3.3. Health behavior change methods and techniques 
To explain the association between beliefs about medication, practical barriers, and 
medication non-adherence to patients (knowledge objective, see Table 1), easy-to-
understand patient education was needed. We therefore developed a simple health 
behavior model (Figure 2), based on elements of the Health Belief Model [29] (used 
in the field of non-adherence [24]), and the Integrated Change Model (the latest 
version of the widely used ASE model (Attitude-Social Influence -Self-efficacy model) 
in the Netherlands [30]). 
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Figure 2 
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This simple model was also used as a visual tool and as a stepping stone during the 
intervention (details of use are described in Section 3.4 and in Table 2). 
The central communication style of the intervention had to comply with two 
requirements, derived from the central intervention objectives of 'beliefs' and 
'practical barriers': 
1. the communication style should be open and non-judgmental. As it could be 
uncomfortable for patients to talk about their non-adherence, personal beliefs 
about medication, and their own practical barriers, patients should feel safe to 
express their thoughts and feelings; 
2. the communication style should be suitable for exploring individual necessity and 
concern beliefs about medication and individual ambivalence regarding the pros 
and cons of medication. According to our needs assessment, beliefs vary highly 
among individuals, and people are more likely to elaborate on information when 
messages are personalized [16]. 
The task group decided that motivational interviewing (MI) could be a useful 
communication style to explore patients' individual ambivalence and the balance 
between necessity and concern beliefs about medication. Ml is a non-judgmental, 
patient-centered approach that facilitates behavior change by helping patients to 
explore and resolve their individual ambivalence about behavior change [14]. Ml has 
proven to be successful in different individual and group behavioral settings [31-33]. 
Expressing empathy, developing discrepancy (e.g., in the balance of necessity 
and concern beliefs), avoiding argumentation and confrontation, rolling with 
resistance, and supporting self-efficacy are underlying Ml principles [14]. These 
principles can be translated into the following Ml techniques: (1) reflective listening; 
(2) expressing acceptance and affirmation; (3) monitoring patients' readiness to 
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change beliefs and behavior (ensuring that resistance is not generated by pushing 
patients to change beliefs or behavior); (4) affirming the patient's freedom of choice 
and self-determination regarding changing beliefs and behavior; and (5) giving the 
patient a more active role than the intervention leader [14). To master these 
techniques, our intervention leaders followed a course in Ml at a renowned Ml 
center in the Netherlands. 
The task group decided on the following intervention format: two Ml-guided 
group sessions (1.5 hours each, 5-7 RA patients (a manageable group size) led by a 
pharmacist, an individual homework assignment between the two sessions 
(therefore sessions took place one week apart), and a follow-up call by the 
pharmacist eight weeks after the last group meeting. 
The group format was used to accomplish the intervention objectives of 'social 
influence/modeling' (whereby modeling is a technique in itself) and 'self-efficacy'. 
People can enhance self-efficacy, for example, by observing and listening to others 
according to Bandura's social cognitive theory [34]). The number of sessions was set 
at two to keep the intervention short and time-efficient, to enable discussion about 
the outcomes of the individual homework assignment, and to repeat shared 
information from the first session, as repeating messages increases the likelihood of 
information being recalled [35). The aim of the follow-up call also was recall of 
information. As trustworthy messengers increase the chance of behavior change 
and adopting messages [36], the task group decided that a pharmacist should lead 
the interventions and that a rheumatologist should provide education about RA and 
RA medications (see knowledge objectives in Section 3.2) during the second session. 
All developed intervention materials are described in Section 3.4. 
3.4. Program development and production 
All separate intervention mapping steps were combined in the intervention protocol 
[37). Table 2 summarizes the protocol content and shows the link between this 
content and determinants, intervention objectives, methods, and techniques. 
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Table 2 Intervention content: function and corresponding determinants, intervention objectives, methods and techniques 
Intervention section 
First group session 
1.1. Welcome 
1.2. . Introduction of simple 
behavior model (Figure 
2) 
1.3. Spec1ficat1on and 
personalization of 
s1mple model to 
participants, regarding 
beliefs and practical 
barriers 
Function 
Getting to know each other. 
Understanding intervention 
etiquettes, content,. context and aim 
intervention. Creating a safe and 
relaxed atmosphere 
Concerns deterrninant(s) 
and intervention objectives 
(see Table 1) 
(See ~) Knowledge : understanding 
that beliefs about 
medication and practical 
barners contribute to non-
adherent medication 
behavior 
Making patients thmk about their All intervention objectives 
own necessity and concern beliefs except for self efficacy (see 
about medication and barriers in Table 1) 
medication tak1ng by means of the 
simple model (the model was used 
as visual tool) 
~~--~------------------------------Used methods and techniques 
Trustworthy messenger 
Use of PowerPoint 
Pat ient education with s1mple behavior model (Figure 2) 
Use of PowerPo1nt 
Ml-techniques: expressing acceptance and affirmation, 
g1v1ng patients more active role than intervention leader 
Simple behav1or model as stepping stone 
Personalization of information 
Modeling 
Use of flip-over's (to write down beliefs/barriers inherent 
in the group) 
- Table 2 continues -
- Table 2 continued-
Intervention section 
--·- -- -·- - ----
Function 
1.4. Explaining and Understanding how assignment can 
conducting be conducted, and how 1t will be 
homework discussed dunng the second session 
ass1gnment (1n the homework assignment, the 
participants re-evaluate their own 
beliefs and barriers to be well 
prepared for second session) 
1.5. Closure of f1rst 
session 
Second group session 
2.1. Welcome 
2.2. Shortly repeating 
simple behavioral 
model (see F1gure 2) 
and beliefs/barriers 
Sharing of experiences with first 
session, rece1ving 'take home' 
message from intervention leader 
Reflecting on previous session, 
heanng about content second 
intervention 
'Warm1ng up' : memorizing the 
behavioral model and the 
beliefs/barriers, Inherent 1n the 
group in the first session . 
Rheumatologist can use this 
information 1n his presentation (see 
Sect1on 2.3) 
Concerns determinant(s) and 
intervention objectives 
--- - - ----,--------------
Using methods and techniques 
(see Table 1) 
- --------- ------ ---- ---- -- -- -- -
Beliefs about medication Ml-techniques giving pat1ents more active role than 
(see Table 1) intervention leader, affirming patient's freedom of 
Practical barriers choice and self determination (nobody is obliged to 
(see Table 1) decide to change beliefs or non-adherent behav1or) 
Individual homework assignment, conducted with 
part'lc1pant workbook (guides patients in making re 
evaluating their own beliefs and barriers) 
Personalization of information 
All the intervention objectives in 
Table 1 except for self efficacy 
Repeating information 
Repeating information 
Repeating Information 
Simple behavior model (see F1gure 2) 
Use of PowerPo1nt 
- Table 2 continues-
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-Table 2 continued-
Intervention section 
2.3 . Presentation of 
rheumatologist 
and diSCUSSing 
beliefs I barriers, 
living in the group 
2.4 . Individual input of 
patients regarding 
the1r own beliefs 
and barriers 
2.5 . Closure of second 
SeSSIOn 
Function 
Learning about RA~-nd-;;;-;dication (use) 
from a rheumatologist, companng beliefs 
and barners as mentioned 1n session 1 
w1th mformation of the rheumatologist, 
asking questions to rheumatologist 
Individual patient tells his/her most 
important beliefs about medication and 
practical barriers and places them 1n the 
s1mple behavioral model. other 
participants and mtervent1on leader 
provide fee.dback and solutions 
Providing suggestions about 'what to do 
when medication taking is difficult in 
future' (regardmg barners), evaluating 
sessions, explaining follow-up call 
Concerns determinant(s) and 
Intervention objectives 
(see Table 1) 
Using methods and techmques 
---~·..,....----· - -- -~--,-----
All the Intervention goals in Table Ml-techniques : reflective listening, expressing 
1 except for self efficacy acceptance and affirmation 
Repeatmg information 
Modeling 
All intervention goals in Table 1 
except for knowledge 
Practical barners, self efficacy 
(see Table 1) 
Trustworthy messenger 
Use of PowerPoint and flip-over's of previous 
session 
All mentioned Ml-techniques in Section 3.3 
Simple behavior model 
Modeling 
Personalization of mformation 
Individual input of participants accordmg to 
homework assignment 
All ment1oned Ml-techniques in Section 3.3 
Modeling 
- Table 2 continues-
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------ ---- --- --·-·---=----::-------------:-
lnterventron section Function Concerns deterrninant(s) and 
Follow-up call 
Follow up call by 
intervention leader 
Repeating personal beliefs and barriers 
wrth participant, evaluating effect of 
intervention on adherence 
---- --- ----------
intervention objectives 
(see Table 1) 
Beliefs, practical barriers (see 
Table 1) 
Using methods and techniques 
Ml-techniques: reflective listening, expressing 
acceptance and affirmation, monrtonng readiness 
for change (ensuring not jumprng ahead of 
patrent), affrrmatron patrents freedom of choice 
regarding changrng beliefs and behavior 
Repeating information 
Personalization of information 
Telephone call to the indrvidual patient by 
1nterventron leader 
----------
In sum, using Ml techniques, a pharmacist invited participants to reflect on their 
own concern and necessity beliefs and on practical barriers regarding DMARD use, 
to share those beliefs and barriers with their peers in a non-threatening 
environment and, eventually, to change unrealistic beliefs and to resolve practical 
barriers. For example, one participant believed that her medication was poisoning 
her body. The intervention leader, amongst others, acknowledged that DMARDs do 
have side effects, but he also emphasized that not taking DMARDs as prescribed 
would do even more harm to her body. The other participants' opinions about this 
information were subsequently discussed and, in this way, the participant was 
invited to change her point of view about DMARDs. 
All intervention materials and their function are shown in Table 3. 
Table3 Intervention materials and their function 
Material Function 
----------·-··--·--·- ·--·-· - -- .. ---- --InterventiOn protocol Describes intervention background, content and perform'1ng 'rules' in detail 
Workbook for Is a shorter and more pract1cal version ofthe Intervention protocol, to guide 
intervention leader Intervention leader through the sessions 
Short guide for Gives rheumatologist a quick overview of intervention objectives, so he (or she) 
rheumatologist can place his presentation about RA and medicines in the right context 
PowerPoint To gu1de the sessions There is a presentation for session one, session two and 
presentations for the rheumatologist 
Flip-over's To guide the sessions (giving participants an overview of beliefs and practical 
barriers. inherent in the group) 
Workbook for 
participants 
Th1s workbook contams: 
an overview ofthe 1ntervent1on; 
examples of ex1sting beliefs about medication and practical barners; 
the s1mple, behavioral model; 
the homework assignment; 
detailed information about RA and RA-medication (use); 
space for personal notes and 
important internet links and contact details oft he clinic and clinic 
pharmacy 
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3.4.1. Pilot of intervention 
During the pilot, the expert panel and the patient panel reported that they found 
the provided information easy to understand and that they appreciated the 
motivational interviewing communication style, as they found it to be open and non-
judgmental. Although accuracy of the applied Ml techniques was not checked with a 
validated instrument like MITI [38], the panels observed a consistent application of 
Ml skills during the intervention. Moreover, overall patient satisfaction about the 
intervention was high (see Table 4). Patients thought that the provided information 
was transparent and understandable, and found the atmosphere to be relaxed. 
Table4 
Item 
Pilot results of patient satisfaction questionnaire (N=12, two group sessions piloted twice) 
Median (range) 
Satisfaction about general session charactenstics 
N of sessions too less (0)- too much (6) 
Time between sessions (1 week) too short (0)- too long (6) 
Duration of sessions (1.5 hours) too short (O) -too long (6) 
Group s'1ze too small (0) -too big (6) 
Transparency of provided information 
2.5 (0-4) 
3 (0-3) 
3 (0-5) 
3 (3-4) 
Participant workbook, hard to understand (0)- easy to understand (6) 5 (2-6) 
Information provided by intervention leader (pharmacist) unclear (O) - clear 6 (3-6) 
(6) 
Information provided by rheumatologist unclear (0)- clear (6) 
Communication style characteristics 
6 (4-6) 
'Enough opportunity to d1scuss my own experiences and problems with 5 (J.-6) 
medication', totally disagree (O) -totally agree (6) 
Intervention leader: 
not stimulating (O) -very stimulating (6) 
not listening well to part·lcipants (O) -listening well to part1c1pants (6) 
General atmosphere during the sessions very tensed (O)- very relaxed (6) 
5 (3-6) 
6 (3-6) 
6 (5-6) 
The patients, however, found the number of sessions to be slightly too low. 
Nonetheless, the number of sessions was not increased as the task group wished to 
keep the intervention short. The intervention was, however, adapted in response to 
three concerns expressed by both the expert panel and the patient panel: (1) the 
intervention leader had to give participants more opportunity to express 
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themselves. As a result, the active role of the participant was emphasized in the 
intervention leader workbook; (2) at the start of the intervention, the intervention 
leader should have told participants that it was not compulsory to answer personal 
questions. Apparently, this made participants to feel 'unsafe'. Hence, indicating that 
answering personal questions is not compulsory was explicitly added as action point 
for the intervention leader in the workbook; (3) the rheumatologist's white coat was 
considered undesirable, so the workbook was adapted accordingly. 
3.5. Evaluation of the intervention 
The effects of the intervention will be determined in a single-blind, randomized, 
controlled trial (number in trial register: NCT00968266). 120 eligible, non-adherent 
RA patients (non-adherent defined as taking <80% of medication according to the 
Compliance Questionnaire Rheumatology [21]) were randomized into the 
intervention group or control group. The control group received care as usual in the 
form of a brochure about currently used medication. 
The primary outcome of interest is medication adherence, measured by the 
Compliance Questionnaire Rheumatology [21], the Medication Adherence Report 
Scale [22] and pharmacy refill rates [39,40]. The primary parameter of interest is 
beliefs about medication (measured by the Beliefs about Medicines Questionnaire 
(BMQ [41]). Outcomes and parameters are measured at baseline (questionnaires 
three weeks before start of the experimental and control intervention) and at one 
week, six months, and one year follow-up after the intervention. The results are 
expected to be available in 2013. 
4. DISCUSSION AND CONCLUSION 
4.1. Discussion 
To the best of our knowledge, this is the first study that transparently describes the 
systematic development and content of a short, time-efficient intervention to 
improve medication adherence to DMARDs in non-adherent RA patients. The 
intervention targets the balance between necessity and concern beliefs about 
medication and tends to resolve practical barriers in medication taking. As 
medication non-adherence negatively affects patients' disease activity and quality of 
life, effective interventions to improve adherence are urgently needed. 
The development process of this study had several strengths. lnitia!!y, this is the 
first RA medication adherence intervention in which intervention mapping (IM) has 
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been applied and for which the development process has been thoroughly 
described. IM structured the development process and enabled systematic use of 
theory, empirical evidence, and practical perspectives in the development of the 
intervention. In contrast, most development processes for health interventions are 
characterized by the ad hoc use of theories and empirical evidence [18], or they are 
only marginally described. 
A second strength of our development process was the multidisciplinarity of the 
task group, which enabled use of broad knowledge, experiences and visions. 
Furthermore, sufficient time, staff, and budget were available to allow the task 
group to thoroughly carry out every step of the IM framework. 
A potential limitation of the development process was that it was not as linear as 
proposed by the IM framework. Parts of step 1 (mapping determinants), step 2 
(formulating intervention objectives), and step 3 (collecting health behavior change 
methods and techniques) were performed in a more parallel rather than sequential 
manner. However, we do not believe that this parallel approach has affected the 
quality of our intervention, since designing processes are iterative and recursive in 
nature [42]. Planning models like IM, moreover, are intended to prompt 
intervention developers to ask themselves the appropriate questions and to make 
the appropriate decisions [16]. 
The intervention itself has strong features compared with other motivational 
interviewing-based interventions for medication non-adherence in chronic diseases 
such as HIV [43-46], glaucoma [47], and asthma [48]. In contrast to these 
interventions, our intervention is short and time-efficient: brief interventions might 
be as effective as intensive treatments [49]. Furthermore, and in contrast to other 
studies, we only targeted non-adherent patients. This not only makes our 
intervention more time-efficient, but also makes Ml-based communication during 
the intervention more meaningful. Finally, most previously reported interventions 
target individual patients during several one-to-one meetings, which is more 
expensive and not necessarily more effective than group-based formats [50,51]. 
However, one could argue that a group format might compromise Ml 
effectiveness as the format might prevent each individuals' specific needs from 
being met [14]. Nonetheless, this thought is not in line with the demonstrated 
successes of group-based Ml interventions [31-33]. Moreover, our intervention does 
address individuals' specific needs, for example through the individual homework 
assignment and the discussion of individual beliefs and barriers. 
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Regarding content of our intervention, there is one significant difference with other 
Ml-based interventions for medication non-adherence [43-48]. Although the latter 
do address beliefs, knowledge or barriers regarding medication taking, none 
systematically focus on changing the balance between necessity and concern beliefs 
about medication. Instead, significant effort is put into mapping participants' 
motivation for behavior change and into behavioral goal setting. However, we 
believe that a realistic balance between necessity and concern beliefs about 
medication is necessary and that barriers should be addressed before focusing on 
behavior change. 
The focus on changing the balance between necessity and concern beliefs (in 
addition to resolving practical barriers) is a fairly unique feature of our intervention 
compared to other Ml-based and non-MI-based interventions for non-adherence in 
chronic conditions. Despite the apparent link between beliefs about medication and 
non-adherence [20,23,24,27,28,41,52,53], other interventions fail to (thoroughly) 
target those beliefs [9]. 
A potential limitation of the intervention could be the use of a manual during the 
intervention, as manual-guided Ml might be associated with smaller effect sizes [31]. 
This might occur because, for example, the intervention leaders might end a session 
by drawing up a concrete behavior change plan (as the manual prescribes), 
regardless of whether patients seemed ready to do su, thereby violating Ml itself 
[31]. However, the manual used in our intervention explicitly states that pressuring 
participants to decide on adherence intentions or to make behavior change plans is 
not allowed. In fact, acknowledgement of different needs in individual participants is 
a key feature of our intervention. A major strength of using manuals, moreover, is 
that they facilitate standardization of the intervention. 
4.2. Conclusion 
By applying the IM framework, the task group was able to create a unique, efficient 
and promising intervention to improve medication adherence in non-adherent RA 
patients. In line with other authors [15,18], we believe that the IM framework can 
improve intervention development. Our RCT will indicate whether the intervention 
has desirable effects on beliefs about medication and non-adherence. 
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4.3. Practice implications 
Pharmacists and rheumatologists who performed the intervention found the 
intervention feasible. Moreover, general patient satisfaction about the intervention 
was high according to the intervention pilot data. Thus, if the RCT demonstrates 
sufficient effectiveness ofthis intervention in reducing medication non-adherence in 
RA patients, the intervention could be embedded in clinical practice. 
The content of this paper could serve as guideline for the development of other 
interventions and could thereby contribute to a meaningful integration of theory, 
empirical evidence and practice perspectives in interventions. 
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Effectiveness of a group-based intervention 
to change medication beliefs and improve 
medication adherence in patients with 
rheumatoid arthritis: a 
randomized controlled trial 
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ABSTRACT 
Objective To assess the effect of a group-based intervention on the balance 
between necessity beliefs and concern beliefs about medication and on medication 
non-adherence in patients with rheumatoid arthritis (RA). 
Methods Non-adherent RA patients using disease-modifying anti-rheumatic drugs 
(DMARDs) were randomized to an intervention or control arm. The intervention 
consisted, amongst others, of two motivational interviewing-guided group sessions 
led by the same pharmacist. Control patients received brochures about their 
DMARDs. Questionnaires were completed up to 12 months follow-up. 
Results 123 patients (mean age: 60 years, female: 69%) were randomized. No 
differences in necessity beliefs and concern beliefs about medication and in 
medication non-adherence were detected between the intervention and control 
arm, except at 12 months' follow-up: participants in the intervention arm had less 
strong necessity beliefs about medication than participants in the control arm 
(b: -1.0 (95% Cl:-2.0, -0.1)). 
Conclusion This trial did not demonstrate superiority of our intervention over the 
control arm in changing beliefs about medication or in improving medication 
adherence over time. 
Practice implications Absent intervention effects might have been due to, amongst 
others, selection bias and a suboptimal treatment integrity level. Hence, targeting 
beliefs about medication in clinical practice should not yet be ruled out. 
Keywords 
Medication adherence; beliefs about medication; rheumatoid arthritis; randomized 
controlled trial; motivational interviewing 
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l.INTRODUCTION 
Adherence to disease-modifying antirheumatic drugs (DMARDs) in patients with 
rheumatoid arthritis (RA) is not optimal and ranges from 22% to 107% [1-5]. As non-
adherence can reduce treatment efficacy and can intensify disease activity, pain, 
joint damage and a lower quality of life [6-8], interventions to improve adherence 
are warranted. 
Existing interventions to improve medication adherence in chronic diseases are 
mostly complex and of limited effect [9]. To date, three studies have assessed the 
effectiveness of a medication adherence intervention in RA [10-12]. Only one of 
these studies demonstrated a slight improvement in adherence to D-penicillamine 
following a patient education program [11], but this program was intensive (51 
individuals x seven sessions x 30 minutes). 
Time-efficient and effective adherence interventions are, thus, needed. 
Therefore, we developed a short, group-based intervention to improve medication 
adherence in non-adherent patients with RA using DMARDs [13]. Of the five WHO 
domains comprising possible targets for adherence improving interventions (i.e., the 
socio-economic, healthcare system, condition-related, therapy-related and the 
patient-related domain) [14], our intervention focusses on the patient-related 
domain. It aims to improve adherence by resolving patients' practical barriers to 
taking medication, and by improving patients' individual balance between necessity 
beliefs and concern beliefs about medication. Despite the apparent association 
between these beliefs and medication adherence [15-22], they have seldom been 
the main focus of adherence-improving interventions [13]. 
This randomized clinical trial evaluated the effectiveness of our group-based 
intervention on medication beliefs (primary outcome of interest) and adherence in 
non-adherent patients with RA. 
2. METHODS 
2.1. Design 
This is a single-center, researcher-blinded randomized clinical trial. Participants were 
randomly allocated to two arms at a ratio of 1:1, and were asked to complete 
questionnaires at baseline (TO), and at one week (T1), six months (T2), and one year 
(T3) after the second group session (Section 2.3). In addition to questionnaires, refill 
data were used to assess medication adherence. This trial was approved by the local 
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medical ethical board (CMO 2009/090; NCT00968266), and has been reported 
according to the CONSORT guidelines [23]. 
2.2. Participants and recruitment 
Patient inclusion took place between September 2009 and February 2011 at the Sint 
Maartenskliniek (SMK Nijmegen, the Netherlands), a clinic specialized in 
rheumatology, rehabilitation and orthopedics. 
Consecutive, adult patients having RA for at least one year according to the 2010 
ACR-criteria [24] and using at least one DMARD were screened for eligibility by their 
rheumatologist during regular outpatient visits. Patients with severe mental or 
physical constraints or illiterate in the Dutch language were excluded. Eligible 
patients filled in an informed consent form and questionnaires (including the 
Compliance Questionnaire Rheumatology for adherence assessment (CQR)) [25] at 
home. Subsequently, as we only wanted to include non-adherent patients, patients 
taking ~80% of prescribed medication according to the CQR were telephonically 
invited for trial participation. Interested patients were scheduled for an intake 
meeting with one of the two involved researchers [BvdM/HZ]: trial information was 
discussed and written informed consent was obtained. 
2.3. Interventions 
2.3.1. Intervention arm (arm 1: sessions) 
The systematic development of the intervention (based on the Intervention 
Mapping framework)[26] and its content is published by Zwikker et al. in this journal 
[13]. 
The intervention consisted of two motivational interviewing (MI) guided [27] 
group sessions (one week apart, with 5-7 RA patients), designed to improve 
patients' balance between necessity beliefs and concern beliefs about medication 
and to resolve patients' practical barriers to medication taking. During the 
Intervention Mapping process, beliefs about medication and practical barriers were 
selected as intervention targets by an interdisciplinary expert group, based on a (1) 
literature study, (2) cross-sectional study, and (3) focus groups. Ml was chosen as 
central communication style, amongst others, for its suitability to explore patients' 
individual ambivalence regarding necessity- and concern beliefs about medication. 
Two pharmacists alternately led the pair of sessions. During these sessions, the 
participants made an inventory of their own medication beliefs and practical 
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barriers to take medication. These were non-judgmentally discussed in the group, 
with co-participation of a rheumatologist during the second session. Participants 
were encouraged to provide constructive feedback and solutions. The session closed 
with handing out brochures about the DMARDs that the patients were using. 
Four of nine pairs of sessions were randomly audio-recorded and analyzed: an 
independent assessor checked treatment integrity in terms of potential omission 
errors in the intervention content [28] and the degree of patient-centeredness (or Ml 
'ambiance' as measured with the validated BECCI-instrument [29], see Appendix 1). 
2.3.2. Control arm (arm 2: brochures) 
Participants allocated to the control arm received brochures at home about the 
DMARDs they were using at the time, with a request to thoroughly read the 
brochures. 
2.4. Trial randomization and implementation 
Appendix Figure I presents the randomization and implementation process. 
A blinded, computer-generated randomization list was obtained [BvdB] for 
subjects in permuted blocks of 10 [30]. Based on order of inclusion and availability, 
patients were allocated to one of nine clusters between 2009 and 2011 (one cluster 
consisted of 12-14 patients, half of whom were allocated to arm 1 and the other half 
to arm 2). The researcher was responsible for data collection and - analyses, and 
remained blind to treatment allocation. 
2.5. Measures 
2.5.1. Baseline characteristics (TO) 
Socio-demographic factors measured were age, sex, living with others, educational 
level, and employment status. Clinical factors measured were disease duration and 
physical functioning (such as physical abilities and pain severity, see Appendix Table 1). 
Electronic hospital/pharmacy data were used to assess the types of DMARDs used 
at baseline, and to assess the presence of anti-CCP and rheumatoid factor values in 
the participants (descriptive use only). 
2.5.2. Primary measures (TO, Tl, T2, T3) 
Beliefs about medication were measured using the validated Beliefs about 
Medicines Questionnaire [19], which consists of two parts. Part one, the BMQ 
Effectiveness of an intervention to change beliefs and adherence: RCT I 89 
'specific', has two subscales of five items each, measuring patients' beliefs about the 
necessity of prescribed medication (e.g., "Without my medicines I would be very 
ill"), and their concerns about potential adverse consequences of taking the 
medication. Within the subscales, items are scored from 5 (strongly agree) to 1 
(strongly disagree) and are summed to obtain a total score ranging from 5 to 25. 
Higher scores indicate stronger beliefs. By subtracting the concerns score from the 
necessity score, a necessity-concerns differential score can be calculated (ranging 
from -20 to +20, where positive scores mean that patients perceive that benefits of 
medication outweigh costs, and vice versa). 
Part two, the BMQ 'general', assesses general beliefs about pharmaceuticals as a 
class of treatment [20], and also has two subscales of four items each. The 'overuse' 
subscale includes beliefs about the way in which medicines are endorsed by doctors 
(e.g., "Doctors place too much trust on medicines"). The 'harm' subscale includes 
beliefs about the potential of medication to harm (e.g., "Medicines do more harm 
than good"). The scoring method is identical to the BMQ 'specific': total subscale 
scores range from 4 to 20. 
2.5.3. Secondary measures (TO, Tl, T2, T3) 
Medication non-adherence was assessed with the Compliance Questionnaire 
Rheumatology [25]. The CQR is able to detect whether a patient takes :5: 80% of 
prescribed medication (binary score) with a sensitivity of 62% and a specificity of 
95%. 
Non-adherence was also measured using a dichotomized score of the five-item 
Medication Adherence Report Scale (MARS [31], non-adherent when total score 
:5:23[22,41]) and using pharmacy refill data [42]. Using these data, Medication 
Possession Ratios (MPR: days of DMARD supply divided by the number of days 
within an observation period) were calculated [32]. (Calculation) details about the 
non-adherence measures and other secondary measures that might be affected by 
our intervention [17] are provided in Appendix Table I [33-40]. 
All questionnaires used were validated and had a sufficient level of internal 
consistency in this RA sample (alpha: 0.68-0.95). Reminders were sent to stimulate 
patients to fill in the questionnaires. 
2.6. Sample size and data analyses 
To detect a difference in the BMQ differential score of two points at 12 months' 
follow-up between the two arms [15], we aimed to include 60 participants in each 
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arm (based on an alpha of 0.05, beta of 0.2, a pilot-derived SO of 3.9, and taking 
28% drop-outs into account). 
Data analyses were based on the intention-to-treat principle [23], and on 
complete cases. For all outcomes except refill rates (MPRs), intervention effects 
were analyzed using generalized estimating equations (GEE [43]) with robust 
standard errors [44], two-sided p set at 0.05, and an assumed unstructured 
correlation working matrix. Beforehand, severely skewed outcomes were 
dichotomized (MARS and SIMS, cut-off at 95% of their scales [22,41]). Furthermore, 
one fixed set of confounders was selected from the baseline measures (selected 
when visually unbalanced between the arms [45], univariately associated with~ one 
outcome measure, and when not strongly correlated to other potential 
confounders). Time was handled as a dummy variable [46]. 
Intervention effects as assessed by refill data, and differences between the non-
adherent trial participants and the non-adherent patients who refused to participate 
were tested by means oft-tests (unequal variances assumed) or Chi-square tests. 
Baseline scores of the initial sample and the remained sample at 12 months' follow-
up were compared using standardized mean differences to assess the influence of 
attrition on the study results [47]. All data analyses were verified by a statistician. 
3. RESULTS 
3.1. Participants and attrition 
1819 RA patients were assessed for eligibility; the participant flow trough the trial is 
depicted in Figure 1. The 123 non-adherent, randomized patients did not differ in 
terms of baseline characteristics and outcome measures from the 118 non-
randomized, non-adherent patients. 
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Figure 1 
Plarmed el1g1bility screening by 
meumatQiogistlassistant 
"" 1819 
No questionnaires sent (n = 654): 
No (full) screening by rheumatologist 157 
NoRAor<oneyearRA 110 
No DMARD use 64 
Mental, physical or communicative impairment 110 
1 
Objection rheumatologist, unknown reasons 23 
Objection patient 184 
other 6 
1-----------I>P· Questionnaires sent (n = 1166), but no adherence score 
calculated (n = 327): 
No informed consent 5 
Adherence score calculated 
n"838 
Randomized 
n=123 
Allocated to aiTil 1 (sessions) 
n;63 
Received treatment n = 57 
Did ool receive treatment. n = 6 (2x 
hmdered. 2x ill. 2x too busy) 
I 
Paltents, treated by tntervention 
leader: 
E!vdB n=31 
VH: n=26 
Loss to follow-up: n = 10 
of whom dropped out: n = 6 (reaSQns: 
see 'did not receive treatment', + 1x ill, 
1x personal ctrcumstances 
Included 111 effect analyses 
(intention-to-treat). n = 63 
Participant flowchart 
Allocated to arm 2 (brochures) 
n=60 
R-eceived treatment n = 60 
Loss to follow-up. n = 1 
of whom dropped out n = 0 
Included m effect analyses 
Qntenlion-to..treat): n = 60 
No score needed (sufficient patients included) 32 
Non-response 289 
other 1 
Excluded (n = 716): 
Not eligible (adherent to medication) 597 
Non-adherent <n = 118l but: 
No permission to contact for the trial 20 
Patient refused to participate (after receiving trial 
study information) because of (n = 98): 
content group sessions 5 
personal health/circumstances 13 
too much traveling for group sessions 27 
notime 15 
other I unknown reasons 38 
Overall attrition in the baseline sample up to 12 months after baseline was 8.9%, 
and had no influence on the main outcomes of this study. 
3.2. Baseline sample characteristics 
Most participants were female and lived together with others. A quarter of the total 
sample was highly educated. Also, participants had a mean disease duration of >14 
years (Table 1). 
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Table 1 Baseline study sample characteristics 
CharacteriStics 
Socio-demographic characteristics 
Age (years) 
Female 
Living with others 
t 
Higher education 
Currently employed/studying 
Clinical characteristics 
Disease duration (years) 
n DMARDs used*· § 
1 DMARD 
2 DMARDs 
~3 DMARDs 
Route of DMARD administration 
Oral* 
Parenteral§ 
Rheumatoid factor (positive) 
Anti-CCP (positive) 
RADAI disease activity (0-10)'11 
VAS pain score (G-100 mm)'ll 
HAQ Disability Index (0-3) 'II 
Arm 1 (sesSions) n = 63 
60.4 (12 1) 
4'2 (66.7%) 
44 (72.1%) 
15 (24.6%) 
28 (48.'2%) 
15.3 (105) 
25 (41.7%) 
29 (48.3%) 
6 (10.0%) 
43 (717%) 
41 (683%) 
29 (784%) 11 
24 (727%) 11 
25 (17) 11 
27 2 (192) 
1.0 (0.7) 
Arm 2 (brochures) n = 60 
59.3 (11.3) 
43 (71.7%) 
50 (84.8%) 
15 (25.4%) 
31 (51.7%) 
142 (9.1) 
36 (61.0%) 
17 (28.8%) 
6 (10.2%) 
34(57.6%) 
38 (64.4%) 
30(790%) 11 
24(686%) 11 
25 (19) 11 
268 {21.0) 
0.9 (07) 
. ..- ....... t-··- -------------------
Data are means (SD) or numbers(%). Higher education means having at least a bachelor's or master's 
degree. *Azathioprine, hydroxychloroquine, leflunomide, methotrexate, prednisone/prednisolone or 
sulfasalazine. § Adalimumab, depomedrol, etanercept, methotrexate, abatacept, infliximab, or mabthera. 
Four patients received infusion mono-therapy. 11 >10% missing data. Number of non-missing cases in 
intervention and control arm is 37/38 for the rheumatoid factor, 33/35 for anti-CCP, and 51/52 for the 
RADAI score, respectively. 'IIHigher scores= greater disability I disease activity I pain. 
Descriptive data on all outcome measures at baseline and follow-up are presented 
in Appendix Table II. 
3.3. Effects of the intervention 
Table 2 presents outcomes regarding beliefs about medication and non-adherence 
at baseline and 12 months' follow-up, and the corresponding adjusted effect sizes. 
Effectiveness of an intervention to change beliefs and adherence: RCT I 93 
n 
::,-
OJ 
~ 
ro 
..., 
.!:> 
TO: baseline (n = 119) 
Beliefs about medication 
BMQ specif1c necessity (5-25{' 
BMQ specific concerns (5-25 )'~ 
BMQ differential (-20 to +20)§ 
BMQ general overuse (4-20)* 
BMQgeneral harm (4-20)* 
Medication non-adherence 
CQR, non-adherent 
MARS, non-adherent 
% ref1ll adherence 
Arml 
(sessions) 
18.8 (3 6) 
13.3 (3.4) 
5.6 (4.7) 
110(2.5) 
9.9 (2.5) 
36 (62.1%) 
32 (54.2%) 
944% 
- .-.-·- -~----· 
Arm2 
(brochures) 
18.8 (3.3) 
14.3 (3.3) 
4.6 (4.8) 
11.1 (2.7) 
10.0 (2.6) 
40 (67.8%) 
33 (56.9%) 
103.1% 
T3: 12-month follow-up (n = 115) 
Arml Arm2 
(sessions) (brochures) 
18.2 (3.8) 19.1 (3.3) 
12.8 (3.5) 136 (3.5) 
5.5 (5 .1) 5.5 (4.2) 
10 6 (2 .8) 10.9 (2.5) 
9.8 (2.5) 10.1 (2.3) 
28 (50.9%) 29 (49.2%) 
30 (54.6%) 28 (46.7%) 
966% 102.0% 
-1.0 (-2.0, -0.1)11 
0 .0 (-1.0, 11) 
-11 (-2.4, 0.3) 
-0.2 (-11, 0.7) 
-0 2 (-0.9, 0.5) 
OR(95%0)t 
1.3 (OS, 3.3) 
1.7 (0.8, 3.8) 
Difference in means (95% Cl)~ 
2.2% (-111%, 15.6%) 
Descriptive data are means (SD) or numbers (%). Effect sizes (except for refill rate adherence) adjusted for age, sex, living with others yes/no, disease duration, 
parenteral medication yes/no, and baseline depression score (HADS). t Regression coefficient or odds ratio (OR) with 95% confidence interval for the difference in 
outcome values between the intervention arm and control arm at 12 months' follow-up, corrected for baseline. Control arm = reference category. OR: odds of being 
non-adherent at 12 months' follow-up is smaller (OR <1) or bigger (OR >1) for participants in the intervention arm in comparison with participants in the control arm. 
*Higher scores indicate stronger beliefs. §Positive scores mean that necessity beliefs about medication are stronger than concern beliefs about medication, and vice 
versa . 
11 P value s 0.05. ~The mean change in refill adherence in participants in t he intervention arm minus the mean change in refill adherence in participants in the 
control arm. 
Generally, no differences in BMQ scores were detected between both arms over 
time. Only at 12 months' follow-up, participants in the intervention arm did have 
less strong necessity beliefs about medication than participants in the control arm. 
No differences between the two arms could be detected for other secondary 
outcome measures, except pain and accepting illness cognitions: at one week 
follow-up, participants in the intervention arm reported less pain (adjusted b: -7.8, 
95% Cl -13.7, -1.8), and stronger accepting illness cognitions (unadjusted b: 0.9, 95% 
Cl 0.1, 1.8, adjusted b not significant) than those in the control arm. 
3.4. Additional analyses 
Three additional analyses were performed. 
First, we studied changes in outcomes between the intake meeting and baseline, 
since we noted that non-adherence had changed between these moments 
(decreased from 100% of patients being non-adherent, to 65%). It appeared that the 
balance between necessity - and concern beliefs about medication had improved 
(paired t-test, difference 0.9, 95% Cl -0.0, 1.8). Also, the amount of change in CQR 
adherence in the participants depended on the researchers involved in the inclusion 
procedure (44% of patients included by researcher 'A' became adherent at baseline, 
versus 25% of patients included by researcher 'B'; p = 0.03). This association was 
also reflected in the refill rates: the mean refill rate was 98% at baseline, and 104% 
at 12 months' follow-up in those patients included by researcher 'A', versus 100% 
and 93% by researcher 'B', respectively (p < 0.05, paired two sample t-test). 
Second, in a sensitivity analysis, we found that the direction of our results did not 
change when excluding patients who were medication-adherent at baseline. 
Third, treatment integrity analyses were performed (Appendix I}. 49% of the 
intervention content, as described in the intervention protocol [13] was conducted. 
In practice, participants had a greater need for education about medication than for 
discussions about medication use; the intervention leaders felt it was important to 
serve this need. The degree of patient-centeredness during the intervention was 3.1 
on a scale ofO ('not at all') to 4 ('a great extent'). 
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4. DISCUSSION AND CONCLUSION 
4.1. Discussion 
This study evaluated the effects of a short, group-based intervention, which 
primarily aimed to change the balance in beliefs about medication, and 
subsequently, to improve medication adherence to DMARDs in non-adherent 
patients with RA. However, the intervention was not superior to the control arm in 
changing beliefs or improving adherence. 
Our results are in line with the systematic review by Haynes and colleagues [9], 
which states that most existing interventions to improve medication adherence are 
not particularly effective. However, our results do not correspond with the studies 
by Clifford and Bender [15,48], who found that their telephone interventions elicited 
more positive beliefs about medication and better adherence than the control 
condition. Since baseline measures were missing [15] or no long term effects had 
been examined [48] in these studies, however, our results seem to be more solid. To 
place our results in context, more studies about the effectiveness of targeting 
beliefs about are needed, though. 
There are several explanations for the absence of intervention effects. 
First, there may not have been sufficient room for improvement in beliefs and 
adherence: beliefs and adherence had already favorably changed before the actual 
intervention took place. This might have been due to the phenomenon of 
'regression to the mean' [49], Hawthorne effects [SOL but also to our intake 
meeting [51], a notion supported by the correlation between the change in 
adherence and the two researchers involved during intake. 
Second, although we established a good level of patient-centeredness, the total 
treatment integrity level of our intervention was suboptimal. This might have 
affected our study results. In contrast, it is still unknown to what extent a 
suboptimal treatment integrity level affects treatment outcomes [28], so more 
research into the topic of treatment integrity is needed. 
Third, this trial suffered from selection bias by including patients with a long 
disease duration (mean: >14 years). Modifying existing beliefs and adherence 
behaviors in patients with such a long disease duration might be harder to establish 
than forming new beliefs and behavior in recently diagnosed RA patients who are, 
essentially, busy with adopting a new lifestyle [52]. 
Last, ineffectiveness of our intervention might be due to focusing on patient-
related factors only, while non-adherence is also caused by other types of factors 
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according to the WH0[14]. Targeting beliefs about medication in RA patients, 
however, still remains an understandable choice according to a recent systematic 
review of Pasma et al. [53], indicating beliefs about medication to be one of the 
most relevant and modifiable determinants of non-adherence in RA patients. 
This study has both limitations and strengths regarding internal validity. Non-
adherence rates differ according to the questionnaires and the refill rates, for 
example (60% versus 1,5% non-adherence). The refill rate, however, is a medication 
possession measure, rather than a medication adherence measure [54]. Moreover, 
a strong feature of this trial is the combination of three different adherence 
measures [55]. Neither the self-report questionnaires nor the refill rate data showed 
superiority of the intervention arm over the control arm in changing beliefs or 
adherence, indicating robustness of findings. 
This study has also strengths and limitations regarding external validity. A 
limitation is that we do not know if our non-adherent trial participants represent 
non-adherent RA patients in general, since no comparison material is available. A 
strength was the low attrition rate in our trial [56]. 
4.2. Conclusion 
This trial did not demonstrate superiority of our intervention over the control arm in 
changing beliefs about medication, in improving medication adherence or in 
improving any other secondary outcome measures over time. 
4.3. Practice implications 
Beliefs about medication are relevant and modifiable determinants of non-
adherence in RA patients. Hence, the potential value of targeting beliefs about 
medication and practical barriers to take medication in improving medication 
adherence should not yet be ruled out in clinical practice. Ineffectiveness of our 
intervention, namely, might have been due to selection bias, Hawthorne effects, and 
a suboptimal level of treatment integrity. Further research on other types of 
interventions which are embedded in clinical practice (non-trial setting) and with 
early RA-patients is warranted. 
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Every 
week 
Every 
week 
Tasks of the secretarv 
Assigning tnaatment to patients aooording 
to randomization liSt (in oombinallon with 
Ofder of pabent lllQiusron) 
Dividing pebents mto dusters 
(based on order of mclusion and 
availability of patients) 
4weeks 
before start • 
interventions 
Mailing randomization outoome to 
the individual patients in upcoming 
cluster 
InfOrming ~rcher about patient 
composition af upcom~ng ciU$ler 
(note: researcher remruns blind for 
trealment aDocation) 
3weeks 
before start 
interventions 
1 week Maliing remmder to patients in upoommg 
before start Cluster about the intervention they will 
interventions receive 
In week of 
intervention 
round 
Tasks of the secretarv and intervention leader 
Paberlts !lHocaled to arm 1 I'E!CleiW 
brochure(s} AND atiend group session 1 
homework assignment 
Patients alloeeled to arm 1 attend group 
session2 
Tasks of the researcher 
Sending baseline questioonaire (TO) to 
patients in upcoming round 
Mailtng remtnder about basel1118 
questionnaire to nor..responding patients 
Tasks of the secretarv 
Patients allocated to arm 2 recerve 
brochure(sl at home 
Tasks of the researcher 
1weekafter group session 2 Sending T1 questionnrure to patients in arm 1 and ann 2 (and a reminder, 2 weeks taler) 
8 weeks after 
group session 2 
6 morlths after 
group session 2 
Task of the intervention leader 
Folle1N·UP call to indiVIdual partiCipants 
allocaled to arm 1 
I asks of the researcher 
Sending T2 quesllonnaue to peJ1ents in arm 1 and arm 2 (and a remmder. 2 weeks later) 
12 morlths after group session 2 SendlllQ T3 questronna1re to patients in arm 1 and arm 2 (and a ramtnder, 2 w~ later) 
Appendix Figure I Trial randomization and implementation process 
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Appendix Table I Outcome measures 
Outcome _mea_ s_u_re_s-......,Qu,...-estJ--. onnalre/lrlstr-um_e_n_t--D"escriptlon 
-· ·---- ·-- ----··---
Medication non- Compliance Questionnaire 
adherence Rheumatology[25] 
Med1cat1on non-
adherence 
Medication non-
adherence 
RA disease activity 
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Medication Adherence 
Report Scale[31] 
Dispensing data from both 
community pharmacies 
and the hospital's 
outpatient pharmacy[32] 
Rheumatoid Arthrit'ts 
Disease Activity Index 
(RADAI)[33] 
Validated with the Medtcation Electronic 
Monitoring System in RA patients. The CQR has 19 
items which reflect statements about drug-tak"tng 
behavior. Items are scored on a scale ranging from 
1 (don't agree at all) to 4 (agree very much) Items 
4, 8, 9, 11, 12 and 19 have to be reversely 
recoded. Miss·tng "ttems are subst"ttuted with the 
patient's average on all non-missing items when 
the amount of miss"tng items ts smaller than four; 
otherwise, no score is calculated. To obtain a 
dichotomous CQR non-adherence score, first a 
discrimtnant Z-score has to be calculated by 
means of a funct'ton (for example Z-score =-
• • + 
3 4777 ~ (04448 cqr1)- (0 9517 cqr2) 
(16758 cqr3), etcetera) Non-adherence "ts 
defined when subjects have a Z-score < -05849. 
Five ttems, including statements about stopping, 
forgett"tng or altering medication doses, scored on 
a 5-point scale ranging from 1 (always true) to 5 
(never true) Items are summed to obtain a total 
score ranging from 5-25, were htgher scores mean 
better adherence. 
Two Medication Possession Rat'tos were calculated 
per patient, per DMARD The MPRs were 
calculated as the total of number of days of 
DMARD supply from the first to the last dispense 
date (excluding days' supply on the last date) 
wtthin an observation period of 365 days before 
(the first MPR) or 365 after (second MPR) the 
intervent'ton, divided by the number of days from 
the ftrst to the last dispense date within the 
observation period. If a patient was us"tng multiple 
DMARDs, MPR values within a single observation 
period were averaged. 
Five items, measuring global disease activity/pain, 
current duration of morning stiffness, and current 
tender JOints Score range 0-10, with higher 
scores indicating more disease activ"tty 
-Appendix Table I continues -
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OutcOOieffieasures Questionnaire/Instrument Description 
------·-----.. --- ··-- -·- ·--- ·---
Patient's usual Health Assessment 20 1tems, measuring eight dimensions of 
abilities in past Questionnaire Disability functioning (dressing and grooming, arising, eating, 
week Index (HAQ-DI)[34] walking, hyg1ene, reaching, gripping, and common, 
daily activities) . ~ix dimensions need a valid score 
to obtain the total score . Score range 0-3, with 
higher scores indicating more disability Note that 
we took aids and devices Into account in calculating 
the HAQ-DI score 
Pain severity 
Satisfaction with 
information about 
medicines 
Illness cognitions 
Self-efficacy 
Anxiety and 
depression 
HAQ v1sual analogue scale 
(vas)[34,35] 
Satisfaction with 
Information about 
Medicines Scale (SIMS)[36] 
Illness Cognition 
Questionnaire (ICQ) [J7] 
Arthritis Self-Efficacy Scale 
(UVR) [38,39] 
Hospital Anx1ety and 
Depression Scale 
(HADS)[40] 
Scale range 0 mm (no pain) to 100 mm 
(unbearable pam) 
17 items, measuring the extent to which patients 
feel they have received enough information about 
prescribed medicines. Score range 0-17, with 
higher scores indicating h1gher overall satisfaction. 
We dichotomized the score at 95% of its scale 
(satisfied when total score :5:15) . Next to a total 
score, the SIMS has two suhscales, respectively 
identifying a pat1ent' s satisfaction with information 
about the act1on and usage of medication 
Three subscales of six items each, measuring 
'helplessness' as a way of emphasizing the aversive 
meaning of a d1sease, 'acceptance' as a way to 
diminish this aversive meaning, and 'perceived 
benefits' as a way of adding a posit1ve mean1ng to a 
disease. Score range 6-24, w1th higher scores 
indicating more helplessness, acceptance, 
perceived benefits 
Measures the patient's perce1ved ab11ity to perform 
spec1fic behav1ors a1med at controlling disability. 
The UVR has three subscales self-eff1cacy related 
to physical funct1on (8 Items), to coping with pam (5 
items), and to coping with other symptoms 
associated with arthritis (such as depression and 
fat1gue, 6 1tems). 
Score range 1-5, w1th higher scores lnd1cat1ng 
stronger self-efficacy 
14 1tems Total score range: 0-42, w1th higher 
scores indicating a higher degree of 
anxiety /depression. 
The HADS has two subscales, one for anxiety and 
one for depression, with 7 items per scale. Subscale 
score range 0-21; subscale scores higher than 8 are 
indicative for anx;ety or depression 
...... ... --.---··-·--·-· - -------------------------------
All items in a questionnaire need a valid answer to obtain a total score, unless mentioned otherwise 
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f-' Appendix Table II Scores for primary and secondary outcome measures at baseline and follow-up 0 
n Measures TO: baseline (n = 119) Tl: 1 week follow-up (n = 115) T2: 6 months follow-up {n = 115) T3: 12 months follow-up (n = 115) 
::T 
ru Arm1 Arm2 Arm1 Arm2 Arm1 Arm2 Arm1 Arm2 "0 
rl-
~ (sessions) (brochures) (sessions) (brochures} (sessions) (brochures) (sessions) (brochures) 
-J>. 
n score n score n score n score n score n score n score n Score 
Primary 
outcome 
measure 
Beliefs 
about 
medtcatian 
BMQ 59 18.8 60 18.8 55 19.1 60 19 0 55 19.0 60 19 0 55 18.2 59 19.1 
specific (3 .6) (3 .3) (31) (3 0) (3.4) (3 .1) (3.8) (3.3) 
necessity 
(5-25) t 
BMQ 59 13.3 60 14.3 55 12.8 60 13.5 54 12.8 60 14.0 55 12 8 59 13.6 
specific (3.4) (33) (3 .8) (3.8) (3.8) (3.6) (3.5) (3.5) 
concerns 
(5-25) t 
BMQ 59 5.6 60 4.6 55 62 60 5.5 54 6.2 60 4 .9 55 5.5 59 5 .5 
differential (4 .7) (4.8) (5 .0) (4.5) (4.6) (4.7) (5 .1) (4 .2) 
(-20tlll 
+20)* 
- Appendix Table II continues -
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- Measures .. - - --· - 10: baseiiiie(n,;. i19)- -- - - Ti~i week tollov;uj) (n., iiS)____ - 12; 6'months fonow~p(n .. tis) ___ __ T3. ii months touow-up (n-;;;"iiS) 
BMQ 
general 
overuse 
t (4-20) 
BMQ 
general 
harm 
(4-20) t 
Secondart 
outcome 
measures 
Med1catton 
non-
adherence 
Arm1 
(sessions} 
n 
58 
58 
score 
110 
(2 .5) 
9.9 
(2.5) 
Arm2 
(brochures) 
n 
59 
58 
score 
111 
{2 .7) 
10.0 
(2 .6) 
CQR, non- 58 36 59 40 
adherent (62 .1%) {67.8%) 
MARS, non- 59 32 58 33 
adherent (54.2%) {56.9%) 
%refill 58 94.4% 57 103.1% 
adherence 
n 
55 
Arml 
(sessions) 
score 
10.7 
(2 .6) 
55 9.9 
(2.6) 
Arm2 
(brochures) 
n 
59 
59 
score 
109 
(28) 
10.0 
(2.6) 
55 30 60 40 
{66.7%) (546%) 
55 30 60 
(54.6%) 
28 
{46.7%) 
n 
54 
54 
55 
55 
Arml 
(sessions) 
score 
110 
(2 .8) 
9.8 
(2.4) 
Arm2 
{brochures) 
n 
59 
59 
score 
11.2 
(3.1) 
103 
(2.7) 
28 58 33 
{569%) (509%) 
27 59 
(494%) 
33 
{55 .9%) 
n 
55 
55 
55 
55 
56 
Arml 
(sessions) 
score 
10.6 
(2 .8) 
9.8 
(2.5) 
28 
{50.9%) 
30 
{54.6%) 
96.6% 
Arm2 
(brochures) 
n 
60 
58 
Score 
10.9 
(2 .5) 
10.1 
(2.3) 
59 29 
(49.2%) 
60 28 
(46.7%) 
57 102.0% 
- Appendix Table II continues -
"""' -Appendix Table II continued:::: ___ 
"""' N 
Measures TO: baseline (n = 119) n : 1 week follow-up (n = 115) T2; 6 months follow-up (n = 115) T3; 12 months follow-up (n = 115) 
(') 
::::,-
OJ Arm1 Arm2 Arm1 Arm2 Arm1 Arm2 Arm1 Arm2 
"0 
M (sessions) (brochures) (sessions) (brochures) (sessions) (brochures) (sessions) (brochures) ~ 
.j:>. 
n score n score n score n score n score n score n score n Score 
Cit meal 
characteristics 
RADAI d1sease 51 2.5 52 2.5 48 2.4 51 2.7 48 2.2 54 2.6 51 2.0 56 2.3 
activity (1 .7) (1 .9) (16) (1.8) (1 .8) (1 .8) (1.5) (1 .7) 
(0-10)t 
VAS pa1n 57 27.2 59 268 53 22 .3 58 31.9 54 24.8 59 26.8 54 25 .1 60 26 2 
score (19.2) (21.0) (18.5) (21.9) (19.8) (19.3) (20.0) (20.6) 
(G-100 mm) t 
HAQ D1sab1lity 57 1.0 58 0.9 55 1.0 59 1.0 55 1.0 60 0.9 55 10 57 1.0 
Index (0-3} t (0.7} (0.7} (0.7} (0.7} (0.7} (0.7} (0.7} (0.7} 
Cognitive and 
psycho/ogtcal 
factors 
SIMS 56 22 57 19 51 27 59 24 51 31 56 34 55 31 55 29 
(satisfaction (39 .3%} (33.3%) (52.9%} (40.7%} (60.8%) (60.7%} (56.4%} (52.7%} 
with 
information) · 
Satisfied in 
general 
· Appendix Table II continues -
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Measures TO: baseline (n = 119) Tl: 1 week follow-up (n = 115) T2: 6 months follow-up (n = 115) T3: 12 months follow-up (n = 115) 
---- ··- ···· · 
Arml Arm2 Arml Arm2 Arml Arm2 Arml Arm2 
(sessiOns) (brochures) (sessions) (brochures) (sessions) (brochures) (sessions) (brochures) 
m n score n score n score n score n score n score n score n Score ~ 
- -·--·-· ·-· ------· a with info 56 34 57 2.9 51 36 59 41 51 38 56 42 55 47 55 37 
< 
about act10n (85.5%} ro (60.7%) (50.9%} (70.6%} (69.5%} (74.5%} (75 .0"/o) (67.3%) 
:::J 
ro and usage of V> 
V> 
medication 0 
_, 
Ill with ·info 56 28 57 2.4 51 29 59 n 51 35 56 37 55 34 55 30 :::J 
:::J about (50.0%} (42.1%} (56.9%} (45 .8%} (68.6%} (66.1%} (61.8%) (54.6%} 
..... 
~ potential 
< problems ro 
:::J 
d. 
0 
With 
:::J medication 
..... 
0 
n ICQIIIness 59 9.9 59 10.6 53 9.5 59 107 55 9.4 60 10.3 54 9.5 60 10.5 
:::r 
cognitions (2 .9} (2 .8} (2 .7} (3 .2} (2 .8} (2 .6} (2 .8} (2 .9} OJ 
:::J 
(6-24} :t ()Q ro 
o- helplessness ~ 
ro Vi, 
OJ acceptance 57 18.2 58 
:::J 
17.7 53 18.6 59 16.9 55 19.1 57 17.5 54 18.6 59 17.5 
Q_ 
OJ 
(3 7) (39} (3.5} (38} (3.4} (4.1} (3 .4} (4.0) 
Q_ 
:::r 
ro 
ro 
:::J perceived 59 13.2 56 140 55 13.8 60 14.1 55 13.8 59 14.4 52 13.9 59 14.1 n 
!1? benefits (4.7) (4.6} (4.9} 
:;lJ 
(4 .6} (5 .0} (4 .8} (4.7} (5 .1} 
(') 
-l 
-Appendix Table II continues -
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-J>. 
Measures TO: baseline (n = 119) 
n 
Tl: 1 week follow-up (n = 115) T2: 6 months follow-up (n = 115) T3: 12 months follow-up (n = 115) 
:::r 
QJ Arm1 Arm2 Arm1 Arm2 Arm1 Arm2 Arm1 Arm2 
""0 
.... (sessions) (brochures) (sessions) (brochures) (sessions) (brochures) (sessions) (brochures) ~ 
-J>. n score n score n score n score n score n score n score n Score 
UVR self- 59 3.7 60 3.5 55 3.8 60 3.5 55 36 60 3.5 55 37 59 3.5 
efficacy (0.8) (0.8) (0.7) (0.8) (0.8) (0.8) (0.9) (0.7) 
t (1-5) : 
pa in 
physical 59 4.0 60 4.1 55 4.1 60 4.1 55 4.1 59 4.0 55 4.0 60 4.1 
functioning (0.8) (0.9) (0.9) (0.9) (0.9) (1.0) (09) (1.0) 
symptoms 59 4.1 60 38 55 4.1 60 3.9 55 4.1 60 3.8 55 4.1 60 3.9 
(0.7) (0.7) (0.6) (0.7) (0.6) (0.7) (0.7) (0.7) 
HAD5 59 7.0 60 8.8 55 6.2 60 9.1 55 7.3 59 8.1 54 7.5 59 8.3 
anxiety and (4.5) (6.8) (4.9) 
t 
(6.3) (5 .9) (6.0) (5.3) (5.7) 
depression : 
total score 
(0-42) 
Anx1ety 59 3.9 60 4.6 55 3.2 60 4.7 55 3.9 59 4.4 54 4.2 59 4.3 
(0-21) (2.8) (4.0) (2.8) (3.8) (3.4) (3 .5) (3.5) (3 .2) 
depression 59 3.1 60 4.1 55 3.0 60 4.4 55 3.4 59 3.7 54 3.4 59 40 
(0-21) {2 .5) (3.4) (2.7) (3 2) (3.0) (3.1) (2.5) (3.2) 
- · - - f --·- . -- · 
Data are means (SD) or numbers(%). Higher scores indicate stronger beliefs, more disability I disease activity I pain, more helplessness, acceptance, perceived 
benefits I stronger self-efficacy concerning pain, physical functioning and other symptoms I more anxiety and depression (score> 8 =psychiatric condition). 
*Positive scores mean that necessity beliefs about medication are stronger than concern beliefs about medication, and vice versa. 
Part two 
Exploring on K)e!iefs about rnedication 
to improve adherence in pot1ents vvl'!·h 
rr1eurT1atoid arthritis 

Chapter 5 
Psychosocial predictors of 
non-adherence to chronic medication: 
systematic review of longitudinal studies 
Z:wikker HE, von den Bemi SJ, Vriezeko!k JE, 
van c~e·n 1:ndt3 Ci-L vc~n l)uirnen S. 
ABSTRACT 
Objectives Several cross-sectional studies suggest that psychosocial factors are 
associated with non-adherence to chronic preventive maintenance medication 
(CPMM); however, results from longitudinal associations have not yet been 
systematically summarized. Therefore, the objective of this study was to 
systematically synthesize evidence of longitudinal associations between 
psychosocial predictors and CPMM non-adherence. 
Materials and methods PUBMED, EMBASE, CINAHL and PsychiNFO databases were 
searched for studies meeting our inclusion criteria. The reference lists and the lSI 
Web of Knowledge of the included studies were checked. Studies were included if 
they had an English abstract, invo.lved adult populations using CPMM living in 
Western countries, and if they investigated associations between psychosocial 
predictors and medication non-adherence using longitudinal designs. Data were 
extracted according to a literature-based extraction form. Study quality was 
independently judged by two researchers using a framework comprising six bias 
domains. Studies were considered to be of high quality if ~four domains were free of 
bias. Psychosocial predictors for non-adherence were categorized into five pre-
defined categories: beliefs/cognitions; coping styles; social influences and social 
support; personality traits; and psychosocial wellbeing. A qualitative best evidence 
synthesis was performed to synthesize evidence of longitudinal associations 
between psychosocial predictors and CPMM non-adherence. 
Results Of 4,732 initially-identified studies, 30 (low-quality) studies were included in 
the systematic review. The qualitative best evidence synthesis demonstrated limited 
evidence for absence of a longitudinal association between CPMM non-adherence 
and the psychosocial categories. 
The strength of evidence for the review's findings is limited by the low quality of 
included studies. 
Conclusions and implications of key findings The results do not provide psychosocial 
targets for the development of new interventions in clinical practice. This review 
clearly demonstrates the need for high-quality, longitudinal research to identify 
psychosocial predictors of medication non-adherence. 
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Keywords 
Medication adherence; psychosocial factors; systematic review; longitudinal studies; 
somatic, chronic diseases 
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INTRODUCTION 
In conditions such as rheumatoid arthritis, diabetes, and hypertension, long-term 
therapy with chronic preventive maintenance medication (CPMM) is essential for 
reducing risks of disease progression, comorbidity, and mortality. However, 
sufficient medication adherence to CPMM is a prerequisite for reducing these risks.1 
Medication non-adherence, or the extent to which patients do not take their 
medications as agreed with their healthcare provider, averages 50% among patients 
suffering from chronic diseases in developed countries.2 Non-adherence can result 
in poorer health outcomes and a lower quality of life in patients.3 For example, 
patients who did not adhere to beta-blocker therapy were four and a half times 
more likely to have complications from coronary heart disease than those who did 
adhere to therapy.4 Non-adherence also affects healthcare utilization. For instance, 
poorer adherence among elderly patients with moderate-to-severe asthma was 
associated with a 5% increase in annual physician visits, whereas better adherence 
was associated with a 20% decrease in annual hospitalization.5 
Considering the undesired consequences of non-adherence to CPMM, 
interventions are needed to improve medication non-adherence. According to the 
World Health Organization (WHO), possible targets for these interventions can be 
divided into five domains:2 socio-economic factors, healthcare system factors, 
condition-related factors, therapy-related factors, and patient-related factors. 
Although none of the factors within these domains are consistently associated with 
non-adherence across conditions, some tend to be better predictors of non-
adherence than others (like poverty, the nature of the disease, and side effects)Y 
Also, psychosocial factors like beliefs about medication, self-efficacy, and social 
support could be promising intervention targets. These are mostly modifiable (in 
contrast to factors like poverty or side effects), and according to reviews about 
cross-sectional studies, they appear to be associated with non-adherence in various 
somatic, chronic conditions. 6-13 Beliefs about medication were the most powerful 
predictors of adherence (among demographic and medical factors) in one cross-
sectional study,9 while another cross-sectional study identified low-self-efficacy as a 
significant predictor of non-adherence across different countries, for example. 11 
However, there is no insight into psychosocial factors predicting non-adherence in 
longitudinal studies with a longer follow-up period (<::3 months). Such knowledge 
would be helpful in designing effective adherence interventions in clinical practice. 
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This is the first review which aims to systematically synthesize evidence of 
longitudinal associations between psychosocial predictors and CPMM non-
adherence across adult patients living in Western countries. Since non-adherence 
literature is scattered across diseases/4 we combined studies from various somatic, 
chronic conditions to increase the robustness of our findings. 
METHODS 
PRISMA-guidelines were followed in performing this systematic review. 15 The steps 
taken regarding data searches, study selection, data extraction, study quality 
assessment, data synthesis, and data analyses are elaborated below. 
Data sources and searches 
In March 2011, according to a pre-defined search strategy, four electronic databases 
(PUBMED, EMBASE, CINAHL and PsychiNFO) were searched for studies up to 
February 2011. With this search, a first set of studies was included; the reference 
lists of these studies were hand searched to find additional studies. The studies were 
also entered into the lSI Web of Knowledge citation index (August 2011). The 
resulting list of studies, citing one of the initial included studies in our review, was 
also searched. 
The search strategy (see Supplemetary materials) contains key words on 
medication adherence, chronic somatic diseases, adults, longitudinal designs, and 
Western countries. Countries in Africa, Latin-America, South-America, Asia 
(excluding Indonesia and Japan), and Turkey were considered as non-Western 
according to Statistics Netherlands.16 Non-Western countries were excluded, 
because underlying mechanisms of medication non-adherence could differ from 
those in Western countries due to socio-economic and cultural differences.17 
In this review, we focused on two of the three components of adherence (ie, on 
initiation and implementation adherence, thus the extent to which a patient's actual 
medication dosing regimen corresponds with the prescribed dosing regimen from 
initiation to last dose). We did not include discontinuation of medication.1 
As using CPMM terms in the search strategy was unfeasible, we used the 
corresponding diseases for which the CPMMs were prescribed as search terms 
instead. The disease terms were selected as follows: 
1. Chronic preventive maintenance medications were defined. CPMMs were 
regarded as drugs that 1) are intended to be used chronically to prevent the 
Psychosocial predictors of non-adherence: systematic review of longitudinal studies I 121 
occurrence or worsening of a disease or its complications; and 2) may have an 
immediate effect, but must also have a long-term effect {>3 months). 
2. From the full November 2010 Anatomical Therapeutic Classification System 
{ATC)-7 medication list of drugs available in the Netherlands, 246 CPMMs 
{Supplementary materials) were independently selected by two pharmacists 
{BvdB and VH). There was an initial agreement of 96% on medications being 
CPMM. Disagreements were resolved by discussion between the pharmacists. 
3. Disease indications for the 246 CPMMs were subsequently clustered by BvdB 
according to the International Classification of Diseases {WHO). Finally, 20 
disease terms were used in the search strategy. 
Study selection 
Studies were selected based on the criteria in Table 1. 
Studies exclusively recruiting subpopulations in special conditions {like prisoners, 
pregnant women) were excluded. Their results only pertain to a specific group of 
patients, therefore, including them might have introduced bias into this systematic 
review. 
Two reviewers {BvdB and HZ) independently assessed studies for eligibility in two 
phases: 1) screening based on title and abstract; and 2) screening based on full text. 
Disagreements between BvdB and HZ were resolved by discussion; a third reviewer 
{CvdE) made decisions in case disagreements could not be resolved. Studies in 
Spanish or Portuguese were judged by LvdA. During the study selection process, 
three authors were contacted about statistics, outcome measure, or study design to 
determine eligibility for this review.20-22 
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Table 1 Inclusion and exclusion criteria 
Domain 
Study population 
Study types 
Outcome measure 
Inclusion cnterta 
Study population ~ 18 years, living in a Western country and using 
chronic preventive maintenance medication for one or more somatic, 
chrome conditions as specified m the search strategy 
Longitudinal retrospective or prospective study design, at least 
exam1nmg associations between predictor 'X' measured at baseline and 
outcome 'Y' measured ~three months after baseline t 
Med ication non-adherence is (one of) the primary outcomes of the 
study. All adherence instruments (eg, different questionnaires, refill 
data, MEMS) are el1g1ble for inclusion 
Exdusion artena 
Stud1es exclusively recruiting subpopulations in special 
. . 
cond1t1ons, like alcohol addicts, prisoners, pregnant women 
Study is cross-sectional, controlled trial, case report, 
(systematic) review, meta-analysis, editorial, letter. 
comment, mterview, newspaper article, case-control study, 
. . 
intervention study, thes1s or validation study 
Outcome is discontinuation of medication 
- Table 1 continues-
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Domam 
Psychosocial predictors 
Other 
lndusion criteria 
Psychosocial predictors are defined as predictors, pertaining to the 
influence of social factors on an individual's mmd or behavior, and 
to the interrelation of behavioral and social factors18 
The term 'psychosocial' also covers mternal, psychological 
predictors (eg, anxiety) 1n this systematic review. 
All predictor instruments (eg, different quest1onna1res I scales) are 
eligible for mclusion 
English abstract available* 
Exdusion criteria 
Predictors measuring addiction to stimulating agents, psychosocial 
co-morbidity (eg, diagnosed depression according to DSM-IV 
criteria, and cognitive impairment Illness symptoms, however, like 
depressive mood states and anxiety, are included in the rev1ew), 
socio-demograph1cs, knowledge, cognitive status, behavior, 
satisfaction about treatment and health care, overall outcome 
measures (eg, social funct1on1ng of patient, general health status, 
perce1ved quality of life, behavioral intentions), predictors outside 
. 
perception of md1v1dual patient (eg beliefs of physicians) 
In addition, predictors for which was unclear what they measured 
(eg, 'HIV-mastery'19 or 'coping' without specifying the type of 
coping); predictors for which results had not been reported in 
stud1es 
No English abstract available, unpublished studies wh1ch could not 
be retrieved after substantial efforts 
These criteria were formulated during the selection process. We did not exclude subpopulations based on socio-demographic features. Veterans or government 
employees, for example, are not in a 'special' condition per se. 
t 
When the outcome is measured multiple times after baseline, and one summary measure over the total, observational time after baseline is calculated, than the 
observational time should be at least 6 months. For example, studies measuring daily adherence for 3 months after baseline, and calculating one summary adherence 
measure for a patient over these 3 months are excluded, because the mean time point of the summary adherence measure is 1.5 months after baseline. 
*Please note that studies of all languages are eligible, but at least an English abstract should be available. 
Abbreviations: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; HIV, human immunodeficiency virus; MEMS, medication event 
monitoring System. 
Data extraction and quality assessment 
For data extraction, a literature-based, standard form was developed.23' 24 
Information regarding study setting, design, descriptive statistics, measures, and 
analysis were extracted by HZ; BvdB arbitrarily selected 15% of the included studies 
to check appropriateness of all extracted data of these studies, and also checked all 
doubts indicated on the form by HZ. 
If multiple adherence measures were presented in one study (eg, about dosing, 
timing, or taking medication)25, we only extracted data about taking medication. 
Two authors were contacted during the extraction process to check the duration of 
a follow-up period of ~3 months26 or to explain ambiguities.19 
We adapted the framework developed by Hayden et al27 to judge methodologic 
study quality. Our framework contained 23 items divided into six bias domains: 
study participation, study attrition, prognostic, outcome and confounding 
measurement, and analyses. Each item was scored as 'yes' (no unacceptable 
amount of bias introduced), 'partly' (unsure) and 'no' (unacceptable amount of bias 
introduced). For every bias domain, a transparent method was used to reach overall 
judgment about the presence or absence of bias (see Table 51). Studies with ~four 
domains judged as 'yes' were considered high-quality studies; studies with <four 
domains were considered low-quality studies. 
Using three randomly selected studies not included in the review, the framework 
was piloted by BvdB and HZ, who also performed the actual quality assessment. 
Disagreements were resolved by discussion and, when necessary, a third reviewer 
[CvdE] made final decisions. On the domain level, a weighted extent of agreement 
between BvdB and HZ (quadratic weighting scheme) was calculated due to the 
ordinal nature of the scores.28' 29 
Data synthesis and analysis 
Because over 70 non-identical psychosocial predictors (non-identical by name 
and/or measurement instrument) were studied in this review, and because of the 
variety of instruments used to measure non-adherence, a qualitative instead of a 
quantitative analysis was considered to be appropriate.30 Therefore, the results 
regarding associations between psychosocial predictors and medication non-
adherence were qualitatively synthesized in four steps. 
In step 1, psychosocial categories were formulated. Initially, all psychosocial 
elements as mentioned in general health behavior models and theories31' 32 were 
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listed (HZ). Subsequently, based on consensus, the elements were clustered by HZ 
and three psychologists (SvD,JV,LK) resulting in the categories of Figure 1. 
A Beliefs and cognitions 
I about medication and treatment 
II about illness 
Ill regarding self-efficacy & locus of control 
B Coping styles 
I task-onented 
II emotion-oriented 
C Social influences & social support 
I regard1ng med1cal caregiVer 
II regarding friends & family 
Ill in general 
D Personality tra1ts 
E Psychosocial weUbeing 
I mood state 
II perceived stress(ors) 
Figure 1 Psychosocial categories 
Next, the psychosocial predictors within the studies of the review were assigned to 
one of the categories in Figure 1 (HZ and the psychologists). In this way, the 
considerable number of single, non-identical predictors was dealt with. 
In step 2, for each psychosocial predictor within a category and within a study, 
the presence of a significant univariate and multivariate association with medication 
non-adherence was determined (see Table 52). Statistical significance was set at 
P<0.05. 
In step 3, results within studies were synthesized per psychosocial category. 
When ~75% of variables within a single psychosocial category were significantly and 
consistently (ie, same predictors in same direction) associated with non-adherence, 
a 'yes' was assigned (ie, association present). When ~75% of variables were 
significantly, but inconsistently, associated (eg, four of five predictors in category 
about depressive symptoms, of which two are positively related to non-adherence 
and two are negatively related), the term 'conflicting' was assigned. When <75% of 
variables were significantly and consistently associated, a 'no' was assigned. 
Multivariate results were preferably used to synthesize results in this step. When 
multivariate results were not reported, univariate results were used. 
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In the fourth and final step, a best evidence synthesis (BES) per psychosocial 
category between studies was performed to summarize evidence of longitudinal 
associations between the predictors in the psychosocial categories and medication 
non-adherence. We defined four levels of evidence as used in previous reviews of 
longitudinal studies:69-71 
1. Strong evidence: consistent findings (~75% of studies within psychosocial 
category report same conclusion about association; ie, 'yes, present' or 'no, not 
present') in at least two high-quality studies. 
2. Moderate evidence: consistent findings in one high-quality study AND at least 
two low-quality studies. 
3. Limited evidence: findings in one high-quality study OR consistent findings in at 
least two low-quality studies. 
4. Conflicting evidence: inconsistent findings in at least two studies irrespective of 
study quality (ie, <75% of studies report same conclusion about association). 
Note that this level of evidence was checked first before assigning strong, 
moderate or limited evidence level to a category. 
The level of evidence was undeterminable when ~one study of low quality was 
available for a psychosocial category. 
Sensitivity analyses were performed to examine the robustness of findings, 
regarding the cut-off point for methodological quality, diseases, adherence 
measurement, and statistical analyses (ie, focusing on univariate analyses only). 
Also, an additional analysis on single predictors was carried out, since associations 
between single predictors like 'avoidance coping' and non-adherence could be 
overshadowed by combining them into a single category with generally non-
significant psychosocial predictors, such as hopelessness and confusion. Three steps 
were taken: 1) all significant predictors (p~0.05) were listed; 2) each of these 
predictors was grouped with identically named, significant and non-significant 
predictors; and 3) when at least two studies were available for those predictors, the 
BES rules were applied. 
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RESULTS 
Study inclusion 
Of 4,732 non-duplicate references, 30 met our inclusion criteria (Figure 2).19' 25' 26•33-
36'38'39.42-49'51-60'64-66 In all, 1,255 records were identified by screening the reference 
lists and the lSI Web of Knowledge citation index of the initial included studies. 
Initially, the percentage of agreement regarding the eligibility of studies was 86% 
(of the 272 studies selected on title and abstract, agreement was obtained in about 
235 studies after reading the full text. Disagreements were mainly due to 
misconceptions about psychosocial predictors (eg, clinically diagnosed depression 
versus symptoms of depression), study design, and adherence measure (ie, 
discontinuation or execution adherence). For one study,56 disagreement could not 
be resolved by discussion and thus a final decision was made by CvdE. 
Figure 2 
Records tdenlified by 
database search 
n = 3665 
v 
Records Identified by cdabon ondex and 
hand search 
n = 1255 
Double records removed 
n= 188 
~ 
Did not meet 
Records screened on tttle and abstract Records excluded inclusion criteria : 
--+ n = 4459. II Study not 
n = 4732 n = 4460 available: n = 1 
FuH-text arttcles assessed for eltglb tlrty 
n=272 
Full-text articles meeting selection 
cntena / tncluded 
n = 30 
Flowchart of study inclusion process 
Full-text artiCles 
excluded 
n =242 
Abbreviation : CPMM, chronic preventive maintenance medication 
No longitudinal 
study design or too 
short follow-up 
period (< 3 months): 
n = 141 . 11 No 
psychosocial 
predictors: n : 31 II 
Type of adherence 
measure {eg, 
discontinuation, 
persistence): n = 
2611 Adherence not 
primary outcome 
measure: n = 15 II 
<18 years: n = 12 1/ 
No CPMM: n = 6 11 
Living in non-
Western country: n 
= 4 II No somatK:, 
chronic disease as 
specified in search 
strategy: n = 2 II 
Other (eg, thesis): n 
=5 
128 I Chapter 5 
Study characteristics and quality assessment 
Table 2 displays study characteristics, measures, and results. A comprehensive table 
of measures and results is presented in Table 52. 
The included studies (all based on different data sets) covered CPMMs for 
asthma, diabetes, heart diseases/hypertension, human immunodeficiency virus 
(HIV), and organ transplants. Medication type was not explicitly mentioned in four 
studies/8'39.48' 66 but we assumed CPMM was used since CPMM is the standard 
medical treatment for the 20 selected diseases in this review. In most studies, 
patients were recruited from medical clinics or hospitals and the sample size ranged 
from 50-1,911. Attrition rates varied from 0%-71%. Participants were predominantly 
men and often ;:::37 years of age and a disease duration of >2 years. The observation 
period between baseline and last adherence measurement was ;:::3 and <12 months 
in ten studies and ;:::12 months in 20 studies, with a maximum of 60 months. 
Medication adherence was mostly measured by self-report (18 studies, 
predominantly questionnaires); seven studies used a validated adherence 
questionnaire.33' 36'46.49' 53.55 Other adherence measurements were carried out by 
reviewing medical records or the medication event monitoring system (MEM5). In 
15 studies, both univariate and multivariate analyses were reported. 
All 30 included studies were judged to be 'low-quality' (Table 53). This was mainly 
due to poor descriptions and/or bias regarding the study sample, the use of non-
validated questionnaires, the lack of accounting for confounding variables, and a 
poor description of the data analyses. Most studies, moreover, did not appropriately 
describe actions taken in case of missing data. 
A total of 180 bias domains were judged (30 studies by six domains). Initially, 
BvdB and HZ fully agreed on 78 domains, partially agreed (ie, 'partly' versus 'no' or 
'partly' versus 'yes') on 79 domains and fully disagreed (eg, 'yes' versus 'no') on 23 
domains, resulting in a weighted agreement of 76%. Disagreements were caused by 
poor description of methods, different interpretations of missing data, differences in 
calculating study attrition rates, and different interpretations regarding the 
appropriateness of study sample descriptions. On this latter point, disagreements 
about three studies35'52"56 could not be resolved by discussion between BvdB and HZ 
and, thus, CvdE made the final decision. 
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Study 
Ponieman, 
2009
33 
Venturini, 
199934 tt 
Gazmara-
rian} 
200635 
. 
Study characteristics and results 
Setting Sample characteristics Measures and results 
USA; 
patients from 
general 
internal 
medicine 
cl in1c 
USA; 
patients from 
HMO-
providing 
health services 
USA, 
commun ity-
dwelling 
patients'~~ 
Sample size, 
%loss to 
follow-up 
261,23% 
786, 0% 
1549, u.d. 
t Age , % female Disease duration t Adherence*· Psychosodal. 
follow-up cat., number of 
period§ predictors" 
ASTHMA (inhaled corticosteroids) 
48 (13), 82% Age of onsets 20 Self-report AI, n=S 
years 50% of (MARS), 3 Alii, n=3 
sample months 
DIABETES (oral and/or parenteral antidiabetics) 
59 (mean), 24- n.r. Record review, El, n=1 
92 (range), 49% last time point 
flexible, but 
within 24 
months 
HEART DISEASE & HYPERTENSION (cardiovascular medication) 
Age 65-69 35%, u.d. 
70-74 28%, 75-
79 20%, 80-84: 
12%, > 84: 6%, 
(female) : 58% 
Record rev1ew, 
12 months 
Clll, n=1 
Association Ndomains 
•• present between btasfree 
category and 
adherence/ 
non-adherence 'll 
No (U : yes, M: no) Oof6 
No (U : no, M : no) 
No (U : n.r., M : no) 2 of 6 
No (U : no, M : n.t .) 3 of6 
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"N;bi, 2008·:~:6--FI~nd i 
local 
government 
employees 
Gregoire, 
200636 
Canada; 
hyperten51ve 
adults with 
prescriptions 
from 
network of 
pharmacies 
Sample size, 
%loss to 
follow-up 
1021, u.d. 
692,26% 
Miller, 
198538 
Site not 141, 21% 
reported : 
patients 
from 
mstitut1ons 
providing 
cardiac 
rehabilitation 
'!I'll programs 
t Age , %female 
26-63 (range), 
32% 
59 {13), 56% 
Disease duration t 
0-2 years : n = 311 
2-5 years: n = 222 
5-10 years : n = 292 
>10years: n= 196 
47 month5 
(adherent group), 
44 months (non-
adherent group) 
56 (mean), 32- n.r . 
70 (range), 
22% 
Adherence*· 
follow-up 
period§ 
Record review, 
12 months 
Self-report 
(Morisky Scale), 
3 months 
Self-re.port 
(HBS), 6-9 
months 
Psychosodal. 
cat., number of 
predictors« 
D,n=4 
El, n=2 
AI, n=1 
All, n=5 
Clll, n=1 
AI, n=l 
Cll, n=l 
Association 
present between 
category and 
adherence/ 
non-adherence~ 
N domains 
•• bias free 
- -- -----··--
Yes(U : no,M : yes) 1of6 
No (U : no, M : n.t .) 
No (U : no, M : no) Oof6 
No (U : no, M : no) 
No (U : no, M : no) 
No {U : n.r ., M : no) 0 of 6 
No (U : n.r., M : no) 
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Study Sett1ng Sample characteristics Measures and results 
n 
::; 
QJ 
Sample size, t t Adherence*· PsychosociaL Association N domains "0 Age , %female Disease duration 
..... .. ~ %loss to follow-up cat., number of present between bias free 
ll1 follow-up period§ predictors11 category and 
adherence/ 
non-adherence 'i 
--· --·~ Molloy, UK; patients 295,11% 61 (mean), 32- 0 years (acute) Self-report, 12 Clll, n=2 No (U : no, M no) 1 of6 
200839 admitted to 87 (range), months 
hospita Is w1th 23% 
Acute 
Coronary 
Syndrome ~11 
HIV (antiretroviral medication} 
Deschamps, Belgium; 60,28% 43 (9) n.r. MEMS, 5-6 AI, n=3 No (U : no, M : n.r.) 1 of6 
200425 outpatients at adherent months after Alii, n=1 No (U : no, M : n.r.) 
university group, 41 (8) measunng Bl, n=3 No iU : no, M· n.r.) 
hospital non-adherent psychosocial Bll, n=4 No (U : no, M: n.r.) 
group, 16% constructs Clll, n=2 No (U : no, M : n.r.) 
D,n=l No (U : no, M : n.r.) 
El, n=2 No (U : no, M: n.r.) 
Holmes, USA; HIV- 116, 0%§§ 44 (median), 5 years (median) MEMS, 12 AI, n=l No (U : no, M: no) 2 of6 
200719 clin1c patients 25-69 (range), months (or All, n=2 No (U : no, M : no) 
19% when viral load Cl, n=1 No (U : no, M : n t) 
of~lOOO Clll, n=1 No (U : no, M : n.t .) 
copies/ml was El, n=1 No (U : no, M : no) 
reached) Ell, n=1 No (U : no, M : no) 
- Table 2 continues-
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-o -stUdY Setting ------·-Sample Characteristics ·Measures and-n!suliS .. 
V> 
-< 
n t 
Disease duration t Adherence*· :::r Sample siZe, Psychosocial. Association Ndomams 0 Age , %female 
V> %toss to cat, number of present between •• 0 follow-uP bias free n 
predictors8 iii' folfow-up penod § category and 
~ adherence/ (!) 
non-adherence 'II ()_ 
!=+ .L--....- .--
- -- · Q Delgado, Canada; 316,0% n.r ., n.r. n.r . Record review, El, n=1 No (U : yes, M : no) 1 of6 
V> 
200342 pat1ents 12 months 0 
...., 
enrolled in :::l 
0 community 
'i' 
ru drug ()_ 
:::r treatment (!) 
;o 
:::l 
program 
n (!) 
V> 
-< Singh, USA, new, 52,12% 40 (median), n.r. Record review, Bll, n=1 No (U : no, M : no) 1 of6 V> ,...,. 
199643 23-68 (range), 6 months (!) veteran CJJI, n=2 No (U : no, M : no) 3 
ru patients seen 0% El, n=4 No (U : no, M : no) 
!:1'. 
n at medical 
..... (!) center :::;, 
C'il 
::;;; 
0 Singh, S1te not 138,11% 41 (med1an), n.r. (but 7% Record rev1ew, Bl, n=3 No (U : no, M : n.r.) 1 of6 ...., 
0 199944 reported : 24-71 (range), therapy-naive) 6 months Bll, n=6 No (U : no, M : n.r.) :::l 
(JQ pat1ents in 7% Clll, n=4 No (U : no, M : n.r.) ;:::;: 
c HIV-med1cal El, n=1 No (U : no, M : n.r.) 9: 
:::l centers 
~ 
V> 
rt 
c 
()_ 
- Table 2 continues-(!) 
V> 
...... 
w 
w 
f-' 
- Table 2 continued-w 
..,. 
Study Setting Sample characteristics Measures and results 
n 
::::,-
OJ 
Sample size, t t Adherence*' Psychosodal. Association N domains "0 Age , %female Disease duration .... 
•• ~ %loss to follow-up cat., number of present between bias free 
LT1 follow-up period§ predictors11 category and 
adherence/ 
non-adherence 'II 
Bottonari, USA; patients 78,69% 36 (7), 4% n.r. Self-report D, n=2 No (U : no, M : n.r.) Oof6 
2005
45 treated in (5traightfor- El, n=1 No (U : no, M : n.r.) 
lmmuno- ward), 6-9 Ell, n=3 No (U : no, M : n.r.) 
deficiency months 
clinic 
Godin, Canada, 400,6% 43 (8), 4% > 5 years HIV- Self-report AI, n=1 Yes (U : n.r.,M :yes) 1 of6 
2005
46 patients from infected : 73% (stra1ghtfor- Alii, n=2 No (U : n.r., M : no) 
med1cal HIV- ward), 12 Cl, n=l No (U : n.r, M : no) 
cl inics months Clll, n=l No (U : n.r., M : no) 
D,n=1 No (U : n.r., M : no) 
Kacanek, USA; pat1ents 225,0% 45 (7), 23% n.r. Self-report El, n=1 Yes (U : yes, M :n.t.) 2 of 6 
2010
47 recruited by (straightfor-
media and ward); max 30 
physician months 
networks 
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Measuresand rewliS' . 
-o Study Setting Sample characteristics 
~ 
n t DiSease duration t Adherence*· ::r Sample size, Psychosocial . Association Ndomalns 0 Age , %female 
V> 
'Xi loss to cat., number of present between ~· 0 follow-up bias free n follow-up predictorsB ~ period§ category and 
'0 adherence/ 
iil non-adherence~ 0,_ 
~ Q Martini, Italy; '214, 71% < 30 13%, 30- n.r . Self-report AI, n=2 No (U : no, M : n.r.) 0 of6 
V> 
200248 (straightfor-0 outpatients 39 56%, > 39 : Cl, n=1 Yes (U : yes, M : n.r.) _, 
::l using 31%, ward); 12 
0 
combination (female) : 36% months ::l 
c:, 
therapy ~ 0,_ 
::r 
(1) 
iil 
::l Mellins, USA; HIV- 128,25% 38 (mean). 22- 5 years Self-report Alii, n=l No (U : no, M : n.r.) Oof6 n ~ 
200349 infected 66 (range). (AACTG, El, n=1 No (U : no, M : n.r.) ~ )G. mothers 100% straightfor- Ell, n=2 Yes (U : yes, M : n.r.) 
(1) recru ited in ward). T1 after 3 
Cll waiting room of 4-5 months, T2 cr. 
n adult clmic 8-18 months 
iil after Tl < iii' 
~ 
0 
Nilsson Sweden; 203,29% 45 (9). 22% Mean year of Self-report No (U: n.r., M : no) 1 of6 ...... AI, n=3 
0 Schonnes- patients diagnosis= 1990 (stra1ghtfor- All, n=1 No (U : n.r ., M : no) ::l 
01:1 
recruited by ward), 24 Alii, n=2 No (U : n.r ., M : no) ;:;: son, 
c 
200651 clinic nurses months Bll, n=2 No (U : n.r ., M : no) 0. s· Cl, n=l No (U : n.r ., M : no) ~ 
V> Clll, n=2 No (U : n.r., M : no) ,..,. 
c D,n=1 No (U : n.r ., M : no) 0,_ 
ro· El, n=3 No (U : n.r ., M : no) V> 
1-' 
Ell, n=l No (U : n.r ., M : no) 
w 
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en - ··- ··--- --- · --~--·-· --·· . ··--··----·· Study Setting Sample characteristics Measures and results 
n 
:::;,- t t 
Adherence*· OJ Sample size, Age , %female Disease duration Psychosocial. Association N domains 
-o 
..... %loss to cat., number of present between •• ~ follow-up bias free 
V1 follow-up period§ predictors11 category and 
adherence/ 
non-adherence • 
---- - -Thrasher, USA; 1911 .. 33%§§ Minority vs. Mean year first Self-report Clll, n=1 No (U : no, M : n.r.) 1 of6 
200852 patients m non-minonty: < diagnosed w1th (straightfor- El, n=2 Yes (U : yes, M: n.r.) 
public use of 35 : 35% HIV: 1992, ward), 12 
HCSUS data set mmonty group, minority group, months 
30% non- 1990, non-
minority group. minority group 
%female . 33% 
vs. 12%, 
respective.ly 
Horne, UK; 136, 14% 38 (9), n.r. 5 years Self-report AI, n=2 Yes (U : yes, M: yes) 3of6 
2ool3 outpatients, (straightfor- El, n=1 No (U : no, M : n.t .) 
el igible to ward), 12 
receive HAART months 
Mugavero, USA; 474, 39% 40 (median), n.r. Self-report Ell, n=4 No (U : yes, M: no) 3 of6 
200954 pat1ents 35-46 (IQR). (AACTG, 
receiv1ng care 29% straightfor-
at infectious ward), 27 
disease clm1cs months 
- Table 2 continues -
"'C 
~ 
n 
:y 
o 
V> 
0 
n 
n;· 
"Q 
ro 
D.. 
~ 
0 
Vl 
0 
-::::l 
0 
::::l 
Q, 
D.. 
:::,-
~ 
ro 
::::l 
n 
ro 
~ 
~ 
ro 
3 
!lJ 
!:!. 
n 
..... 
ro 
:o;, 
ro 
:;;: 
0 
-0 
::::l 
~-2" 
9: 
::::l 
!lJ 
~ 
c 
D.. 
ro 
V> 
- Table 2 continued-
··--·· ~--· · ·- ·· .. ·- ·· ---- -.. ·~- ·--· · · -· ·-------------
Study Setttng Sample characteristics 
Sample siZe, 
%loss to 
foHow-up 
t Age , % female Disease duration t 
Measures and results 
Adherence*· 
follo'N-IJP 
period§ 
Psychosocial. 
cat., number of 
predictors11 
Association 
present between 
category and 
adherence/ 
non-adherence 11 
·----· - ---- - ---··--·-·--·- - ···- ·"·- .. --.-· ·---.. ----~- --.- .. . - ..... -·--·-··---- ---·-··---... - .... --. Carrieri, France; 1110, 13% 37 (median), Yes (U : yes,M: yes) F1rst time s1nce Self-report Cll, n=l 
200555 patients 22% Yes (U : yes,M : yes) f1 rst positive H IV- (AACTG, El, n=1 
Stilley, 
201056 
starting 
HAART-
regimen 
USA, 
transplant 
pat1ents, 
recruited 
before 
hospital 
discharge or 
at early clinic 
visit 
1S2, 29% 
test in years 3.8 straightfor-
(median), 0.5-8.2 ward), 60 
(JQR) months 
TRANSPLANT -RElATED (immunosuppressant medication) 
55 (10), 33% n.r. MEMS, 6 Bl, n=1 
months CJJ, n=l 
D, n=2 
El, n=l 
No (U : no, M : n.r.) 
No (U : no, M : n.r.) 
No (U : no, M : n.r.) 
No (U : no, M : n.r.) 
N domains 
•• bias free 
2 of6 
1 of 6 
De Geest, 
199857 
Belg1um, 101,0% 56 (median), 20.. 
69 (range), 13% 
3 (median), 1·6 
(range) years 
since 
transplantation 
MEMS, 6 
months 
Alii, n=1 
Clll, n=1 
El, n=1 
Ell, n=l 
Yes(U : n.r.,M :yes) 2of6 
convenience No (U : n.r., M: no) 
sample of No (U : n.r., M : no) 
outpatients No (U : n.r., M : no) 
• Table 2 continues-
f-.> 
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Study Setting Sample characteristics Measures and results 
n 
:::r 
QJ 
Sample size, t t Adherence*· Psychosocial. Association N domains "0 Age , %female Disease duration ,.... .. 
<:!; %loss to follow-up cat., number of present between bias free 
Ul follow-up period§ predictors11 category and 
adherence/ 
non-adherence 'II 
Russell, USA; so, 26% 60 (S), 38% n.r. MEMS, 12 Alii, n=1 No (U : no, M : n.r.) 0 of 6 
201058 convenience months Clll, n=1 No (U : no, M : n.r.) 
sample of renal El, n=2 No (U : no, M : n.r.) 
transplant 
patients 
Weng, USA; 829,66% 48 (median), n.r. MEMS, 12 Alii, n=l No (U : yes, M : no) 2 of6 
200S59 patients 39-S7 (IQR), months post- Cll, n=l No (U : no, M : n t .) 
recruited at 39% transplanta- El, n=1 No (U : no, M · n.t .) 
time of renal tion Ell, n=1 No (U: no, M : n.t .) 
transplantation 
Dew, USA; 108,22% < SO years : 49%, n.r. Self-report Alii, n=1 No (U : no, M: n.t .) 2 of6 
199660 heart (female) : 16% (straight Bl, n=2 No (U : no, M: n.t .) 
transplant forward), 12 Bll, n=1 Yes (U : yes, M: yes) 
patients from months post- Cll, n=2 No (U : no, M: no) 
academic transplanta- El, n=3 No (U : no, M: no) 
hospJtal 1111 tion 
- Table 2 continues -
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Dew, 
200864 
USA; 
patients 
rece!ving first 
lung 
transplantation 
in academic 
hospital 
Sample characteristics 
Sample size, 
%loss to 
follow-up 
178,29% 
t 
Age , %female 
37% <50 years, 
(female) : 48% 
Dobbels, 
200965 
Belgium, heart, 186, 24% 52(12), 33% 
liver and lung 
transplant 
patients listed 
at university 
hospitals 
Disease duration t 
n.r . 
n.r. 
Measures and results 
Adherence*· 
follow-up 
period§ 
Self-report 
(straightfor-
ward), 24 
months 
Selkeport 
(straightfor-
ward), 12 
months post-
transplanta-
t 1on 
Psychosocial. 
cat., number of 
predlctors11 
Alii, n=3 
Cll, n=2 
D,n=1 
El, n=3 
Clll, n=2 
D, n=S 
El, n=2 
Assoaatlon 
present between 
category and 
adherence/ 
non-adherence 'll 
N domains 
- ... --
No (U yes 
M : no) 
No (U : yes, M : no) 
No (U : yes, M : no) 
No (U : yes, M : no) 
bias free 
No (U : n.r., M : no) 1 of 6 
No (U : n.r., M : no) 
No (U : n.r., M : no) 
•• 
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Study 
DIMatteo, 
199366 
Setting 
USA; patients 
from five 
medical 
specialties in 
HMOs, large 
mult1specialty 
groups or solo 
practices H , 
1111 
Sample characteristics 
Sample size, 
%loss to 
follow-up 
t 
Age , %female 
t 
Disease duration 
Measures and results 
Adherence*· 
follow-up 
period~ 
Psychosocial. 
cat, number of 
predictors11 
OTHER (diabetes and/or hypertension and/or heart disease) 
Max. 1828, 
u.d. 
60(8). 54% n.r. Self-report 
(straightfor-
ward), 24 
months 
Bll, n=l 
Cl, n=2 
Clll, n=l 
Ell, n=l 
Association 
present between 
category and 
adherence/ 
non-adherence 11 
No (U : n.r., M no) 
No (U : n.r., M no) 
No (U : n.r., M : no) 
Yes (U : n.r., M: yes) 
Ndomains 
bias free •• 
Oof6 
---.------·- -·---~- - -~---------------------------·--·-- " --------· ···- --------·--·- ···-~----·--- -- ·- --------------····--·---·-·--'~----·-···--·-----~------·----------------·-· ....... ._~ ------ ------~-- -_.,. ______ ___________ ---··----· ------------------· -··-·------------··--------- --------- ------- ------
n.s. =non significant (as reported in concerning study). n.r. =not reported. n.t. =not tested. u.d. =undetermined (because of inadequate description in study). 
Abbreviations in this table are explained in the Supplementary materials. t Mean (and for age: sd) in years reported unless indicated otherwise. *with 'straight 
forward', we mean that participants were directly asked to indicate how many medication doses they missed. For example: 'How many pills did you take this week?'. 
§Follow-up period= number of months between baseline (unless indicated otherwise) and last adherence measurement. 11Th is column shows the number of 
psychosocial predictors measured in the concerning study, and the assigned psychosocial category. Details about the single predictors are presented in Table 52. A= 
Beliefs and cognitions about I) medication and treatment; II) illness; Ill) self-efficacy & locus of control. B =coping styles I) task oriented, II) emotion oriented. C = 
Social influences & social support I) regarding medical caregiver; II) regarding friends & family; Ill) in general. D =personality traits. E =psychological wellbeing: I) 
mood state; II) perceived stress/stressors. 11 No =no significant association between psychosocial category and medication adherence/non-adherence within study 
.. 
when p,;; 0.05. Yes= significant association when p,;; 0.05. U: univariate. M: multivariate. To determine methodological quality, six bias domains per study were 
judged. Here, the total amount of bias free domains is reported (for further details, see Table 53) tt Retrospective design. *'Diagnosis for coronary heart disease, 
hypertension, diabetes mellitus and/or hyperlipidaemia. §§ %loss to follow-up assumed by HZ/BvdB. 1111Type of medication is immunosuppressants, antihypertensives 
and/or antivirals. 1111 Use of chronic preventive medication assumed. ••• Significance of p,;; 0.05 assumed by HZ/BvdB 
Best evidence synthesis 
Table 3 shows there is limited evidence for the absence of a longitudinal association 
with medication non-adherence in all of the eleven psychosocial subcategories. 
Table3 Level of evidence for longitudinal associations between psychosocial categories and 
medication non-adherence 
Psychosocial category Nof Quality 
studies 
A about 9 All low 
Beliefs and medication 
cognitions and 
B. 
Coping 
styles 
treatment 
II. about 
illness 
Ill self-
efficacy & 
locus of 
control 
I. task-
oriented 
II. emotion-
oriented 
C. regardmg 
Social med1cal 
influences 
&. social 
support 
caregiver 
II. regarding 
fnends& 
family 
Ill m general 
3 All low 
10 All low 
4 All low 
6 All low 
5 All low 
6 All low 
14 All low 
Longitudinal 
association 
2xy~~.o,s,-· 
] X nO 19. ~-~.5:il,36,3S.48,51 
3 x noJ.S',3b.sl 
1 x yes57 
9 x nols.33A6.49.s l.sa. 
50.~ 
1 x yes48 
4. X nolS.46.SJ,66 
14xno 
19.3,JS.J6,39 . .ti3A·i,46.s:t s;.s 
7 S&,b5,6C 
Level of evidence 
No association 
(limited evidence) 
No association 
(limited evidence) 
No association 
(limited evidence) 
No associ~tion 
(limited evidence) 
No association 
(limited evidence) 
No association 
(limited evidence) 
No association 
(limited evidence) 
No association 
(limited evidence) 
-Table 3 continues -
Psychosocial predictors of non-adherence: systematic review of longit udinal studies I 141 
- Table 3 continued-
--·--
PsychOSOCial category Nof Quality LongitUdinal Level of !!Vidence 
studies association 
--~ - -·· 
D. 8 All low 1 x yes 26 No association 
Personality 7x no (lim1ted evidence) 
traits .(S q5,-%_ 51,56.St:.65 
E. I. mood state 21 All low 3 x yes'-7.52,55 No assoc1at1on 
Psychosocial 18 x no19 :'5,"6.3<,• 1- (limited evidence) 
wellbeing ~5,49_ 5\53 56-b(l M.~ 
II. perce1ved 8 All low 2 x yes•9,s6 No assoc1at1on 
st ress/st res- 6 x nol9,<5,51 5<:,57. 59 (limited evidence) 
sors 
Beliefs and cognitions 
Regarding category AI (beliefs and cognitions about medication and treatment), two 
of nine studies found a longitudinal, multivariate association between having a 
positive attitude towards taking medication and adherence (odds ratio [OR]=1.56, 
95% confidence interval [CI] 1.18, 2.06)46, and between necessity beliefs and 
concern beliefs about medication and adherence (OR = 2.19, 95% Cl 1.02, 4.71 and 
OR = 0.45, 95% Cl 0.22, 0.96 respectively) .53 One other studl3 found univariate 
associations between necessity and concern beliefs about medication and 
adherence, but these associations did not hold in the multivariate analysis. 
One study demonstrated a longitudinal, multivariate association between low 
self-efficacy and medication non-adherence,57 however, the effect size was small. 
Univariate, but not multivariate associations between self-efficacy and adherence 
were demonstrated in two studies.59' 64 
Coping styles 
No univariate and multivariate associat ions were found between the task-oriented 
coping style category and medication adherence. 
Regarding emotion-oriented coping styles, one of six studies revealed a multivariate 
association with non-adherence (eg, OR of 9.71 for avoidance coping).60 
Furthermore, avoidance coping as a single predictor was associated with non-
adherence in three offour studies measuring this construct.25A3' 60 
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Social influences and social support 
Two of the 25 studies demonstrated significant associations between predictors 
within the category social influences and social support and (non-)adherence, but 
only one of these studies reported on a multivariate association between having 
support from a partner and non-adherence (regression coefficient = -0.15, 95% Cl 
-0.25, -0.05).55 Receiving practical social support was associated with better 
adherence as single predictor.39'44 
Personality traits 
One of eight studies showed a multivariate, longitudinal association between the 
category of personality traits and medication non-adherence:26 a lower sense of 
coherence (a global life orientation in which life is perceived as comprehensible, 
manageable and meaningful)72 was associated with greater non-adherence (OR 
0.55, Cl 0.31-0.96). Associations between other predictors within the personality 
traits category and non-adherence were lacking. 
Psychological wellbeing 
Regarding categories El (mood state) and Ell (perceived stress/stressors), no 
associations between predictors in those categories and medication non-adherence 
could be established for the vast majority of studies (24 out of 29). Two of the five 
studies which did show significant associations reported on multivariate analyses: 
the regression coefficient for depressive symptoms was 0.18 (95% Cl 0.07, 0.29) in 
predicting non-adherence;55 t he standardized beta for health dist ress was -0.22 (CI 
not reported) in predicting adherence.66 
Table 52 can be consulted for detailed information about associations between 
single psychosocial predictors and medication adherence/non-adherence. 
Sensitivity analyses 
The sensitivity analyses confirmed that, generally, no association was found 
between the psychosocial categories and medication non-adherence (Table 54). 
The additional analysis on single predictors showed no association between most 
single, psychosocial predictors and medication non-adherence. However, conflicting 
evidence was found for having a positive attitude towards taking medication,38.46 
necessity beliefs and concern beliefs about medication,33' 53 self-efficacy in 
medication-taking/5'33.46' 51'57'58 the coping style "planful problem solving"/5'44 and 
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(the number of) stressful (life) events.39,4s,49 Limited evidence was found for an 
association between escape-avoidance coping and medication non-
adherence/5,44'60'66 and for an association between receiving practical, social 
support and medication adherence.39.44 
DISCUSSION 
To the best of our knowledge, this is the first systematic review summarizing 
evidence of longitudinal associations between psychosocial factors and non-
adherence to CPMM, irrespective of somatic disease. Due to the low quality of the 
included studies, limited evidence was found for absence of longitudinal 
associations between categories of psychosocial predictors and medication non-
adherence. In general, findings were robust according to sensitivity analyses. 
Our findings of longitudinal associations between psychosocial factors and 
medication non-adherence are in line with the few conducted cross-sectional 
studies about associations between medication adherence, coping styles, 
personality traits, and psychosocial wellbeing (except depressive symptoms) in 
somatic conditions. The findings in these cross-sectional studies are ambiguous at 
best.8.73-77 For example, an active coping style was associated with medication 
adherence in some studies8'77 but not in others,73'75 and stress was associated with 
lesser adherence in a study of Holt et al/6 but was unrelated to non-adherence in a 
study of Ediger et al.74 
In contrast to coping styles and personality traits, depression is often studied as 
possible predictor of medication non-adherence. Here, our results are not in line 
with results from other reviews, reporting depression to be a predictor of 
medication non-adherence.6'78-83 Initially, this discrepancy might be explained by the 
fact that clinical depression is within the scope of most other studies, but beyond 
the scope of our systematic review since we did not study morbidity as a predictor 
of non-adherence; instead, we studied depressive symptoms. Second, an 
explanation might be that those other reviews included studies with, mainly, cross-
sectional designs. Feelings of depression might increase and decrease over the 
course of a disease. A high degree of depressive feelings might correlate well with 
non-adherent behavior at that same time, but just might not be predictive of non-
adherent behavior in the future due to · this changeability. Thus, longitudinal 
associations between depressive feelings and non-adherence might not be 
applicable. 
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This thought might also apply to discrepancies in findings between our review 
and other reviews on associations between beliefs about medication/treatment, 
poor social support, and non-adherence. These other reviews underline the 
importance of beliefs about medication/treatment and poor social support in 
predicting medication non-adherence6' 10,7s-ss in contrast to our review findings, but 
again, those other reviews are mainly based on studies with cross-sectional designs. 
In terms of internal validity, a strength of this review is that we, in contrast to 
others, systematically defined and categorized psychosocial factors. By doing so, we 
were able to 1) draw a concise number of conclusions about associations between 
psychosocial predictors and medication non-adherence in a reproducible manner; 2) 
address the heterogeneity between single, psychosocial predictors; and 3) address 
an important goal of a systematic review: converging information. The pitfall of 
categorization (eg, the possibility of overlooking significant associations between 
certain, single predictors and non-adherence, by pooling them with other types of 
[non-significant] predictors), was avoided by performing an extended sensitivity 
analysis on single predictors. This analysis revealed our conclusions to be robust for 
almost all single, psychosocial predictors included in this review. 
Another strength of this review is that we systematically synthesized results 
using a best evidence synthesis in contrast to most other reviews, which tend to be 
characterized by narrative designs.6' 10' 78'79'82'83'85 Narrative designs often do not rely 
on systematic methods to assign weight of evidence; eg, by incorporating 
methodological quality of included studies.86 Although no review procedure 
eliminates the chance that reviewers' biases will affect the conclusions drawn,86 the 
application of a best evidence synthesis makes a review procedure transparent and 
reproducible. 
A limitation of this systematic review is that we used chronic disease terms 
instead of medication terms in the search strategy, and, consequently, we may have 
missed relevant studies about chronic preventive maintenance medication. 
However, we assume that the number of missed studies is minimal, since diseases 
are usually mentioned in medication adherence studies. 
Another limitation could be the use of results of univariate analyses to draw 
conclusions about associations in the absence of multivariate analysis data, as 
univariate analyses could lead to an overestimating of the strength of associations. 
However, our sensitivity analyses on data from univariate analyses confirmed the 
robustness of our findings. 
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Concerning external validity, a strong feature of this review is that it focused 
exclusively on longitudinal associations between psychosocial predictors and 
medication non-adherence, thereby providing insight into the temporality and 
robustness of associations. However, only 5 of the 30 studies included in our review 
corrected for baseline non-adherence.34' 54' 57' 65' 66 Failure to account for baseline non-
adherence when suggesting predictive longitudinal associations is considered a 
liberal approach, 87 since baseline non-adherence is likely to explain a substantial 
part of the variance in non-adherence over time. Because we did not find any 
associations using a liberal approach, however, we believe it is unlikely that handling 
a strict longitudinal approach in this review would have altered our findings. 
Another limitation concerning external validity is that the poor quality of the 
included studies prevented us from drawing firm conclusions about the lack of 
associations between psychosocial predictors and medication adherence. The lack 
of a gold standard for adherence measurement82 also restricts the validity of our 
findings. The adherence measures used in the included studies of this review (self-
report, refill data, and electronic monitoring) do not measure actual ingestion, and 
the use of self-report and electronic monitoring might have introduced response 
bias because of participants' awareness of the measurements. However, all 
medication adherence related research has to deal with the limitations of adherence 
measurements. For now, our review provides the best evidence currently available, 
and clearly demonstrates the need for more high-quality, longitudinal research into 
associations between psychosocial predictors and medication non-adherence. 
Two recommendations for future research can be made. First, future 
longitudinal research into psychosocial predictors of medication non-adherence 
should be of high quality. Researchers should, for example, use valid measures of 
psychosocial predictors and medication non-adherence and should thoroughly 
describe which steps were performed in the study, especially those relating to 
handling missing data and avoiding bias. 
Second, the research gap in longitudinal studies into associations between 
psychosocial predictors and medication non-adherence in patients with conditions 
such as rheumatic diseases, migraine disorders, gout, glaucoma, and stomach ulcers 
(see Supplementary materials) should be complemented . Although we assume that 
review findings will also apply to these diseases, this assumption needs to be 
confirmed. 
The conclusion of this systematic review is that there is limited evidence for absence 
of longitudinal associations between psychosocial predictors and medication non-
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adherence. Consequently, our results do not provide psychosocial targets for the 
development of new interventions in clinical practice. However, the usefulness of 
psychosocial predictors in improving medication adherence should not be ruled out, 
as more high-quality research is needed to confirm or refute the conclusion of this 
review. Such future research could also further explore the associations found in this 
review between escape-avoidance coping and medication non-adherence, and 
between receiving practical, social support and medication adherence. 
--··---------------------------------··---------
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SUPPLEMENTARY MATERIALS 
Pubmed search strategy 
(((adult[MeSH Terms] OR mature[tw] OR adult[tw]) 
AND 
((lschaemic heart diseases[TW] OR angina pectoris[TW] OR Myocardial 
lschemia[TW] OR asthma[TW] OR Diabetes mellitus[TW] OR diabetes mellitus[TW] 
OR hypercholesterolaemia[TW] OR hyperlipidaemia[TW] OR Dyslipidemias[TW] OR 
Gastric ulcer[TW] OR Duodenal ulcer[TW] OR Stomach Ulcer[TW] OR glaucoma[TW] 
OR glaucoma[TW] OR heart failure[TW] OR Heart failure[TW] OR arrhythmias[TW] 
OR Arrhythmias, Cardiac[TW] OR "Human immunodeficiency virus" OR HIV 
disease[TW] OR HIV-disease[TW] OR HIV infections[TW] OR HIV-infections[TW] OR 
Hypertensive diseases[TW] OR Hypertension[TW] OR Ulcerative colitis[TW] OR 
Crohn's disease[TW] OR Inflammatory Bowel Diseases[TW] OR Arthropathies[TW] 
OR gout[TW] OR Malignant neoplasm of breast[TW] OR Breast Neoplasms[TW] OR 
Hereditary angioedema[TW] OR Angioedemas, Hereditary[TW] OR 
transplantation[TW] OR Organ Transplantation[TW] OR migraine[TW] OR Migraine 
Disorders[TW] OR osteoporosis[TW] OR arthropathy[TW] OR Systemic connective 
tissue disorders[TW] OR psoriatic arthropathy[TW] OR rheumatoid arthritis[TW] OR 
Systemic lupus erythematosus[TW] OR Systemic sclerosis[TW] OR Arthritis, 
Psoriatic[TW) OR Arthritis, Rheumatoid[TW) OR Lupus Erythematosus, Systemic[TW] 
OR Scleroderma, Systemic[TW) OR Arterial embolism[TW] OR thrombosis[TW) OR 
venous embolism[TW] OR Embolism and Thrombosis[TW] OR Paget Disease[TW] OR 
Osteitis Deformans[TW]) OR (Myocardiallschemia[MH] OR asthma[MH] OR diabetes 
mellitus[MH] OR Dyslipidemias[MH] OR Stomach Ulcer[MH] OR glaucoma[MH] OR 
Heart failure[MH] OR Arrhythmias, Cardiac[MH] OR HIV infections[MH] OR 
Hypertension[MH] OR Inflammatory Bowel Diseases[MH] OR gout[MH] OR Breast 
Neoplasms[MH] OR Angioedemas, Hereditary[MH] OR Organ Transplantation[MH] 
OR Migraine Disorders[MH) OR osteoporosis[MH] OR Arthritis, Psoriatic[MH] OR 
Arthritis, Rheumatoid[MH] OR Lupus Erythematosus, Systemic[MH] OR Scleroderma, 
Systemic[MH] OR Embolism and Thrombosis[MH] OR Osteitis Deformans[MH))) 
AND 
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((medication adherence[MH] OR patient compliance[MH]) OR (medication 
compliance[TW] OR medication non-compliance[TW] OR medication non 
compliance[TW] OR medication noncompliance[TW] OR medication adherence[TW] 
OR medication non-adherence[TW] OR medication non adherence[TW] OR 
medication nonadherence[TW] OR medication adherance[TW] OR medication non-
adherance[TW] OR medication non adherance[TW] OR medication 
nonadherance[TW] OR medication persistence[TW] OR medication non-
persistence[TW] OR medication non persistence[TW] OR medication 
nonpersistence[TW] OR medication persistance[TW] OR medication non-
persistance[TW] OR medication non persistance[TW] OR medication 
nonpersistance[TW] OR medicine compliance[TW] OR medicine non-
compliance[TW] OR medicine non compliance[TW] OR medicine 
noncompliance[TW] OR medicine adherence[TW] OR medicine non-adherence[TW] 
OR medicine non adherence[TW] OR medicine nonadherence[TW] OR medicine 
adherance[TW] OR medicine non-adherance[TW] OR medicine non adherance[TW] 
OR medicine nonadherance[TW] OR medicine persistence[TW] OR medicine non-
persistence[TW] OR medicine non persistence[TW] OR medicine 
nonpersistence[TW] OR medicine persistance[TW] OR medicine non-
persistance[TW] OR medicine non persistance[TW] OR medicine 
nonpersistance[TW] OR medical compliance[TW] OR medical non-compliance[TW] 
OR medical non compliance[TW] OR medical noncompliance[TW] OR medical 
adherence[TW] OR medical non-adherence[TW] OR medical non adherence[TW] OR 
medical nonadherence[TW] OR medical adherance[TW] OR medical non-
adherance[TW] OR medical non adherance[TW] OR medical nonadherance[TW] OR 
medical persistence[TW] OR medical non-persistence[TW] OR medical non 
persistence[TW] OR medical nonpersistence[TW] OR medical persistance[TW] OR 
medical non-persistance[TW] OR medical non persistance[TW] OR medical 
nonpersistance[TW] OR drug compliance[TW] OR drug non-compliance[TW] OR 
drug non compliance[TW] OR drug noncompliance[TW] OR drug adherence[TW] OR 
drug non-adherence[TW] OR drug non adherence[TW] OR drug nonadherence[TW] 
OR drug adherance[TW] OR drug non-adherance[TW] OR drug non adherance[TW] 
OR drug nonadherance[TW] OR drug persistence[TW] OR drug non-persistence[TW] 
OR drug non persistence[TW] OR drug nonpersistence[TW] OR drug persistance[TW] 
OR drug non-persistance[TW] OR drug non persistance[TW] OR drug 
nonpersistance[TW] OR drugs compliance[TW] OR drugs non-compliance[TW] OR 
drugs non compliance[TW] OR drugs noncompliance[TW] OR drugs adherence[IW] 
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OR drugs non-adherence[TW] OR drugs non adherence[TW] OR drugs 
nonadherence[TW] OR drugs adherance[TW] OR drugs non-adherance[TW] OR 
drugs non adherance[TW] OR drugs nonadherance[TW] OR drugs persistence[TW] 
OR drugs non-persistence[TW] OR drugs non persistence[TW] OR drugs 
nonpersistence[TW] OR drugs persistance[TW] OR drugs non-persistance[TW] OR 
drugs non persistance[TW] OR drugs nonpersistance[TW])) 
AND 
(Prospective Studies[MH] OR Longitudinal Studies[MH] OR Cohort Studies[MH] OR 
Follow-up Studies[MH] OR Retrospective Studies[MH] OR Prospective Studies[TIAB] 
OR Longitudinal Studies[TIAB] OR Cohort Studies[TIAB] OR Follow-up Studies[TIAB] 
OR Retrospective Studies[TIAB] OR observational stud*[TIAB] OR predict*[TW] OR 
prognos*[TW] OR prognostic factor*[TW] OR course[TW] OR determinant*[TW])) 
NOT 
"Africa"[Mesh] OR "Latin America"[Mesh] OR "Asia, Centrai"[Mesh] OR 
"Borneo"[Mesh] OR "Brunei"[Mesh] OR "Cambodia"[Mesh] OR "East Timor"[Mesh] 
OR "Laos"[Mesh] OR "Malaysia"[Mesh] OR "Mekong Valley"[Mesh] OR 
"Myanmar"[Mesh] OR "Philippines"[Mesh] OR "Singapore"[Mesh] OR 
"Thailand"[Mesh] OR "Vietnam"[Mesh] OR "Bangladesh"[Mesh] OR "Bhutan"[Mesh] 
OR "lndia"[Mesh] OR "Afghanistan"[Mesh] OR "Bahrain"[Mesh] OR "lran"[Mesh] OR 
"Egypt"(Mesh] OR "lraq"[Mesh] OR "lsraei"[Mesh] OR "Jordan"[Mesh] OR 
"Kuwait"(Mesh] OR "Lebanon"(Mesh) OR "Oman"[Mesh] OR "Qatar"[Mesh] OR 
"Saudi Arabia"[Mesh] OR "Syria"[Mesh] OR "United Arab Emirates"[Mesh] OR 
"Yemen"[Mesh] OR "Nepai"[Mesh] OR "Pakistan"[Mesh] OR "Sri Lanka"[Mesh] OR 
"China"[Mesh] OR "Korea"[Mesh] OR "Mongolia"[Mesh] OR "Taiwan"[Mesh] 
NOT 
(youth[TIAB] OR child*[TIAB] ) 
NOT 
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(Clinical Triai[MH] OR case reports[PT] OR review[PT] OR meta-analysis[MH] OR 
Cross-sectional Studies[MH] OR Case-control Studies[MesH:NoExp] OR Clinical 
Triai*[PT] OR case report*[PT] OR review*[PT] OR meta-analys*[PT] OR case 
report*[TIAB] OR case-report*[TIAB] OR review*[TIAB] OR systematic review*[TIAB] 
OR meta-analys*[TIAB] OR randomized controlled triai*[TIAB] OR randomised 
controlled triai*[TIAB] OR clinical triai*[TIAB] OR controlled clinical triai*[TIAB] OR 
cross-sectionai*[TIAB] OR cross sectionai*[TIAB] OR Case-control Studies[TIAB] OR 
case-controi[TIAB] OR case controi[TIAB] OR Editorial[ptyp] OR Letter[ptyp] OR 
Comment[ptyp] OR lnterview[ptyp] OR Newspaper Article[ptyp]) 
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Chronic preventive maintenance medication 
A02BA01 Cimetidine B01AC04 Clopidogrel 
A02BA02 Ranitidine B01AC06 Acetylsalicylic acid 
A02BA03 Famotidine B01AC07 Dipyridamole 
A02BA04 Nizatidine B01AC08 Carbasalate calcium 
A02BA07 Ranitidinebismutcitrate B01AC09 Epoprostenol 
A02BB01 Misoprostol B01AC21 Treprostinil 
A02BC01 Omeprazole B03BB01 Folic acid 
A02BC02 Pantoprazole COlAAOS Digoxin 
A02BC03 Lansoprazole COlBAOl Quinine 
A02BC04 Rabeprazole C01BA02 Procainamide 
A02BCOS Esomeprazole C01BA03 Disopyramide 
A07EA04 Betamethasone COlBBOl Lidocaine 
A07EA06 Budesonide C01BB04 Aprindine 
A07EA07 Beclomethasone C01BC03 Propafenone 
A07EC01 Sulphasalazine C01BC04 Flecainide 
A07EC02 Mesalazine COlBDOl Amiodarone 
A07EC03 Olsalazine C01DA08 lsosorbidedinitrate 
A lOA Insulin C01DA14 lsosorbidemononitrate 
A10BA02 Metformin C01DX16 Nicorandil 
AlOBBOl Glibenclamide C01EB17 lvabradine 
AlOBB03 Tolbutamide C02AB01 Methyldopa 
AlOBB07 Glipizide C02CA01 Prazosin 
A10BB09 Gliclazide C02CA04 Doxazosin 
AlOBB12 Glimepiride C02CA06 Urapidil 
AlOBFOl Acarbose C02DB02 Hydralazine 
A10BG02 Rosiglitazone C02DC01 Minoxidil 
AlOBG03 Pioglitazone C02KD01 Ketanserin 
AlOBHOl Sitagliptine C02KX01 Bosentan 
A10BX02 Repaglinide C02KX03 Sitaxentan 
A11CC03 Alfacalcidol C03AA03 Hydrochloorthiazide 
A11CC04 Calcitriol C03AA04 Chlorthiazide 
AllCCOS Colecalciferol C03BA04 Chlortalidone 
A12AA01 Calcium phosphate C03BA11 lndapamide 
A12AA02 Calciumglubionate C03CA01 Furosemide 
A12AA03 Calciumgluconate C03CA02 Bumetanide 
A12AA04 Calciumcarbonate C03DA01 Spironolactone 
Al2AAOS Calcium lactate C03DA04 Eplerenone 
A12AA07 Calciumchloride C03DB01 Amiloride 
A12AA12 Calciumacetate C03DB02 Triamterene 
A12AA30 Calciumlevulinate C04AC01 Nicotinic acid 
B01AA03 Warfarin C04AD02 Xantinolnicotinate 
B01AA04 Fenprocoumon C07AA02 Oxprenolol 
B01AA07 Acenocoumarol C07AA03 Pindolol 
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C07MOS Propranolo l ClOABOl Clofibrate 
C07M07 Sotalol C10AB02 Bezafibrate 
C07AB02 Metoprolol C10AB04 Gemfibrozil 
C07AB03 Atenolol C10AB08 Ciprofibrate 
C07AB04 Acebutolol ClOACOl Colestyramine 
C07ABOS Betaxolol C10AC02 Colestipol 
C07AB07 Bisoprolol C10AC04 Colesevelam 
C07AB08 Celiprolol C10AD02 Nicotinic acid 
C07AB12 Nebivolol C10AD06 Acipimox 
C07AG01 Labetalol C10AX09 Ezetimib 
C07AG02 Carvedilol G03XA01 Danazol 
C08CA01 Amlodipine G03XC01 Raloxifene 
C08CA02 Felodipine G04BD02 Flavoxate 
C08CA03 lsradipine G04BD04 Oxybutynin 
C08CA04 Nicardipine G04BD07 Tolterodine 
C08CAOS Nifedipine G04BD08 Sol ifenacin 
C08CA06 Nimodipine G04BD10 Darifenacin 
C08CA07 Nisoldipine G04CA01 Alfuzosin 
C08CA08 Nitrendipine G04CA02 Tamsulosin 
C08CA09 Lacidipine G04CA03 Terazosin 
C08CA12 Barnidipine G04CB01 Finasterid 
C08CA13 Lercanidipine G04CB02 Dutasterid 
C08DA01 Verapamil H02M02 Fludrocortisone 
C08DB01 Diltiazem H02AB01 Beta methasone 
C09AA01 Captopril H02AB02 Dexamethasone 
C09M03 Lisinopril H02AB04 Methylprednisolone 
C09M04 Perindopril H02AB06 Prednisolone 
C09MOS Ramipril H02AB07 Prednisone 
C09M06 Quinapril H02AB08 Triamcinolone 
C09M07 Benazepril H02AB09 Hydrocortisone 
C09M08 Cilazapril H02AB10 Cortisone 
C09M09 Fosinopril JOSAEOl Saquinavir 
C09M10 Trandolapri l JOSAE02 lndinavir 
C09M15 Zofenopril JOSAE03 Ritonavir 
C09CA01 Losartan JOSAE04 Nelfinavir 
C09CA02 Eprosartan JOSAEOS Amprenavir 
C09CA03 Valsartan JOSAE06 Lopinavir 
C09CA04 lrbesartan JOSAE07 Fosamprenavir 
C09CA06 Candesartan JOSAE08 Atazanavir 
C09CA07 Telmisartan JOSAE09 Tipranavir 
C09CA08 Olmesartan JOSAElO Darunavir 
ClOMOl Simvastatin JOSAFOl Zidovudine 
C10M03 Pravastatin JOSAF02 Didanosine 
C10M04 Fluvastatin JOSAF03 Zalcitabine 
ClOAAOS Atorvastatin JOSAF04 Stavudine 
C10AA07 Rosuvastatin JOSAFOS Lamivudin 
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JOSAF06 Abacavir MOSBA04 Alendronate 
JOSAF07 Tenofovir MOSBAOS Tiludronate 
JOSAF08 Adefovir MOSBA06 lbandronate 
JOSAF09 Emtricitabine MOSBA07 Risedronate 
JOSAFlO Entecavir MOSBA08 Zoledronate 
JOSAFll Telbivudine MOSBX03 Strontiumranelate 
JOSAGOl Nevirapine N02CX01 Pizotifen 
JOSAG03 Efavirenz N02CX02 Clonidine 
JOSAX07 Enfuvirtide R03BA01 Beclomethasone 
LOlAAOl Cyclophosphamide R03BA02 Budesonide 
LOlBAOl Methotrexate R03BA05 Fluticasone 
L02BG01 Aminoglutethimide R03BA08 Ciclesonid 
L02BG03 Anastrozole R03BC01 Cromolyn sodium 
L02BG04 Letrozole R03BC03 Nedocromil 
L04AA06 Mycophenol acid R03DC03 Montelukast 
L04AA10 Sirolimus S01EA02 Dipivefrine 
L04AA13 Leflunomide S01EA03 Apraclonidine 
L04AA18 Everolimus SOlEAOS Brimonidine 
L04AB01 Etanercept S01EA51 Epinephrine 
L04AB02 lnfliximab SOlEBOl Pilocarpine 
L04AB04 Adalimumab S01EB08 Aceclidine 
L04AC03 Anakinra SOlE COl Acetazolamide 
L04AD01 Ciclosporine S01EC03 Dorzolamide 
L04AD02 Tacrolimus S01EC04 Brinzolamide 
L04AX01 Azathioprine SOlEDOl Timolol 
L04AX03 Methotrexate S01ED02 Betaxolol 
MOlCBOl Aurothiomalate S01ED03 Levobunolol 
M01CB03 Auranofin S01ED04 Metipranolol 
MOlCCOl Penicillamine SOlED OS Carteolol 
M04AA01 Allopurinol 501ED06 Befunolol 
M04AB01 Probenecid 501EE01 Latanoprost 
M04AB03 Benzbromarone S01EE03 Bimatoprost 
MOSBAOl Etidronate S01EE04 Travoprost 
MOSBA02 Clodronate 
MOSBA03 Pamidronate 
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Explanation of abbreviations 
AACTG 
AGSRP 
ALTMBSES 
AM HI 
APIAQ 
ASBSI 
ATS 
ATSFDS 
AWC 
BDI 
BHLES 
BHS 
BMICIS 
BMQ 
BST 
CES-D 
CMHS 
DAS 
Dl 
DOS 
DSBSI 
DSPERI 
FRI 
FTSSH 
GHQ 
HAART 
HADS 
HAT-QUOL 
HCSUS 
HBS 
HMO 
HIE 
HIS 
IDD 
ICS 
ISEL 
LES 
LOT(-R) 
LSS 
LTMSES 
MAH 
MARS 
Adult AIDS Clinical Trials Group 
Adapted Gay Service Research Project 
Adapted Long Term Medication Behavior Self Efficacy Scale 
Adapted Mental Health Inventory 
Adapted Protease Inhibitor Attitude Questionnaire 
Anxiety Subscale of Brief Symptom Inventory 
Anxiety Trait Scale 
Adapted version ofTransplant Symptom Frequency and Distress Scale 
Adapted Ways of Coping 
Beck Depression Inventory 
Buffalo HIV Life Events Survey 
Beck Hopelessness Scale 
Billings and Moos Inventory of Coping with Illness Styles 
Beliefs about Medication Questionnaire 
Burnam Interviewer-administered 8-item Screening Tool 
Center for Epidemiologic Studies Depression Scale 
Cook-Medley Hostility Scale 
Dyadic Adjustment Scale 
Dysregulation Inventory 
Dispositional Optimism Scale 
Depression Subscale of Brief Symptom Inventory 
Demoralization Scale of Psychiatric Epidemiology Research Interview 
Family Relations Index (from Family Environment Scale) 
Finnish Twin Study Scale of Hostility 
General Health Questionnaire 
Highly Active Antiretroviral Therapy 
Hospital Anxiety and Depression Scale 
HIV/AIDS-Targeted Quality of Life Instrument 
HIV Cost and Services Utilization Study 
Health Behavior Scale 
Health maintenance organization 
Horowitz Impact of Events Scale 
Health Intention Scale 
Inventory to Diagnose Depression 
Inhaled corticosteroids 
Interpersonal Support Evaluation List 
Life Experience Survey 
Life Orientation Test 
Life Stressors Scale 
Long Term Medication Self-Efficacy Scale 
Mental Adjustment to HIV 
Medication Adherence Report Scale 
Psychosocial predictors of non-adherence: systematic review of longitudinal studies I 161 
MAS 
MASRI 
MEMS 
MHLCS 
MOS SF-36 
MS 
NEO-FFI 
NSEPQSS 
Pat SS 
POMS 
PPCS 
PRQ 
PSS 
RSEQR 
sc 
SF-36 
SLC(-90) 
SMS 
SPS 
SSAI 
SSAS 
SSQ 
TSQ 
VAS 
Miller Attitude Scale 
Medication Adherence Self-Report Inventory 
Medication Event Monitoring System 
Multidimensional Health Locus of Control Scale 
Medical Outcome Study Health Survey Short Form-36 
Memphis Survey 
N EO Five Factor Inventory 
Neuroticism Scale ofthe Eysenck Personality Questionnaire-Revised Short Scale 
Patient Satisfaction Scale 
Profiles of Mood States 
Perceived Parenting Competence Scale 
Personal Resource Questionnaire 
Perceived Stress Scale 
Rosenberg Self-Esteem Questionnaire 
Symptom Checklist 
Short Form 36 Health Survey 
Symptom Checklist (90) 
Sense of Mastery Scale 
Social Provision Scale 
Social Support Appraisals Index 
Social Support Appraisal Scale 
Social Support Questionnaire 
Transplant Stress Questionnaire 
Visual Analogue Scale 
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TABLES Sl, 52, 53, AND S4 
Table Sl Framework for judging methodological quality 
Bias domiln Criterion 
1. 1.1. The setting of the so~rc; pop~i~dequately describ~d by key 
Study characteristics (setting I geographical location) 
participation 
1.2. The (baseline) study sample is adequately descnbed by key characteristics 
(descriptive data about age, sex, d1agnos1s, disease duration and 
med1cat1on type/group), and no unacceptable level of b1as is present 
1.3. The method of recruitment or sampling 1s adequately descnbed. If 
method of recruitment IS not 'consecutive', then, for example, 
descriptions are given about the sampling frame, numbers, methods to 
identify the sample (such as a descnpt1on of referral patterns 1n 
healthcare) and period of recruitment, and no unacceptable level of bias is 
present 
1.4. Inclusion and exclusion cnteria are adequately described, and no 
unacceptable level of b1as IS present 
1.5. There is adequate participation 1n the study by eligible individuals 
(power analysis 1s descnbed or the sample size (n) is adequate in 
relation to the number of prognostic variables (K) in the statistical 
analyses (;atio n:K exceeds 10:1) 
Score 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
Judgment 
Sx yes= yes 
1x no= no 
Else = partly 
Finale score 
OYes 
0 Partly 
ONo 
- Table 51 continues -
- Table 51 continued-
Bias domain Criterion 
2. 
Study attntion 
3. 
Prognostic 
factor 
measure-
ment 
2.1. Response rate (ie, proportion of study sample completing the study and 
providing outcome data) 1s adequate 
If study sample size~ 50 participants 'yes' when total number of 
participants lost to follow-up was< 10% at follow-up~ three 
months. 'Partly' 1fthis percentage was between 10% and 20%. 'No' : if this 
percentage was~ 20% 
If study sample s1ze >50 participants 'yes', when total number of 
participants lost to follow-up was< 20% at follow-up~ three 
months. 'Partly'· if this percentage was between 20% and 33% 'No' : 1f th1s 
percentage was ~ 33% 
2.2. Attempts to collect information about part1c1pants who dropped out of the 
study are descnbed 1) reasons for loss to follow-up are provided OR 2) 
participants lost to follow-up are adequately described by key 
characteristics and outcomes. No unacceptable level of bias is present 
3.1. A clear description of the main prognostic factors is provided (not 
covariates) AND/OR measures/methods regarding the main prognostic 
factors, at basel1ne and follow-up are adequately described to allow 
assessment of their valid1ty and reliability. 
No unacceptable level of b1as is present 
o ObjectiVe measures (such as number of life-changing events) and clear 
description is 'yes' Poor/no description= 'partly' 
o Validated, subjective measures (eg, op1mons) and clear description = 
'yes' Poor/no description= 'partly' 
o Non-validated, subjective measures and clear description = partly' 
Poor/no description = 'no' 
Score 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
Judgment 
2.1 yes= yes (you 
can leave 2 2 
open) 
2 1 no= no 
OR 2.1 partly, 2.2 
no= no 
Else = partly 
4x yes= yes 
3.1 or 3.2 no= no 
OR 31 or 3.2 
partly (no no's), 
3.3 or 3.4 no = no 
Else = partly 
F1nale score 
OYes 
0 Partly 
0 No 
OYes 
0 Partly 
0 No 
- Table 51 continues -
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- Table 51 continued-
Bias.domain-- · --·--a:~ion 
- ------ ·------:-3.2. The method and settmg of measurement are the same for all study 
participants at baseline and follow-up 
3.3. Contmuous variables are reported or appropriate cut-off points are used 
3.4. Authors appropnately descnbed and dealt w1th missing data on 
prognostic factors 
4. 4.1. A clear descnpt1on of med1cat1on adherence is provided AND/OR 
Outcome measures/methods of med1cat1on adherence (at basel me and 
measurement follow-up) are adequately descnbed, to allow assessment of the1r 
validity and reliability . No unacceptable level of bias is present 
5. 
Confounding 
measurement 
and account 
o Objective measures (such as pill count, ref11\ rates, MEMS) and clear 
description= 'yes' Poor/no description IS 'partly' 
o Validated, subjective measures (eg, questionnaires) and clear description 
='yes' . Poor/no description= 'partly' 
o Non-validated, subjective measures and clear descnpt1on ='partly' . 
Poor/no descnption ='no' 
4.2. The method and setting of measurement are the same for all study 
participants at baseline (1f measured) and follow-up 
4.3. Authors appropriately described and dealt w1th missing outcome data 
5.1. The most Important confounders are measured 
Examples of possible confounders age; socioeconomic 
status/educationallevel/fmanclal Situation/ill iteracy; social 
support/networks; depression/anxiety/emotional distress/lack of acceptance 
of disease; fatigue/pam/physical disability; self-efficacy/coping; reg1men 
complexity/route of administration/number of med1cat1ons, satisfaction wit h 
patient-provider relationship/autonomy 
----···-·-·-
Score Judgment Finale score 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 3x yes= yes OYes 
o Pa rtly 
4 1 or 4.2 no= no O No 
OR 4.1 or4.? 
partly (no no's), 
4 3 no= no 
Else = partly 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No One of 5.1 to 5.4 = O Yes 
no (if 5.1 no, you 0 Partly 
can leave 5.2 to 0 No 
5.5 open) 
OR5.1 to 54 
partly, 5.5 no = no 
- Table 51 continues-
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-Table 51 continued-
B1as domain Criterion Score 
5.2. A clear descnption of the most important confounders meosured IS 0 Yes 0 Partly 0 No 
provided AND/OR measures/methods ofthe most important 
confounders (at baseline) are adequately described to allow assessment of 
the1r validity and reliability. No unacceptable level of b1as is present 
o Objective measures (such as age, sex) and clear description= 'yes'. 
Poor/no description IS 'partly' 
o Validated, subjective measures (eg, opinions) and clear description = 
'yes' Poor/no description= 'partly' 
o Non-validated, subjective measures and clear descnpt1on = 'partly' . 
Poor/no description= 'no' 
5.3. The method and setting of confounding measurement are the 
same for all study participants at baseline 
5.4. Important potential confounders are accounted for in the study 
design (eg, matching for key vanables/ restnction) OR 1n analysis 
stratif1cat1on/mult1variate techmques) 
5.5 . Authors appropnately described and dealt with missing confounding data 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
Judgment 
All partly= partly 
OR 51 to 5.4 
partly, 5.5 yes= 
partly 
OR none of 5.1 to 
54 no, 5.5 no= 
partly 
OR 5.1 to 5.4 yes, 
5.5 not yes = partly 
Else= yes 
Finale score 
- Table 51 continues -
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-Table 51 continued-
--·-·- ···· 
Bias domain Criterion Score 
-~----·--·---- -- ---~----·--·· 6. Analysis 6.1. There 1s sufficient presentation of data to assess the adequacy of the analysis 0 Yes 0 Partly 0 No 
'Yes', if main findings of the study and stat1st1cal methods used are 
clearly descnbed simple outcome data, crude data and estimates of 
random vanabi11ty should be reported, so that the reader can check the 
major ana lyses and conclusions 
6.2. The stat1st1cal tests used to assess the mam outcome are appropriate 
For example. non-parametric methods should be used for small 
sample sizes 
6.3. The strategy for model building (ie, Inclusion of Vdriables) 1s appropnate, and 
is based on conceptual thoughts, a framework or a model 
For example vanables that do not correlate w1th the mam outcome of 
interest are not used m multivariate analysis . Proper vanables are 
entered in logical steps mto the mult ivariate model 
6.4. The selected model is adequate for the design of the study 
For example in repeated measures, a repeated-measure model should be 
used . If outcome is bmominal, logistic regress1on should be used, 
etcetera . If delta outcome is being mvestigated, models should to be 
adjusted for baseline outcome values 
Abbreviation : MEMS, medication event monitoring system 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
0 Yes 0 Partly 0 No 
Judgment 
4x yes= yes 
At least lx no = no 
Else = partly 
Finale score 
DYes 
0 Partly 
0 No 
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Table 52 
First 
author, 
year 
Pomeman, 
200933 
. 
Explanation of measures and results 
Setting, 
n patients 
USA; patients 
from general 
internal 
medicine clinic, 
n = 261 
Measures 
--t 
Adherence, 
follow-up period* 
Adherence by self-
report (MARS), 3 
months 
Psychosocial predictors§ 
Psych 
cat.11 
~ Results 
Univariate 
ASTHMA (inhaled corticosteroids) 
(Items derived from BMQ AI OR = 0.3 (O 2, 0.7) 
and Self-Regulation Theory) : p < 0.05 
concerns beliefs: worried 
about side effects of ICS? 
Concerns beliefs warned AI OR= 0.4 (0.2, 0.8), 
about gettrng addicted to p < 0.05 
ICS? 
Concerns beliefs: if I use ICS AI OR= 0.4 (0.2, 0.9), 
all the t1me they will stop p < 0.05 
working 
Necessity beliefs: Important AI n.s. 
to use ICS when 
symptomatic? 
Necessity beliefs: Important AI OR=58 
to use ICS when (23,14 6), p < 0.05 
asymptomatic? 
Self-efficacy confident 1n Alii OR= 3.5 (1.6, 7.6), 
ability to use ICS as p < 0.05 
prescribed 
Multivariate 
OR= 0.52 
(0.36, 0.74), p 
< 0 001 
** n.s. 
H 
n.s. 
H 
n.s. 
OR=4.15 
(2.54, 6 77), p 
<0001 
OR= 22.3 
(142, 3.52), p 
< 0.001 
Direction of 
association 
(regarding 
.. 
adherence) 
u :. 
M:-
U: -
M : O 
U:. 
M: O 
U:O 
M : O 
U: + 
M : + 
U: + 
M : + 
N 
domains 
bias 
freett 
0 of 6 
- Table 52 continues-
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-Table 52 continued-
... .. -- ·· ··-·----
First Setting, Measures 
author, 
year 
n pat1ents 
--t 
Adherence, 
Psych 
cat. II 
Results 
Psychosocial prediCtors§-- Univariate 
Ponieman, 
200933 
(continued) 
* follow-up p~r...:.cio:..:d'----:-:--·::- ---:-
Self-efficar.y: confident 1n 
ability to control asthma 
Ventunni, 
1999"''§§ 
USA; 
patients from 
HMO-
providing 
health 
serv1ces, n = 
786 
Adherence by 
record review 
(continuous 
measure 
corrected for 
self-reported 
baseline 
adherence), last 
t1me po1nt 
flex1ble, but 
within '24 
months 
Self-efficacy confident in 
controlling future health 
Alii 
Alii 
n.s. 
n.s. 
DIABETES (oral and/or parenteral anti-diabetics) 
Perception of mental health 
(mood state, SF-36) 
El n.r. 
Multivariate 
~~ 
n.s. 
H 
n.s. 
n.s. 
·----·-
Direction of 
association 
(regardtng 
•• 
adherence) 
U:O 
M: O 
U:O 
M: O 
N 
domains 
bias 
free tt 
U: n.r. 2 of6 
M: O 
- Table 52 continues-
- Table 52 continued-
First Setting, 
author, n patients 
year 
Gazmara-
nan, 200635 
1111 
Nabi, 200826 
USA; 
community-
dwelling 
patients, n = 
1549 
Fmland local 
government 
employees, n = 
1021 
Measures 
Adherence t' 
follow-up pertod* 
Non-adherence 
by record 
review, 12 
months 
Non-adherence 
by record 
review (ordinal 
measure), 12 
months 
Psychosocial predictors§ 
Psych 
cat.0 
Results11 
Univariate 
HEART DISEASE & HYPERTENSION (cardiovascular medication) 
Social support (instrument 
n.r .) 
Anxiety (ATS) 
Hostility (FTSSH) 
Optimism (LOT-R) 
Pessimism (LOT-R) 
Psychological distress (GHQ) 
Sense of coherence (SOC) 
([[[ n.s. 
El n.s. 
D n.s. 
D n.s. 
D n.s. 
El n.s. 
D OR = 0.62 (0.36, 
1.05), p < 0.10 
Multivariate 
n.t . 
n.t . 
n.t. 
n.t. 
n.t . 
n.t . 
OR= 0.55 
(0.31, 0.96), p 
<0.05 
Direction of 
assodation 
(regarding 
adherence) 
U: O 
M : n.t . 
.. 
U: 0, M : n.t . 
U: O, M : n.t. 
U: 0, M : n.t. 
U: 0, M : n.t. 
U: 0, M : n.t . 
U: O, M: + 
N 
domains 
bias 
freett 
3 of6 
1 of6 
- Table 52 continues-
- Table 52 continued -
. --· ·· ···-·----- --- ··- . ·---
First Setting, 
author, n patients 
year 
Measures 
Adherence t' 
follow-up period* 
---.. --- - .. - -....... -.----
Gregoire, 
200636 
Canada : 
hypertensive 
adults with 
prescnpt1on 
from 
network of 
pharmacies, 
n = 692 
Non-adherence 
by self-report 
(Morisky Scale), 3 
months 
Psychosocial predictors§ 
· (lnt~rview, self-developed 
items) : beliefs concerning 
efficacy of antihypertensive 
medication 
Beliefs concerning 
hypertension as nsk factcr for 
other diseoses 
How much are you at risk of a 
heart attack because of your 
hypertension 1f you follow 
your doctor's advice7 
How much are you at risk of a 
stroke because of your 
hypertension if you follow 
your doctor's advlce7 
Psych 
cat.n 
AI 
All 
All 
All 
R~;~Jts11 
Univariate 
n.s. 
"No effect" vs . "a 
lot of effect" (ref. 
cat) ; OR= 1.74 
(1.08, 2 81), 
p = 0.02 
n.s. 
n.s. 
Multivariate 
n.s. 
"No effect" vs. 
"a lot of effect" : 
OR= 2.00 (1 .21, 
3.33), p !': 0.05 
n.s. 
n.s. 
Direction of 
association 
(regarding 
adherence) 
U: O 
M : O 
U:-
M : -
U: O 
M : O 
U: O 
M : O 
•• 
·-·------
N 
domains 
bias 
free tt 
· .. - .. - -
0 of 6 
- Table 52 continues-
f-' 
-Table 52 cantinued--...! 
N 
First Setting, Measures Psych Results~ Direction of N 
n author, n patients cat. U association domains ::;:,-
Ill (regarding bias ""0 year 
..... 
•• ~ tt ~ adherence) ree 
Vl t-- § Multivariate Adherence, Psychosocial predictors Univariate 
follow-up period* 
Gregoire, How much are you at risk of All Do not know" vs. n.s. u.o 
200636 heart attack because of your "no to moderate M: O 
(continued) hypertension if you do not do nsk" (ref. cat) : OR 
anything about 1t? = 0.46 (0.19, 1.12). 
p = 009 
How much are you at risk of All "Do not know" vs "Do not know" U:O 
stroke because of your "no to moderate vs. "no to M : O 
hypertension if you do not do nsk" (ref. cat .): OR moderate risk" : 
anythmg about 1t? = 0.44 (0.17, 1.16), OR= 0 40 (0.15, 
p = 0.10 1.09), p = O.Q7 
Social support (Pearlin et al.") Clll n.s. n.s. U:O, M : O 
Miller, 1985"" Site not Adherence by Attitude towards med1cat1on AI n.r. n.s. U: n.r. Oof6 
§§§ reported: self-report taking (MAS) M: O 
patients (continUOUS 
from measure, HBS), 
Beliefs about wh1ch steps of U: n.r. institutions 6-9 months Cll n.s. 
providing the medical regimen people M : O 
cardiac most important to them th1nk 
rehabilitation they should perform (HI!'>) 
programs, n 
= 141 
- Table 52 continues-
- Table 52 continued-
---- --------- ---- -----· ---------------------- --- -·- '11 - -----
Rrst Setting. Measures Psych Results 
author, n patients cat H 
year 
Molloy, 
2008"9 §§§ 
Adherence 1, 
·follow-up period* 
------·-
u K; patients Adherence by 
admitted to self-report, 12 
one of four months 
London 
hospita ls with 
Acute 
Coronary 
Syndrome, n = 
295 
--§ 
Psychosocial predictors 
.. . 
Emotional support (denved 
from Berkman et al.40 and 
Seeman et al.41) 
Practical support 
Clll 
Clll 
Univariate 
n .~ . 
Number of patients 
providing practical 
support 0 39 7% 
adherent.l : 40.5% 
adherent 1 or 
more : 59.2% 
adherent, p=0.004 
Multivariate 
n.s. 
OR= 2.12 
(1 06, 4.26), p 
=0.03) 
· ···--·-·--··-·-
Oirectlon of 
association 
(regarding 
adherence) 
-----U: O 
M :O 
U: + 
M:+ 
... 
N 
domains 
bias 
free 
tt 
1 of6 
- Table 52 continues-
- Table 52 continued -
First Setting, 
author, n patients 
year 
Deschamps, Belgium; out-
200425 patients of 
university 
hospital, n = 60 
Measures 
-- t 
Adherence, 
follow-up period* 
Non-adherence by 
MEMS, 5-6 
months after 
measuring 
psychosocial 
constructs 
Psych Results 'II 
catn 
Psychosocial predicto~ Univariate 
HIV (antiretroVJral medication) 
Anxiety (AM HI) El n.s. 
Copmg style Bl n.s. 
confrontational (AWC) 
Cop1ng style: distancing Bll n.s. 
Copmg style: self- Bll n.s. 
controlling 
Coping style: seek soc1al Clll n.s. 
support 
Coping style : accept Bll n.s. 
responsibility 
Multivariate 
n.r. 
Direction of 
association 
(regarding 
.. 
adherence) 
U: O, M: n.r. 
U: 0, M : n.r. 
U: 0, M: n.r. 
U: 0, M : n.r. 
U: 0, M : n.r. 
U: 0, M : n.r. 
N 
domains 
bias 
freett 
1 of 6 
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- Table 52 continued-
·-i=ir$1:--.. -· .. ···--se_tt_t_n& ___ .. __ M_e_asures----------------p-sy(il·-~ui~'J~. --·- --- ·-· 
author, n patients cat. II 
year 
Deschamps, 
200425 
(contmued) 
t Adherence, 
follow-up penod* 
Psychosoctal predictors§. 
Coping style: escape-avoidance 
(higher score= more escape-
avoidance) 
Coping style planful problem 
solving (h1gher score = more 
planful problem solving) II II II 
Coping style : positive reappraisal 
Univariate 
Bll Adherent patients 
7.2, (2 .2) vs. non-
adherent patients 
10.1 (2.8), p = 0.003 
Bl Adherent patients 
7.5 (med1an), 3 
(IQR) vs. non-
adherent patients 9 
(med1an), 2 (IQR), p 
= 0.049 
Bl n.s. 
Depression (AM HI) El n.s. 
f'erce1ved benef1ts of treatment AI 
(APIAQ) 
Perceived seventy of senousness AI 
of impl ications when not taking 
medications adequately 
Adherent patients 
21 (3.5) vs . non-
adherent pat1ents 
18.7 (3.9), p =- 0 .07 
n.s. 
Multivariate 
Direction af __ N __ _ 
association 
( repdi ng •• 
adherence) 
U: -
M: n.r. 
U: -
M : n.r. 
U:O 
M : r. 
U: O,M : n.r. 
U:O 
M: n.r . 
U: O 
M: n.r. 
domains 
bias 
freett 
- Table 52 continues-
f-' 
- Table 52 continued-
-...! 
0'\ Psych--Results 11 ·-- · ··---·---First Setting, Measures Direction of N 
n author, n pattents cat.11 association domains :::y 
OJ year {regarding bias 
-o 
... .. tt ro adherence) free ~ 
Ul 
-- t--
Psychosocial predictors§ Adherence, Univariate Multivariate 
follow-up period* 
Deschamps, Perceived susceptibility of AI n.s. U:O 
2004"5 developing AIDS when not M : n.r. 
(continued) tak1ng med1cat1ons as 
prescribed 
Positive affect (eg, happiness D n.s. U: 0, M : n.r. 
person) 
Rece1ved social support Clll n.s. U: 0, M : n.r. 
(AGSRP) 
Self-efficacy in taking HAART Alii n.s. U: 0, M : n.r. 
medication (ALTMBSES) 
Holmes, USA, HI\/- Adherence by Depressive symptoms (CES-D) El H1gh adherence n.s. u 0 2 of6 
200719 clinic patients, MEMS, 12 months 12.6 (11.3), low M : O 
n " 116 (or when viral load adherence 16.5 
of~1000 (11.7), p;: 0.06 
copies/ml was 
reached) 
HIV-disclosure worries (HAT- All n.s. n.t . U: 0, M : n.t . 
QOL) 
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- Table 52 continued -
First Setting, 
author, n patients 
year 
Holmes. 
2007' 9 
(continued) 
Measures 
t 
Adherence, 
* follow-up period 
Psychosocial. predictors§ 
Health wornes (higher score= 
fewer worries) 
Med1cat1on worries (higher score = 
fewer wornes) 
Provider trust 
Social support (ISEL) 
St ress (PSS) 
PsYdl-~ults 'II 
cat. II 
Univariate 
All H1gh adherence 79.2 
(23.9},1ow 
adherence 704 
(28.9}, p = 0 .06 
AI High adherence 86.1 
(20.4).1ow 
adherence 83.3 
(18.3}. p = 0.06 
Cl n.s. 
Clll n.s . 
Ell High adherence 12.4 
(7.8). low adherence 
15.3 (8.2), p = 007 
----··-D-ire- cti-on- of- ·---:N.,.---
assodation domains 
(regarding bias 
•• tt 
adherence) free 
MultiVariate 
n.s. U: O 
M : O 
n.s. U: O 
M : O 
n.t . U: 0, M : nt. 
n.t . U: 0, M : n.t . 
n.s. U: O 
M : O 
- Table 52 continues -
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- Table 52 continued--...! 
co 
First Settmg, Measures Psych Results 11 Direction of N n author, n patients cat. 11 association domains :::r-OJ (regarding bias -a year ,... 
ro .. tt 
' 
adherence) free 
lJl 
---+ 
Adherence, Psychosocial predictors§ Univariate Multivariate 
follow-up period* 
Delgado, Canada; Adherence by Depressive symptoms (CES-D) El Not reporting n.s. U: - 1 of 6 
2003''' patients record rev1ew, 12 depress1on 79.8% M : O 
enrolled in months adherent, 
community reporting 
drug treatment depression 68 1% 
program, n = adherent, p = 0.02 
316 
Singh, USA; Non-adherence by Confusion and bewilderment Bll n.s. n.t . U: 0, M : n.t . 1 of6 
199643 new veteran record review, 6 (POMS) 
patients seen at months 
medical center, Depression and dejection El Adherent 14.2 n.s. U: -
n = 52 (SEM 1.9), non- M: O 
adherent 22.1 
(SEM 3.4), p = 
0.04 
Mood disturbance El 39% 1n adherent OR= 1.4 (1.1, U: -
patients, 76% In 1.8), p = 0.01 M : -
non-adherent 
patients, p = 0.03 
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- Table 52 continued-
--·~- - -·- ·----·---· F1rst Setting, Measures 
author, n patients 
year 
Singh, 
199643 
(continued) 
Smgh, 
199944 
S1te not 
reported : 
patients in 
HIV-medical 
centers, 
n = 138 
t " 
Adherence, 
follow-up period* 
Psychosocial prediCtOrs§ 
--------:· ·--··- ·-
Religious support (instrument 
Non-adherence by 
record rev1ew, 6 
months 
n r.) 
Social support (instrument n.r) 
Symptoms of depression (BDI) 
Tens1on and anxiety (POMS) 
Copmg style active-behavioral 
focused (higher score= greater 
applicability of coping style to 
patient, BMICIS) 
Copmg style: active-cognitive 
focused 
Coping style: avoidant coping 
Copmg style: emotion-focused 
Clll 
Clll 
El 
El 
Bl 
Bl 
Bll 
Bll 
Univariate 
n.s. 
n.s. 
n.s. 
n.s. 
(Mean score, 
SEM) : 
Non-adherent 5.2 
(0.5) vs. adherent 
6.6 (0.2), p = 0.01 
n.s. 
Non-adherent 3.3 
(0.3) v~ . adherent 
2.6 (0.2), p = 0.02 
n.s. 
----···---oirect~~-n·at-=--.....,..,N---
Multivariate 
n.t . 
n.t . 
nt. 
n.t . 
n.r. 
association domains 
(regarding bias 
adherence) •• free tt 
U: 0, M : n.t . 
U: 0, M : n.t . 
U: 0, M : n.t . 
U: 0, M : n.t . 
U: + 
M : n.r. 
U: 0, M : n.r. 
U: -
M . n.r. 
U: 0, M : n.r. 
1 of 6 
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- Table 52 continued-
First Setting, 
author, n patients 
year 
Singh, 
1999''• 
(continued) 
Measures 
Adherence t,--- Psychosocial predictors§ 
follow-up period* 
Copmg style : problem-focused 
Hopelessness : future expectations 
Hopelessness: loss of motivation 
(higher score = more 
hopelessness, 8HS) 
Hopelessness: negative feelings 
about future 
Hopelessness: total score 
Quality of life : psychological 
funct1omng (MOS SF-36) 
Sat1sfact1on w1th social support : 
emotional (SSQ) 
Psych 
cat.u 
81 
811 
Bll 
811 
811 
El 
Clll 
Results'~~ 
Univariate 
Non-adherent 6.0 
(OS) vs adherent 
7.1 (0.2), p = 0.02 
n.s. 
Non-adherent 1.75 
(0.5), adherent 0.6 
(0 1), p = 0.006 
n.s. 
n.s. 
n.s. 
n.s. 
Multivariate 
Direction of 
association 
(regarding 
adherence) 
U: + 
M : n.r. 
.. 
U: 0, M : n.r. 
U: -
M : n.r. 
U: O 
M : n.r. 
U: 0, M : n.r. 
U: 0, M: n.r. 
U: o, M : n.r. 
N 
domains 
bias 
freett 
- Table 52 continues -
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00 
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- Table 52 continued-
-- -·--
Rrst Setting, 
author, n patients 
year 
--.--------
Singh, 
199944 
(contmued) 
Measures 
--··t 
Adherence , follow-
up penod* 
Psychosocial predictors§ 
Satisfaction with social 
support : 1nformat1onal (higher 
scores= less satisfaction) 
Satisfaction with soc1al 
support . tangible 
Satisfaction w1th social 
support : total score 
Psych - Resul~'l-----------=0-irecb--on-Ot·--N -- -
cat. H assoaation 
Univariate 
Clll Non-adherent 7.9 
(1.1), adherent 6.1 
(0.3), p = 0.04 
Clll Non-adherent 7.7 
(1 .1), adherent 5 .5 
(0 .3), p = 0.07 
Clll Non-adherent 22 9 
(3 .3), adherent 16.8 
(0.75), p = 0.03 
Multivariate 
(regarding 
adherence) 
U: + 
M: n.r. 
u-o 
M: n.r. 
U: + 
M : n.r. 
.. 
domains 
bias 
free tt 
- Table 52 continues -
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- Table 52 continued-
First Setting, 
author, n patients 
year 
Bottonari, 
200545 
USA; 
pat1ents 
treated in 
immunodef 
iciency 
clinic, n = 
78 
Measures 
Adherence t, 
follow-up period* 
Adherence by self-
report 
(straightforward), 
6-9 months 
Psychosocial predictors§ 
Depressive symptoms (I DO) 
Experience of general (stressful) 
life events (LES) 
HIV-spec1f1c (stressful) life events 
(BHLES) 
Neuroticism: personality style 
indicative of affect1ve instability 
(NSEPQSS) 
Perceived stress (PSS) 
Self-esteem (RSEQR) 
Psych 
cat." 
El 
Ell 
Ell 
D 
Ell 
D 
Results1i Direction of N 
association domains 
(regarding bias 
•• tt 
adherence) free 
Univariate Multivariate 
n.s. n.r. U: O 0 of6 
M : n.r. 
n.s. U: O 
M : n.r. 
n.s. U: O 
M : n.r. 
n.s. u·o 
M : n.r. 
OR = 0.88 (0.77, 0.98), U:. 
p = 0.04 M · n.r. 
n.s. U: O 
M : n.r. 
- Table 52 continues-
- Table 52 continued-
First Setting. 
author, n patients 
year 
Godin, 
2005"" 
canada; . .. 
patients 
from 
medical 
HIV-clinics, 
n =400 
Measures ----psych-R~ults ·-----.. ·--------:D~ire-i:tiOn_Ot __ 
cat. 0 aSSOCiation 
N 
domains 
bias 
freett 
t--
Adherence, 
follow-up period* 
Psychosocial predtctors§ Univariate Multivariate 
- -.... . - ........ - - .. -·- ... - ....... . -.----· ·------ --.. ------- ------ - - ---
Adherence over Change in predictors related to AI n .. r. OR= 156 (1.18, 
t1me by self- adherence over time : 2 .. 06), p::; 0 .. 05 
report attitude towards medication-
( straightforward), ta~ing (more positive attitude = 
12 months greater adherence, self-developed 
scale) 
Optimism (DOS) D 
Outcome expectations (eg, believe Alii 
that specific course of act1on will 
lead to desired outcome, self-
developed scale) 
Patient-doctor satisfaction (Pat SS} Cl 
Self-efficacy regarding medication Alii 
taking (self-developed scale) 
Soc1al support (SPS) Clll 
n.s .. 
n.s. 
n.s .. 
OR = 1 .. 68 (1 .. 27, 
2 .. 22), p s 0.05 
n.s .. 
(regarding 
•• 
adherence) 
______ , ... -.--
U: n.r. 1of6 
M:+ 
U: n.r.,M : O 
U: n.r. 
M : O 
U: n .. r., M : 0 
U: n.r. 
M : + 
U: n.r. 
M : O 
- Table 52 continues -
""" - Table 52 continued-00
.j>. 
First Setting, Measures Psych Results, Direction of N 
n author, n patients cat.0 association domains ::::r 
ru (regarding b1as -a year 
..... .. tt ~ adherence) free 
V1 
Adherence t, Psychosocial predictors§ Univariate Multivariate 
follow-up period* 
·-------
Kacanek, USA; patients Suboptimal Development of depressive El Suboptimal n.t . U:- 2 of6 
20104; recruited by adherence by self- symptoms (BST) adherence in those M : n.t . 
media and report who developed 
physician (straightforward) : depressive symptoms 
networks, n = max. 30 months = 45 .1% vs 25.9% in 
225 those With no 
depressive 
symptoms, p = 0.01 
Martini, Italy; outpatients Adherence by self- (Interview, instrument n.r.): AI In "high adherence" n.r . U: + o of6 
2002<!8 using report (ordinal perception oftherapy: category, therapy M : n.r. 
§§§ combination measure, rel iable7 perceived as 
therapy, n = 214 straightforward "reliable" by 15.6%, 
questionnaire), 12 and "not reliable" by 
months 84.4%. In "variable 
adherence" cat 4.8% 
vs. 95.2%. In "low 
adherence" cat. 0% 
vs.lOO%, p = 0.02 
- Table 52 continues -
- Table 52 continued-
-----~------· ·------
·-·-·--- ·-· .... ·-·--··------- ·----···-----
"'0 F1rst Setting, Measures Psych Results Direction of N 
~ author, n patients cat.n association domains n 
:::r year (regarding bias 0 
"' 
•• tt 0 adherence) free n §[ 
't 
Psvchosodal predictors§ Univariate Multivariate 
-o Adherence, 
iil follow-up period* a_ p; ~-- --- · · 
0 Martini. Perception of therapy AI n.s. U: O v: 200248 §§0 enslaving? M : n.r. 0 
-
(contmued) :;, 
0 
:;, 
Satisfied about doctor /patient I Cl In "h1gh adherence" U: ? 
"' a_ discussion regarding cl inical category" · M : n.r. :::r 
ro 
and therapeutic aspects of "sufficient/highly ...., ro 
:;, treatment? satisfied" = 73 9%, n 
~ "little/not satJsfJed" = 
V> £6.1%. In "variable -< 
"' 
,..,. 
adherence" cat. 80% (I) 
3 vs . 20%. In "low 
"' cr. 
adherence" cat . 50% n 
iil vs . 50%, p = 0 OS 
< iii' 
:E 
0 Mellins, USA; Non-adherence Negative stressful events (PEl) Ell OR= 1.27 (1 09, 149), n.r. U:- Oof6 
-0 2003"~ HIV-infected by self-report p < 0 01 at Tl, OR = M : n.r. 
:;) 
(lQ mothers (MCTG, 1.28 (1.05,1.57), p = ;::;: 
c: recruited in straightforward), 0.02 atT2 a_ 
s· Waiting room Tl after 4-5 ~ 
"' 
of adult clinic, months, T2 8-18 
,..,. 
n = 128 months after Tl c: a_ 
iii' 
"' 
- Table 52 continues-
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- Table 52 continued-co 
0" 
Results 'il First Setting, Measures Psych Direction of N 
n author, n patients cat" assoc1at1on domains :::r 
OJ (regarding bias "0 year 
.... .. tt ~ adherence) free 
l.n 
t 
Adherence, Psychosocial predict~~§ Univariate Multivariate 
follow-up period* 
Mellins, Parenting stress (low scores= Ell OR= 0.86 (0.76, 0.98), U:-
20034" more stress, PPCS) p= M: n.r. 
(continued) 0.02 at T2 
Psychological distress El n.s. U: O 
(aggregated demoralization M : n.r. 
score, DSPERI) 
Self-efficacy 1n carrying out Alii n.s. u 0 
health-related behaviors M : n.r. 
(Chesney eta I 50) 
Nilsson Sweden; Adherence by Anx1ety symptoms (ASBSI) El n.r. n.s. U n r 1 of6 
Schon- pat1ents self-report M : O 
nesson, recru ited by (stra ight-
200651 cl inic nurses, forward ), 24 Bel iefin adherence necessity AI U: n r. 
n = '203 months 
n.s. 
(one item) M : O 
Belief that ART prolongs one's AI n.s. U: n.r. 
life (one item) M : O 
- Table 52 continues-
- Table 52 continued-
--·--·~·--·· - ·-
First -----:--:------------------ -- ---~ ·-····-- l!i.-----------~-Setting, Measures Psycho Results Dir&Ctlon of N 
author, 
year 
Nilsson 
Schon-
nesson, 
200651 
(continued) 
n patients cat. 
--t 
Adherence, 
§--
Psychosocial predictors 
follow-up period* 
. . . 
Belief in future HIV-related All 
health problems (self-
developed scale) 
Belief m Influencing HIV disease Alii 
(MAH) 
Beliefs in ART health concerns AI 
(eg, believe that medication 
makes sicker, one item) 
Coping mode : helplessness Bll 
(MAH) 
Coping mode : resilience {MAH) D 
Depressive symptoms (DSBSI) El 
Global soc1al support Clll 
satisfaction (one 1tem) 
Hopelessness (BHS) Bll 
Life stress (LSS) Ell 
aSSOCiation domains 
(regardtng bias 
•• tt 
adherence) free 
Univariate Multivariate 
···-·----
n.s. U: n.r. 
M : O 
n.s. U: n.r. 
M : O 
n.s. U: n.r . 
M : O 
n.s. U n.r . 
M : O 
n.s. U: n.r . 
M : O 
n.s. U: n .r. 
M 0 
n.s. U: n.r. 
M 0 
n.s. U: n.r. 
M : O 
n.s. U: n.r. 
M : O 
- Table 52 continues -
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- Table 52 continued-00 00 
First Setting, Measures Psych Results 11 Direction of N 
n author, n patients cat.0 association domains ::r OJ (regarding bias "0 year 
.... 
** freett ~ adherence) 
V1 
t 
Adherence, Psychosocial predictors§ Univariate Multivariate 
follow-up period* 
Nilsson Pat1ent-prov1der relationship Cl n.s. U: n.r. 
Schon- (self-developed scale) M : O 
nesson, Perceived pressure to take HIV Clll n.s. U: n.r. 
200651 
medication (self-developed M : O (contmued) 
scale) 
Posttraumatic stress disorder El n.s. U: n.r. 
symptoms related to HIV M : O 
diagnOSIS (HIE) 
Self-efficacy 1n taking Alii n.s. U: n.r. 
medication (self-developed M : O 
scale) 
Thrasher, USA; Adherence by self- (instruments n r.): El OR = 0 98 (0.96, 0.99), n.r. U: - 1 of 6 
200852 pat1ents in report (straight- depressive symptoms p=0.007 M : n.r. 
public use of forward ), 12 Dysthymia symptoms El OR = 0 92 (0.87, 0.96), U: -
HCSUS data- months p =0.001 M : n.r 
set, n = 1911 
Social support Clll n.s. U: O 
M : n.r. 
- Table 52 continues-
- Table 52 continued-
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.,., ___ 
-·-·Psych~utU'il ·- --- · ···--··---
"U Rrst Setting. Measures DireGtlon of N 
"' author, n patients cat.H association domains -<n 
::r year (regarding bias 0 
"' 
•• tt 
0 adherence) free 
n 
a;· 
Adherence t, 
- § 
"0 Psychosoaal predictors Vnivarlate Multivariate 
Cil follow-up period* Q_ 
n 
- --·-- ··------- ···········-·· .. - ·- --- - --- - - -···-· ---~-- -···-··---...... 
0 Horne, UK; Adherence by self- Depressive symptoms (HADS) El n.s. n.t . U: O 3of6 
Vl 2ooi' outpatients, report (vas- scale M : n.t . 0 
...... eligible to from MASRI, :::J HAART concern beliefs about AI High adherence OR = 0.45 U: -0 receive straight forward), 
'i' medication (BMQ) 2.9 (0.6) vs. low (0.22, 0 96), M : -
DJ HAART, n = 12 months Q_ adherence 3.3 p = 0.038 
::r 136 ~ (0.6), p = 0.005 (!) 
:::J HAART necessity beliefs about AI H1gh adherence OR= 219 U: + n 
(!) 
medication 4.0 (0.5) vs . low (1 .02, 4.71), M : + 
"' -< adherence 3.7 p = 0.045 
"' ..... (0 6), p = 0.006 (!) 3 
DJ 
d". 
n 
(i) Mugavero, USA; Non-adherence by Number of severe stressful Ell OR (per event)= n.s. U:- 3of6 
:S. 2009';4 Patients self-report events (LES, modified vers1on) 1.14 {1.03, 1 25) M : O (i) 
::E receiving care (AACTG, 
0 at one of straightforward, -~ Number of stressful events Ell OR (per event) = OR (per U: -0 eight corrected for 
:::J (moderate+ severe stressful 1.09 (1.04, 1.13) event)= 1.10 M : -O"Q infectious basel ine non-;::;: events) (1.04, 1.16) c d1sease adherence), 27 9: 
:::J cl inics, n = months !!!.. 
"' 
474 
...... 
c 
Q_ 
iii" 
"' - Table 52 continues-
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""" -Table 52 continued-<D 0 
First Setting, Measures Psych Results • Direction of N n author, n patients cat.11 association domains :::r QJ (regarding bias u year 
rt (I) .... tt 
..., adherence) free 
V1 
Adherence t, Psychosocial predictors§ Univanate Multivariate 
follow-up period* 
Mugavero, Number of traumatic events Ell OR (per event) = n.s. U: -
20095'; 1.73 (1.24, 2.39) M : O 
(continued) Number oftypes of lifet1me Ell n.s. n.s. U: O 
traumatic experiences M : O 
(composite measure of diverse 
questionnaires) 
Carrieri, France; Non-adherence by Depressive symptoms (CES-D) El b = 0.22 (95% Cl b = 0.18 U: - 2 of6 
200655 patients self-report =0 12, 0.32), p (007, 0 29) M: -
starting (AACTG, <0.001 
HAART- stra 1ghtforwa rd), Support from partner (whether Cll b = -0.16 (-0. 26, - b=-0.15 U + 
regimen 60 months principal or not, Instrument 0.07), p = 0.001 (-0.25, -0.05) M : + 
including at 
n.r.) 
least one 
protease 
inhibitor, n = 
1110 
- Table 52 continues-
- Table 52 continued-
Rrst 
author, 
year 
Stilley, 
201056 
Setting, 
n patients 
USA; 
transplant 
patients, 
recruited 
before 
hospital 
discharge 
or at early 
clime VISit, n 
= 152 
Measures 
'Adherence t,--- Psychosocial pl1ldictorl 
follow-up period* 
Psych 
cat _II 
Result~"---·--·----·-·DlrectiOn of"--N- ---
association domains 
(regarding bias 
adherence) •• free tt 
Univariate Multivariate 
TRANSPLANT -RELATED (immunosuppressant medication) 
Adherence by 
MEMS 
(continuous 
mPasure), 6 
months 
Affect1ve dysregulat1on (degree El 
of negative affectivity and 
irritability, Dl) 
Behavioral dysregulation D 
(impulsiVIty, sensation seek1ng, 
aggrPssion) 
Cogmt1ve dysregulation (less Bl 
strategic thinkmg, problem 
solving, SE'If-monitonng) 
Family environment (family 
support, FRI) 
Hostility (CMHS) 
Cll 
D 
Correlation 
coefficient : n.s. ~~ 
r=0.26, p !': 0.05 
... 
'II 'II 
n.s. 
11~ 
n.s. 
'II~ 
n.s. 
n.r. U:O 
M : n.r . 
ttt U: -
M : n.r . 
U:O 
M : n.r. 
U:O 
M : n.r. 
U:O 
M : n.r. 
1 of6 
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- Table 52 continued-
First Setttng, Measures Psych 
author, n patients catu 
year 
Adherence t, Psychosoctal predictors§ 
follow-up period* 
De Geest, Belgium; Non-adherence Depressive symptoms (BDI) El 
199857 convenience by MEMS 
sample of (ordinal measure, Self-efficacy 1n taking medtcation Alii 
outpatients, n correction for (LTMSES) 
= 101 past adherence), 
6 months) 
Social Support (PRQ) Clll 
Symptom distress (ATSFDS) Ell 
Results~ 
Untvanate 
n.r. 
Direction of 
Multivariate 
n.s. 
association 
(regarding 
adherence) 
U: n.r. 
M: O 
Medtan = 4.85 U: n.r . 
(Q1 = 4.70, Q3 = M : + 
5 00) for 
excellent 
adherers, 4.81 
(Q1=4 70, 
Q3=4 89) for 
moderate non-
adherers, 4.41 
(Q1 =4 30, Q3 = 
4.81) for minor 
adherers, p = 
0.04 
n.s. 
n.s. 
U: n.r. 
M: O 
U. n.r. 
M: O 
.. 
N 
domains 
bias 
free tt 
2 of 6 
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- Table 52 continued-
-------------- ------~----~··----· R~~11 
-o Rrst Setting, Measures Psych Direction of N 
~ author, npatients cat. 11 association domains n 
::r year (regarding bias 0 
v> •• freett 0 adherence) n 
![ 
Adherence t, Psychosodal predictors§ Univa,riate MultiVariate 
-o ;o 
* a. follow-up period ~ ·------· - - ··-- -- - ~--- ··· ·· ·-···--~ ---- -- ·· --
0 Russell, USA; Adherence by Depressive symptoms (BDI) El n.s. n.r. U: O Oof6 Vl 201058 MEMS (ordinal M : n.r . 0 convemence 
...., 
sample of measure), 12 :::l Emotional burden (MS) El n.s. U: O 0 renal months :::l M : n.r . 
' transplant QJ a. 
::T patients, n = Self-eff1cacy 1n taking Alii n.s. U: O (1) 
...., 50 medication (LTMSES) M : n.r. (1) 
:::l 
n 
~ Social support (SSAI) Clll ~ i1.S . U: O 
v> M : n.r. 
..... (1) 
3 Weng, USA; Adherence by Beliefs regarding who or what Alii OR = 1.05 (1.00, n.s. U: + 2 of6 QJ 
d'. 200559 patients MEMS (ord1nal controls and Influences one's 111), p = 0.05 M : O n 
...., 
recruited at measure), 12 health (MHLCS) (powerful ~ 
iii' time of renal months post- others subscale 
:1: transplantat1 t;ansplantation 
0 Depressive symptoms (CE5-D) El n.s. n.t . U: 0, M : n.t . 
_, 
on, n =829 
0 
:::l 
IJQ Perce1ved stressful ness of Ell n.s. n.t . U: 0, M : n.t . ;::;: 
c transplant-related 1ssues (TSQ) 9, 
:::l 
!!!.. 
v> 
..... Perceptions that soc1al needs Cll n.s. n.t . U: 0, M : n.t . c 
a. are being met (fnends and iii' 
v> family sub-score, SSAS) 
f-' 
\D 
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Resultsil First Setting, Measures Psych Direction of N 
n author, n patients cat.0 association domains -::; OJ (regarding bias "0 year 
M •• freett ~ adherence) 
Ln 
f 
Adherence, Psychosocial predictors§ Univariate Multivariate 
follow-up period* 
-· ··- ·--
Dew, USA; Non-adherence by Coping strategies : use of Bl n.s. n.t . U: O 2 of6 
1996 60 heart self-report active-behavioral coping M : n.t . 
transplant (straight forward), {Copmg checklist) 
pat1ents at 12. months post-
academ1c transplantation Coping strategies use of Bl n.t . u 0 
hospital,*** 
n.s. 
active-cognitive coping M : n.t . 
n = 108 
Coping strategies: use of Bll Non-adherent OR=9 71, p< U:-
avo1dance coping(% high) 58.8%, adherent 0.05 M : -
29.9%, p < 0 OS 
Emot1onal status : anger- El Non-adherent OR= 1340, p< U: -
hostility symptoms (SCL-90) 47.1%, adherent 0.05 M : -
12.1%, p<0.001 
Emotional status: anxiety El Non-adherent n.s. U:-
symptoms 82 .4%, adherent M : O 
53%, p< 0.05 
Emotional status: depressive El n.s. n.t . U: O 
symptoms M : n.t. 
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----- -Psych -- ---Results 'If-- ------- - ---- --Arst Setting. Measures Direction of N 
author, n patients cat. II assoCiation domains 
year (regarding bias 
•• tt 
adherence) free 
Adherence t, Psychosodal predictors§ - Univariate Multivariate 
follow-up penod * 
Dew, Sense of mastery (ie control Alii n.s. n.t . U: O 
1996 co over life, SMS) M : n.t. 
(continued) 
Social support: caregiver Cll Non-adherent il .S . U: -
support(% poor) (Spanier61 52 9%, adherent M : O 
Pearlin & Schooler62) 27.0%, p < 0.05 
Soc1al support: friend support Cll n.s. n.t . U: O 
(Moos6') M : n.t. 
Dew, 20086'' USA; Non-adherence by Anger-hostility symptoms (SC) El (Correlation n.s. U: 7 1 of 6 
patients self-report coefficient, M : O 
rece1vmg (straightforward), sigmficant if r ~ 
first lung 24 months 
... 
0.15 ): 
transplanta r2: 0.15 
-tion in 
academic Anxiety symptoms (SC) El r2: 0.15 n.s. U: 7 
hospital, M : O 
n = 178 
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OJ (regarding bias -o year 
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Adherence, Psychosodal predictors§ Univariate Multivariate 
follow-up period* 
. ~ 
Dew, 2008 Care provider locus of control Alii r ~ 0.15 n.s. U: ? 
(continued) (health outcomes due to M : O 
professional? MHLCS) 
Chance locus of control (health Alii r ~ 0.15 n.s. U: 7 
outcomes occur by chance7) M : O 
Degree to which one can rely on Cll r ~ 0.15 n.s. U: 7 
friends for emotional/practical M : O 
support/friend support (Moos63 ) 
Depressive symptoms (SC) El r ~ 0.15 n.s. U: ? 
M : O 
Expectations about the D r ~ 0.15 n.s. U: 7 
future/optimism (LOT) M : O 
Internal locus of control (can I Alii r ~ 0.15 n.s. U: 7 
Influence my health outcome 7 M : O 
MHLCS) 
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follow-up period* 
oew, 2CJ08,., --- -··----
(continuedJ 
Supportiveness (both Cll 
Dobbels, Belg1um : Non-adherence 
200965 heart, liver and by self-report 
lung transplant (straightforward, 
patients listed corrected for 
at u mvers1ty pre-transplant 
hospitals, adherence), 12 
n = 186 months post-
transplantation 
emotionally and practically) of 
recipient's relationship with 
their pnmary family caregiver 
(when low= higher odds) 
(DAS) 
Agreeableness (one's 
orientation along cont inuum 
from compassion to 
antagonism, NEO-FFI) 
Anxiety symptoms (HADS) 
Conscientiousness (ie degree 
of organization, NEO-FFI) 
Depressive symptoms (HADS) 
D 
El 
D 
El 
Univariate 
r:2:0.15 
n.r. 
Multivariate 
Direction of 
association 
(regarding 
adherence) •• 
OR= 2..59 (1.2.0, U: 7 
5.58), p < 0.05 M :-
n.t . or n.s. U: n.r/s . 
M: O 
n.t . or n.s . U: n.r/s. 
M: O 
OR = 0.80 (0.67, U: n r/5. 
0 95), p = 0.01 M: + 
n.t . or n.s. U: n r/s. 
M: O 
N 
domains 
bias 
freett 
1 of6 
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First Setting, 
author, n patients 
year 
Dobbels, 
'200965 
(continued) 
DiMatteo, 
1993661111 
USA, patients 
from five 
medical 
specialties 1n 
HMOs, large 
mult1specialty 
groups or solo 
practices, n = 
max. 1828§§§ 
Measures Psych 
cat" 
Adher~~ +: Psychosocial predictors§ 
follow-up period* 
Extraversion (capacity for joy, D 
need for stimulation, NEO-FFI) 
General received practical and Clll 
informational support (SSQ) 
Neuroticism (NEO-FFI) D 
Openness to experience D 
(toleration for and exploration 
ofthe unfamiliar, NEO-FFI) 
Received specific support with Clll 
medication taking (SSQ) 
Results~ 
Univariate 
OTHER (diabetes and/or hypertension and/or heart disease) 
Adherence by 
self-report 
(straightforward, 
continuous 
measure, 
correction for 
baseline 
adherence), 24 
months 
Health distress (Instrument 
n.r.) 
Ell n.r. 
Multivariate 
n t . or n.s. 
n.t . or n.s. 
n.t . or n.s. 
n.t. or n.s. 
OR= 0 94 (0 .89, 
0 .99), p = 0 .03 
g = -0.22, p = 
0.05 
Direction of 
associ at ion 
(regarding 
adherence}•• 
U: n.r/s .. M : 0 
U: n.r/s., M : 0 
U: n.r/s., M : 0 
U: n.r/s., M : 0 
U: n.r./s., M : + 
U: n.r. 
M:-
N 
domains 
bias 
free tt 
0 of 6 
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cat.11 
Arst Setting, Measures 
author, n patients 
year 
DiMatteo, 
199356 !Ill 
(contmued) 
-- t 
Adherence, 
foil~ period* 
Psychosocial predictors§ 
-··--
Perceptions of phystcian's authoritativeness Cl 
(self-developed scale) 
Satisfaction w1th Interpersonal medical care Cl 
{Sherbourne67) 
Social support (composite measure, 
Sherbourne & Stewart"") 
Tendency to use avoidance cop1ng 
(instrument n r ) 
Clll 
Bll 
Univariate Multivariate 
n .t . or i1 .s. 
n.t. or n.s. 
n.t . or n.s. 
n.t . or n.s. 
association 
(regarding 
adherence) •• 
U: n.r ., M :O 
U: n. r ., M :O 
U: n.r., M :O 
U: n.r., M :O 
domains 
bias 
freett 
-. f·---------------------
n.s. = not significant (as reported in concerning study). n.r. = not reported. n.t. = not tested. Abbreviations are explained in in the Supplementary materials. Binary outcome measure, unless 
indicated otherwise. With a 'Straight forward' question', we mean that participants were directly asked to indicate how many medication doses they missed. For example: 'How many pills did 
you take this week?'.*Follow-up period= number of months between baseline (unless indicated otherwise) and last adherence measurement. §Abbreviations of instruments are explained in 
the Supplementary materials. If no instrument is mentioned for predictor, then previous mentioned instrument is applicable. 11 Psychosocial category, to which a predictor was assigned. A= 
Beliefs and cognitions about I) medication and treatment; II) Illness; Ill) self-efficacy & locus of control. B =coping styles I) task oriented, II) emotion oriented. C =Social influences & social 
support I) regarding medical caregiver; II) regarding friends & family; Ill) in general. D =personality traits . E =psychological wellbeing: I) mood state; II) perceived stress/stressors. ~OR: Odds 
Ratio (95% confidence interval). OR< 1 =lower chance of being adherent or non-adherent (for direction in relevant study, see column 'Adherence, follow-up period') when predictor increases 
or when predictor~ reference category. OR> 1 =greater change of being adherent!'! non-adherent when predictor increases (or when predictor~ reference category). Scores other than OR 
are the mean predictor scores with standard deviation, unless indicated otherwise. '+' =higher level of predictor implies higher adherence at level p s 0.05. '-' = higher level of predictor 
Tt 
implies less adherence at p S 0.05. '0' =no significant association between predictor and adherence at p S 0.05.? =association present, but direction unclear. To determine methodological 
quality, six b"1as domains per study were judged. Here, the total amount of bias free domains is reported (for further details, see Table 53). H Assumed that all variables, tested by univariate 
analysis, were also tested by multivariate analysis. §§Retrospective design. 1111 Diagnosis for coronary heart disease, hypertension, diabetes mellitus and/or hyperlipidaemia. ~~Not reported in 
study is interpreted by HZ/BvdB as not significant."' Significance of p s 0.05 assumed by HZ/BvdB. ttt Negative association assumed. ***Type of medication is immunosuppressants, 
antihypertensives and/or antivirals. §§§Use of chronic preventive medication assumed. ll llllunexpected direction 
N Table 53 Results of judging methodologic quality 0 
0 
First author, year Overall Domain free of bias? 
(") quality :5 
Q) 
u Study Study Prognostic factor Outcome Confoundmg Analysis rt cg participation attrition measurement measurement measurement & LT1 
account 
Botton;;;-20o? 5 Low no no partly partly no no 
De Geest, 19985·; Low no yes partly yes no partly 
Delgado, 2003'2 Low partly yes partly partly partly partly 
Deschamps, 2004"15 Low no partly no yes no no 
Dew, 199660 Low no yes yes partly partly partly 
Dew, ;wos5' Low yes partly partly partly partly partly 
DiMatteo, 199366 Low partly no partly no no no 
Dobbels, 200965 Low yes partly partly partly partly no 
Gazmararian, 200635 Low yes partly partly yes partly yes 
Godin, 200546 Low partly yes no partly partly partly 
Gregoire, 200636 Low partly no no partly no Partly 
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- Table 53 continued--~· ~-~---- _... _ ___________ 
First author, year Overall 
quality 
Study 
participation 
fl;;T~;s, 2ooi19 Low partly 
Kacanek, 2010·" Low no 
Mart1n1, 2002.s Low partly 
Mellins, 2003' 9 Low partly 
Miller, 198538 Low no 
Nabi, 200826 Low partly 
Nilsson Schonnesson,200651 Low partly 
Pon1eman, 200933 Low no 
Russell, 20105~ Low no 
Singh, 19961" Low no 
Singh, 1999"" Low partly 
Domain free of bias? 
Study Prognostic factor Outcome Confounding Analysis 
attrition measurement measurement measurement & 
account 
yes partly partly partly yes 
yes partly partly no yes 
no no part ly no no 
partly partly no no no 
partly partly no partly partly 
partly partly partly partly yes 
yes partly no partly no 
no partly Partly partly partly 
no partly partly no partly 
yes partly partly partly no 
yes partly partly no No 
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QJ 
""0 Study Study Prognostic factor Outcome Confounding Analysis ..... ~ participation attrition measurement measurement measurement & Ln 
account 
Stilley; 2ciio56 Low yes partly partly no no no 
Thrasher, 2008" Low yes partly partly partly partly partly 
Ventunn1, 1999" Low yes partly partly yes partly pa rtly 
Weng, 200559 Low partly no yes partly partly yes 
Molloy, 200839 Low no yes partly no partly partly 
Horne, 200i3 Low yes yes partly partly no yes 
Mugavero, 20095' ' Low yes no yes partly partly yes 
Carnen, 200655 Low no yes no partly partly yes 
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Table 54 
Alteration 
Sensitivity analyses: methodological quality, disease, adherence measur~~s ..;.a_n,_d.cs.:cta-:Otc'-is-=::ti.::..ca::,l-=ac...n.::.a ..!.lyc...se~s:---,-:---:---:---:-:-------------. 
Relevant studies categories affected Change In level of evidence 
Alterations In methodological quality cut-offs 
High-quality study when all six b1as domains judged at 
least as 'partly' (and no 'no-judgment') instead of ~ 
four doma ins judged as 'yes' 
Low-quality study when ~ 4 domams judged as 'no' 
instead of< 4 domains judged as 'yes' 
AlteratiOns in disease 
Only focus on HIV disease 
Only focus on transplant-related diseases 
Focus on asthma, diabetes, heart 
disease/hypertension 
!S,:!6,34,3S . .t:i2_52.,'5!! 
now h1gh-quality, 
otherw1se still low-quality 
Al,ll, Ill & Cl,ll & Ell 
Clll & El 
No association : moderate mstead of limited evidence 
No zssoc1at1on : strong mstead of lim1ted evidence 
-ll';2G-~~3B;3s.•~".o:~951- ·-----Ai(cat~g;;.ies --- No association : strong mstead of limited evidence 
ti0,:546s 
now high-quality, 
otherwise still low-quality 
19.~. 41-49,51-:.;s 
(studies in analysis) 
AI No association : confhctmg mstead of limited evidence 
Cll & D Level undetermined (!> 1 study available) 
SG-so,t3~'""''· 6"'5 ------- - At II/ Bll &-C-~ -----~L-e-ve-:1:-u-n~d:-e-te-r~i ned (.:; 1 study aVailable)" ____ _ 
(studies m analysis) 
- -L6~3B631>.39,66,------·----------- ---·- ... 
All, II I, Bl,ll, Cl, ll, D, Ell Level undetermined (s 1 study available) 
(studies m analysis) 
- Table 54 Continues -
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Alteration 
Alterations in adherence measures 
Focus on objective adherence measures (MEMS, 
record rev1ew) 
Focus on subjective adherence measures (self-report) 
Alterations In statistical analysis 
Only focus on univariate analys1s Instead of 
mult1vanate analysis 
Relevant studies 
J-S,25,26.31;35_ 42-<':~ .56-59 
(studies 1n analysis) 
33,36,38.39.4S-49.si -ss. 6d,64"'65 
(studies 1n analys1s) 
34,38,46.5157.65,66 
(studies omitted due to 
lack of umvariate 
analysis) 
Categories affected Change In level of evidence 
D No association : conflicting Instead of limited evidence 
AII & CI Level undetermined (Sl study available) 
AI No association conflicting instead of limited evidence 
Bl Level of ev1dence undetermined (s 1 study available) 
Bll & El No assoc1at1on ; conflicting Instead of lim1ted evidence 
AI, Alii, Cl, Clll, El & Ell No assoc1at1on : conflicting instead of lim1ted evidence 
- -- -·-·- ··--- --· 
Notes: A= Beliefs and cognitions about: I) medication and treatment; II) illness; Ill) self-efficacy and locus of control. B =coping styles: I) task oriented, II) emotion 
oriented. C =Social influences and social support: I) regarding medical caregiver; II ) regarding friends and family; Ill ) in general. D =personality traits. E = psychological 
well-being: I) mood state; II ) perceived stress/stressors. 
Abbreviations: HIV, human immunodeficiency virus; MEMS, medication event monitoring system 
Chapter 6 
Perceived need to take medicotion is 
associated with medication 
non-adherence in patients with 
rheumatoid arthritis 
Zvvlkker H, von Du!men S, den Broeder A, 
von ch:.:n Bt:!·nt B, 't/ {Jr: cJt3n i:n( i.~?. C~. 
PubHsi'lt.:;ri in: FclHerri ere:ferf~· nc·. (~ c1nci /\ciherGnc;e 20 14;B:' 16:35-45. 
ABSTRACT 
Background This is the first cross-sectional study that aims to examine associations 
between beliefs about medication and non-adherence in patients with rheumatoid 
arthritis (RA) using disease-modifying antirheumatic drugs, taking potential 
psychological confounders into account. 
Methods Eligible patients (diagnosed with RA for ~ 1 year, ~ 18 years, using greater 
than or equal to one disease-modifying antirheumatic drug) were included by their 
rheumatologist during regular outpatient visits between September 2009 and 
September 2010. Included patients received questionnaires. The Beliefs about 
Medicines Questionnaire was used to measure the perceived need to take 
medication (necessity beliefs), the concerns about taking medication (concern 
beliefs), general medication beliefs, and attitudes toward taking medication. 
Medication non-adherence (no/yes) was measured using the Compliance 
Questionnaire Rheumatology (CQR). Associations between beliefs and non-
adherence, and the influence of demographical, clinical and psychological factors 
(symptoms of anxiety/depression, illness cognitions, self-efficacy) were assessed 
using logistic regression. 
Results A total of 580 ofthe 820 eligible patients willing to participate were included 
in the analyses (68% female, mean age 63 years, 30% non-adherent to their 
medication). Weaker necessity beliefs (OR [odds ratio]: 0.8, 95% Cl [confidence 
interval]: 0.8-0.9) and an unfavorable balance between necessity and concern 
beliefs (OR: 0.9, 95% Cl: 0.9-1.0) were associated with CQR non-adherence. Also, 
having an indifferent attitude toward medication (no/yes) was associated with CQR 
non-adherence (OR: 5.3, 95% Cl: 1.1-25.8), but the prevalence of patients with an 
indifferent attitude toward medication was low. The associations were barely 
confounded by demographical, clinical and psychological factors. 
Conclusion Increasing necessity beliefs about medication in clinical practice might be 
worthwhile in improving medication adherence in RA patients. 
--------·- -------
Keywords 
Medication non-adherence; medication beliefs; psychological confounders; cross-
sectional studies; rheumatoid arthritis 
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INTRODUCTION 
Disease-modifying antirheumatic drugs (DMARDs) reduce disease activity and 
radiological progression, and improve long term functional outcome in patients with 
rheumatoid arthritis (RA).1 However, adherence to DMARDs, ie the extent to which a 
patient's medication intake behavior corresponds with agreed recommendations 
from their healthcare provider,2 is not optimal and ranges from 22% (underuse) to 
107% (overuse). 3-7 DMARD non-adherence results in more disease 
activity/radiological damage, loss of function and a lower quality of life.8-10 
Moreover, the annual costs of non-adherence for all conditions in the US have been 
estimated to be $100 billion.11 In view of the negative implications of medication 
non-adherence, effective interventions to improve medication adherence are 
warranted. 
Recently, types of non-adherence have been conceptualized as "unintentional" 
(eg, forgetting medicines)2 and "intentional". Intentional non-adherence is driven by 
a decision not to take medicines as prescribed. According to the Necessity-Concerns 
Framework of Horne and Weinman/2 it is assumed that intentional adherence 
decisions are influenced by a cost-benefit assessment. Herein, personal beliefs 
(assumptions and convictions that are believed to be true by an individual) about 
the necessity of taking the medication for maintaining or improving health are 
balanced against concerns about the potential adverse effects (such as nausea and 
abnormal liver- and blood tests, 13 and also adverse effects like actual medication 
costs for patients)14 of taking the medication. 
Many studies underline the importance of addressing these necessity beliefs and 
concern beliefs about medication to improve adherence. In RA, four studies 
assessed associations between medication non-adherence and necessity and 
concern beliefs about medication (measured with the Beliefs about Medicines 
Questionnaire [BMQ]).15-18 In three of the four studies, stronger necessity beliefs 
were associated with better medication adherence/6-18 whereas in one other study, 
stronger concern beliefs were associated with decreased medication adherence.15 
Although those studies provide some guidance in targeting the most relevant 
medication beliefs in clinical practice, they have some limitations. 
First, only one of the four studies assessing associations between medication 
beliefs and non-adherence in RA patients used a valid adherence measure (the 
dichot·omized Compliance Questionnaire Rheumatology [CQR] score} 17 which 'vvas 
validated against the Medication Event Monitoring System [MEMS]; see 
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Supplementary materials.19 Using unvalidated adherence measures might 
undermine the validity of associations found. 
Second, medication beliefs other than necessity and concern beliefs measured 
with the BMQ are suggested to be associated with non-adherence 16'20-22 but are not 
often included in the existing research. These constructs comprise four attitudinal 
patient profiles toward taking medication (ie, "skeptical", "indifferent", 
"ambivalent", and "accepting"), and general beliefs about the potential of 
medication to harm and about overuse of medication by clinicians. In RA, only one 
study assessed associations between the general medication beliefs and adherence. 
This study demonstrated that the belief that physicians do not overuse medication 
was related to better adherence.16 More studies are needed, however, to know the 
extent to which these constructs are associated with medication non-adherence in 
RA patients. 
Third, no single study (in- and outside the field of RA) examining associations 
between medication beliefs and non-adherence took psychological factors such as 
anxiety/depression, self-efficacy and illness cognitions simultaneously into account 
in the data-analysis, while they appear to play a central role in explaining medication 
non-adherence.23'24 These factors might also be associated with beliefs about 
medication, moreover, and might thus be potential confounders of associations 
between beliefs about medication and non-adherence. It is conceivable that 
patients with stronger accepting cognitions about their illness also have more 
positive views about their medication, and thus, have better medication adherence 
than patients who do not accept their illness, for example. 
The aim of this cross-sectional study is to examine associations between the 
total range of beliefs about medication (as measured with the BMQ) and medication 
non-adherence in RA patients using DMARDs, using the dichotomized CQR 
adherence measure, and taking potential psychological, demographical and clinical 
confounders into account. The results of our study could provide starting points for 
the development of interventions to improve adherence. 
PATIENTS AND METHODS 
This study is approved by the local medical ethical board (CMO 2009/090) and is 
reported according to the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines. 25 
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Design, patients and procedure 
This cross-sectional study was conducted at the Sint Maartenskliniek (a clinic 
specializing in rheumatology, rehabilitation and orthopedic surgery) in Nijmegen, 
the Netherlands. Consecutive RA patients were screened for eligibility by their 
rheumatologist during regular outpatient visits between September 2009 and 
September 2010. Inclusion criteria were having RA for at least 1 year (because 
medication beliefs are still to be formed in patients newly diagnosed with RA)26 
according to the 2010 American College of Rheumatology criteria, 27 being ~18 years 
old, and using ~1 prescribed DMARD. Having severe mental or physical constraints 
and being illiterate in the Dutch language were exclusion criteria. Eligible patients 
willing to participate received study information and a set of questionnaires at their 
home address. Reminders were sent after 2 weeks. All included patients had signed 
informed consent. 
Measures 
Unless indicated otherwise, items were measured by self-report questionnaires. 
Beliefs about medication 
Beliefs about medication were measured using two parts of the validated BMQ:28 
the BMQ "specific" and the BMQ "general". 
The BMQ "specific" has two subscales of five items each, measuring patients' 
beliefs about the necessity of prescribed medication (eg, "Without my medicines I 
would be very ill", and their concerns about potential adverse consequences of 
taking the medication. Within the subscales, items are scored from 5 (strongly 
agree) to 1 (strongly disagree) and are summed to obtain a total score ranging from 
5 to 25. Higher scores indicate stronger beliefs. By subtracting the concern score 
from the necessity score, a necessity-concerns differential score can be calculated 
(ranging from -20 to +20, where positive scores mean that patients perceive that 
benefits of medication outweigh costs, and vice versa). Necessity and concern 
scores were dichotomized at the scale midpoint to create four attitudinal profiles: 
"skeptical" (low necessity, high concerns [score <15 or ~15, respectively]), 
"indifferent" (low necessity, low concerns), "ambivalent" (high necessity, high 
concerns), and "accepting" (high necessity, low concerns).20' 22 
The BMQ "general" assesses general beliefs about pharmaceuticals as a class of 
treatment,20 and has two subscales of four items each. The "overuse" subscale 
includes beliefs about the way in which medicines are endorsed by doctors (eg, 
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"Doctors place too much trust on medicines"). The "harm" subscale includes beliefs 
about the potential of medication to harm (eg, "Medicines do more harm than 
good"). The scoring method is identical to the BMQ "specific": total subscale scores 
range from 4 to 20. 
Medication non-adherence 
Medication non-adherence was primarily assessed with the CQR. The CQR has been 
validated using MEMS in RA patients/9 and is able to detect whether a patient takes 
:!>80% of prescribed medication {binary score: non-adherent versus adherent 
patients) with a sensitivity of 62% and a specificity of 95%. Details about calculation 
of the CQR-score are provided in the Supplementary materials section. 
The five-item Medication Adherence Report Scale (MARS)29 was used as an 
alternative measure for non-adherence in a sensitivity analysis. MARS includes 
statements about stopping, forgetting or altering medication doses. Items are 
summed to obtain a total score ranging from 5 to 25, where higher scores meant 
better adherence. Because the MARS score was severely skewed in this study, we 
dichotomized the score at 95% of its scale (non-adherent when total score :!>23). 17'30 
Potential confounders 
Sociodemographic factors measured were age, sex, living with others (yes/no), 
educational level {high/not high, where "high" means having at least a bachelor or 
master degree), and employment/studying (yes/no) . 
Clinical factors measured were disease duration, disease activity (Rheumatoid 
Arthritis Disease Activity lndex)/ 1 pain (Visual Analogue Scale)/2'33 and physical 
abilities (Health Assessment Questionnaire),32 see Table 51 for details. Electronic 
hospital/pharmacy data34 were used to assess the types of DMARDs taken at the 
time of filling in the questionnaires and to assess the presence of anti-CCP (cyclic 
citrullinated peptide antibody) and rheumatoid factor values in the participants (for 
descriptive purposes only). 
Three psychological factors were measured. The illness Cognition Questionnaire35 
encompasses three generic illness cognitions, namely "helplessness" as a way of 
emphasizing the aversive meaning of a disease, "acceptance" as a way to diminish 
this aversive meaning, and "perceived benefits" as a way of adding a positive 
meaning to a disease. Self-efficacy related to physical function, to coping with pain 
and to coping with other symptoms associated with arthritis (such as depression and 
fatigue) was measured with the Arthritis Self-Efficacy Scale.36' 37 Last, feelings of 
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anxiety/depression were measured by the Hospital Anxiety and Depression Scale.38 
For details about the questionnaires, see Table 51. 
All questionnaires used are validated tools and demonstrated to have a sufficient 
internal consistency in this RA sample. Cronbach's alpha varied from 0.68 to 0.97. 
Sample size and data analyses 
As we aimed to adjust for approximately 25 variables in our data-analyses, we aimed 
to include at least 500 RA patients in this cross-sectional study.39 
Differences between study participants and patients who refused to participate 
were tested by means of chi-square tests, two sample t-tests, or non-parametric 
tests in case of skewed distributions. Then, correlation coefficients between all pairs 
of variables were studied to detect multicollinearity: non-psychological factors were 
removed from further analyses when r~80 (oral conversation with Drs. P. 
Spreeuwenberg, statistician, NIVEL, September 2013). The psychological factors 
were all included in further analyses to study their influence on associations 
between beliefs about medication and non-adherence. 
Subsequently, associations between all scales of beliefs about medication and 
non-adherence were analyzed by logistic regression models in three steps, with 
robust standard errors40 and a two-sided a set at 0.05. Univariate, unadjusted 
models were fit in Step 1. In Step 2, demographic and clinical measures were forced 
into the models attained in Step 1, and in the last step, the psychological factors 
were forced into the models attained in Step 2. In a sensitivity analysis, we repeated 
all steps with the MARS as a non-adherence measure. Note that the four attitudinal 
profiles (Measure section) were handled as dichotomous variables in the analyses 
(eg, patients with a skeptical attitude versus the rest of the patients, whereby "the 
rest of the patients" were the reference group). 
Analyses were performed in STATA10, were based on complete cases, and were 
verified by a statistician. 
RESULTS 
Participants 
A total of 580 (71%) of the 820 eligible patients willing to participate were included 
in the analyses (Figure 1). The 580 patients who returned the questionnaires did not 
differ on age and sex from the 2.40 patients who did not return the questionnaires. 
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Planned eligibility screening by 
rheumatologi$1 
n = 1075 
l 
Screened for eligibility by 
rheumatologist/assistant 
n=908 
1 
Eligible, questionnaires sent 
n =820 
Questionnaires returned and analysed 
n = 580 
Not screened (n = 167): 
Objection of patients: 
Not enough time for screening during outpatient visit: 
Not eligible (n = 86): 
No rheumatoid arthritis: 
No use of DMARDs: 
Not able to participate, mentally: 
Not able to participate, physically: 
Not able to participate, communicatively: 
Objection of rheLmatologist, multiple of above reasons: 
Objection of rheumatologist, unknown reasons: 
Non-response due to (n • 240): 
Personal conditions (e.g., considering oneself too old, 
too weak, too busy, family alfairs): 
Questionnaire content (e.g., too many or too personal 
questions): 
Not using medication at that time: 
Questionnaire not retumed. reasons unknown: 
Abbreviations: DMARD = disease-modifying antirheumatic drugs. 
Figure 1 Participant flow chart 
n= 115 
n =52 
n= 22 
n= 13 
n= 16 
n= 12 
n= 11 
n=8 
n=6 
n= 14 
n= 11 
n=4 
n = 211 
Most participants were female and lived together with other people. Less than 20% 
of the participants were highly educated. Also, the majority of participants used one 
DMARD and had a median disease duration of 14 years (Table 1). 
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Table 1 
vanables 
Sample characteristics 
Sociodemographic factors 
Age (years) 
Female 
Living with others 
High education t 
. 
Currently employed or studying 
Clinical factors 
Disease duration (years) 
Number of DMARDs used 
Route of DMARD administration 
Rheumatoid factor (positive)" 
Anti-CCP (posit ive) 11 
RADAI disease activity (0-10) ~ 
VAS pain sr.ore (G-100 mm)~ 
HAQdisability Index {G-3)~ 
One DMARD 
Two DMARDs 
Three DMARDs 
Oral* 
Parenteral§ 
Nu~~ents DescriptiVeS 
providing data 
580 628 {12.6) 
580 396 {683%) 
571 458 (80.2%) 
571 106 (18.6%) 
552 216 {39.1%) 
556 14 {8-22) 
476 307 {645%) 
476 149 {31.3%) 
476 20 {42%) 
476 272 (57.1%) 
476 296 {62.2%) 
332 260 (78.3%) 
284 199 (70.1%) 
493 2.7 {1.9) 
550 30.8 {22.4) 
563 11 {08) 
• t 
Data are means (standard deviation), medians (interquartile range), or numbers(%). High education 
means having at least a bachelor or master degree. *Azathioprine, hydroxychloroquine, leflunomide, 
methotrexate, predniso(lo)n, or sulfasalazine. § Adalimumab, aurothiomalate, methylprednisolone, 
etanercept, methotrexate, abatacept, infliximab, tocilizumab, or rituximab. 11 For descriptive purposes 
only, so not included in further analysis. 'II Higher scores indicate more disease activity I pain I disability. 
Abbreviations: DMARDs, disease-modifying antirheumatic drugs; Anti-CCP value, anti-cyclic citrullinated 
peptide antibody; RADAI, Rheumatoid Arthritis Disease Activity Index; VAS, visual analogue scale; HAO. 
Health Assessment Questionnaire 
Non-adherence and psychological factors 
In all, 171 of 575 of participants filling in the CQR were non-adherent to their 
medication (29.7%). This was 33.6% (of 562 participants) according to the MARS. 
The correlation between the two adherence measures was low (Spearman's rho = 
0.28, p< 0.01). 
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Participants had stronger necessity beliefs than concern beliefs about 
medication, and the majority of participants had an accepting or ambivalent attitude 
toward their DMARD medication (Table 2) . 
Table 2 Psychological factors 
Vanables 
Beliefs about medication 
Necessity beliefs (5-25) t 
t 
Concerns bel iefs (5-25) 
. 
Necessity-concerns differential (-20 till +20)* 
t 
Overuse beliefs (4-20) 
Harrn bel1efs (4-20)t 
Attitudinal profiles: 
ICQ Illness cognitions (6·24) t 
Helplessness 
Acceptance 
Perce1ved benefits 
t UVR self-efficacy (1-5) 
Pain 
Physical functiomng 
Symptoms 
HADS anxiety/depreSSion (0-42) t 
Skeptical 
Indifferent 
Ambivalent 
Accepting 
Number of patients 
providing data 
536 
535 
527 
546 
542 
527 
527 
527 
527 
542 
544 
538 
570 
566 
559 
567 
Descnpt"rves 
19.9 {3.5) 
14.3 (3.6) 
56 (47) 
10.3 (25) 
10.2 (25) 
14 (2 7%) 
25 (4 7%) 
244 (46.3%) 
244 (46.3%) 
11.7 (4.2) 
17.8 {3.8) 
14.2 (4.5) 
3.6 (08) 
38 {11) 
3.9 (0.8) 
9 3 (6.5) 
- . t,-----------------------------------
Data are means (standard deviation) or numbers(%). Higher scores indicate stronger beliefs, more 
helplessness I acceptance I perceived benefits, stronger self-efficacy concerning pain I physical 
functioning I symptoms, and more anxiety and depression. *Differential= necessity score minus concerns 
score. Positive score means that necessity beliefs about medication are stronger than concern beliefs 
about medication. 
Abbreviations: ICQ Illness Cognition Questionnaire; UVR, Arthritis Self-Efficacy Scale; HADS, Hospital 
Anxiety and Depression Scale. 
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Associations between beliefs about medication and non-adherence 
Unadjusted and adjusted associations between the BMQ constructs and CQR non-
adherence are displayed in Table 3. The significant associations between 
continuously measured BMQ constructs and non-adherence of Step 3 (Table 3) are 
also visually presented in Figure 2. 
The Health Assessment Questionnaire-scale was removed from the analyses due 
to multicollinearity with the Arthritis Self-Efficacy Scale: physical functioning scale. 
Table 3 Associations between beliefs about medication and CQR non-adherence 
------~--~~--------~ BMQ constructs COR non-adherence, OR (95% 0) 
Unadjusted: Step 1 Adjusted: Step 2• 
- ·- ···-·- .-.- ... -.-----
Necessity beliefs 
Concerns beliefs 
Necessity-concerns differential 
Overuse beliefs 
Harm beliefs 
Attitudinal profiles" 
Skeptical 
Indifferent 
-...-
Amb1valent 
Accepting 
(n = 524-543} (n = 332-344) 
-· ·········- ·- ·- -=r ·--·-.. - ·-· . * 
0 9 (0.8- 0.9) 0 8 (0.8- 0 9) 
10 (0 9-1.0) 1 0 (0.9 -1.1) 
09(0.9-10)* o.9 (0.9 -1 o)* 
1.1 (1.0-1.1) 1.1 (10 -12)§ 
1.0 (0.9 -1.1) 11 (10-12) 
2S (0.9-7 2) 1.8 (OS- 5.9) 
39 (1.7-89)* 50 (13 -19.3)9 
0 8 (OS -1.2) 08 (OS-1.4) 
0.8 (0.6 -1 2) 09 (OS-1.5) 
Acijusted: Step 3' 
{n = 297-307) 
·- ·-----·· .. ...... f -
0 8 (0.8- 0.9) 
10 (09-11) 
0.9 (0.9 -1.0) * 
1.1(1.0-1.2) 
1.1 (0.9 -1.2) 
18 (OS-6.0) 
5.3 (11- 25.8)§ 
0 7 (04-1.4) 
0.9 (OS -1. 7) 
In Step 2, models were adjusted for age, sex, living with others (yes/no), high education (yes/no), 
currently employed or studying (yes/no), disease duration, n DMARDs used, route of DMARD 
administration, disease activity (RADAI) and pain (VAS). tin Step 3, models were adjusted for the same 
factors as in Step 2, and additionally for illness cognitions (JCQ), self-efficacy (UVR), and 
anxiety/depression (HADS).The HAQ was left out as potential confounder due to multicollinearity with the 
UVR physical functioning scale. *p~0.01 §p~O.OS 11 Reference group = 'rest of the patients'. So, for 
example, the odds for being non-adherent to medication is bigger for patients with a skeptical attitude 
toward medication compared with patients with a non-skeptical attitude toward medication 
Abbreviations: CQR, Compliance Questionnaire Rheumatology; BMQ Beliefs about Medicines 
Questionnaire; OR, odds ratio; Cl, confidence interval; DMARD, disease-modifying antirheumatic drug; 
RADAI, Rheumatoid Arthritis Disease Activity Index; VAS, Visual Analog scale; ICQ, Illness Cognition 
Questionnaire; UVR, Arthritis Self-Efficacy Scale; HADS, Hospital Anxiety and Depression Scale; HAQ 
Health Assessment Questionnaire; n DMARDs, number of disease-modifying antirheumatic drugs. 
After adjustment for all potential confounders, (weaker) necessity beliefs, a more 
unfavorable balance between necessity and concern beliefs, and having an 
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indifferent attitude toward medication were associated with CQR non-adherence. 
The post-hoc analysis revealed that patients with an indifferent attitude toward 
medication were less adherent to medication compared to patients with an 
ambivalent or accepting attitude (chi-square tests, p=0.001). Overall, the general 
medication beliefs (the harm and overuse scales) were not associated with non-
adherence. 
B0 .-------------------------------------
70 
60 
50 
% 40 
30 
20 
10 
0 
Necessity beliefs: score range (n) 
80 .--------------------------------------
60 
50 
% 40 
30 
20 
10 
0 
Figure 2 
Necessity-concerns differential: score range (n) 
Percentage non-adherent patients per BMQ score range 
Abbreviation: Beliefs about Medicines Questionnaire 
Demographical and clinical factors barely influenced associations between beliefs 
about medication and CQR non-adherence (Step 2, Table 3), as did the psychological 
factors (Step 3, Table 3). The significant association between having an indifferent 
attitude toward medication and non-adherence, however, was confounded by 
216 I Chapter 6 
illness cognitions (perceived benefits of the disease). For details about the 
contribution of single, psychological factors to associations between beliefs about 
medication and non-adherence, see Table 52. 
Sensitivity analysis 
We repeated all analyses with the MARS (data not shown). Now, only (weaker) 
necessity beliefs about medication were associated with MARS non-adherence after 
adjustment for all confounders (odds ratio [OR]: 0.9, 95% Cl: 0.8-1.0). Findings were 
robust regarding the role of demographical, clinical, and psychological confounders. 
DISCUSSION 
This is the first cross-sectional study that assessed associations between the total 
range of beliefs about medication as measured with the BMQ and medication non-
adherence in a large sample of patients with RA, using a va!id adherence measure 
and taking (among others) psychological factors into account. Weaker necessity 
beliefs, a more unfavorable balance between necessity and concern beliefs and 
having an indifferent attitude toward medication were associated with CQR non-
adherence. Psychological, demographical, and clinical factors hardly influenced 
associations found, and thus, some constructs of the BMQ appear to be 
independent predictors of medication non-adherence in RA patients. 
Having weaker necessity beliefs about medication was the only BMQ construct 
that was independently associated with both CQR and MARS non-adherence. The 
strength of the associations was considerable, as a two unit increase on the BMQ 
necessity scale, for instance, would already yield an OR of 0.6 (ie, OR = 0.82)41 for 
patients in being non-adherent to medication. This implies that necessity beliefs 
about medication are a sensible target for adherence-improving interventions. 
According to our results, necessity beliefs about medication, and not concern 
beliefs about medication, were associated with medication non-adherence. This 
corresponds with three16-18 of the four15-18 previous studies assessing associations 
between beliefs about medication and non-adherence in RA patients. An 
explanation for necessity beliefs about medication being more important in 
explaining non-adherence than concern beliefs about medication might be that 
feeling the need to take medication is a prerequisite for actually taking medicines. 
So, regardless of the level of concerns about medication, patients probably will not 
take their medication if they do not perceive taking medication as being necessary. 
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In contrast to most other studies, we were able to examine the role of the 
general medication beliefs in predicting non-adherence next to the role of necessity 
and concern beliefs about medication. Overall, our results indicate that there were 
no associations between these general harm and general overuse beliefs about 
medication and non-adherence. An explanation might be that general beliefs are 
most relevant when new and unfamiliar treatment is prescribed. Their influence 
might diminish when patients become more familiar with their treatment and as a 
consequence, start to develop necessity and concerns beliefs about their 
medication. 16 
We were the first to assess associations between the attitudinal profiles and 
non-adherence in patients with RA. Corresponding to other studies/0-22 more non-
adherence was present in patients with an indifferent attitude toward medication 
compared to patients with an ambivalent or accepting attitude toward medication. 
Maybe, patients with an indifferent attitude toward their medication might feel less 
dependent on their medication for controlling their disease. This thought is 
supported by our data; it appears that patients with an indifferent attitude toward 
medication feel less helpless than patients with a non-indifferent attitude toward 
medication (regression coefficient b: -2.1, 95% Cl: -3.8, -0.4). Also, they have a 
higher self-efficacy related to physical functioning (b: 0.5, 95% Cl: 0.1, 1.0). An 
alternate explanation might be that patients with an indifferent attitude toward 
their medication might also have an indifferent attitude toward their health in 
general. 
This study has its strengths and limitations regarding internal validity. The first 
strength is that we assessed associations in a large sample of RA patients. Second, 
we were the first to correct for feelings of anxiety/depression, illness cognitions, and 
self-efficacy when modeling associations between beliefs about medication and 
non-adherence and third, we used the validated, dichotomized CQR-score as the 
main adherence measure. However, the CQR is a self-report measure of adherence. 
Self-report measures of adherence reflect the patients' motivation and ability to 
take medication, while adherence measured by electronic pill count or 
pharmacy refill data, for example, reflect a different concept: availability of 
medication.18A2 Hence, caution is necessary when comparing our results based on 
self-report with results obtained by other adherence measurement methods.18A3 
Also, true ingestion of medication could not be proved by self-report. Most other 
adherence measurement methods also suffer from this limitation, however.2 We 
believe that using the CQR for adherence measurement was the best choice for this 
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study, because it has been validated against the MEMS in RA patients, 
questionnaires are easy to use, and no gold standard to measure adherence is 
available.2 
Due to the cross-sectional design of this study, we were not able to assess the 
causality of associations between beliefs about medication and non-adherence. So, 
it is unclear if beliefs about medication led to non-adherence or whether non-
adherent behavior influenced beliefs.44 However, there still is insufficient knowledge 
about the presence (or absence) of longitudinal associations between beliefs about 
medication and non-adherence.45 Like adherence itself, beliefs about medication 
might change over time. A high level of necessity beliefs about medication might 
correlate well with adherent behavior at that same time, but might not be predictive 
of adherent behavior in the future. So, cross-sectional designs might be as 
informative as longitudinal designs. 
This study also has its strengths and limitations regarding external validity. On 
average, our sample of RA patients had a long disease duration (median: >14 years), 
making our results not generalizable to patients with recently diagnosed RA. 
However, our population did not differ from other RA populations15-17 on other 
demographic and clinical characteristics, making our results generalizable to RA 
populations with a long disease duration. 
Practice implications 
Attempts to increase necessity beliefs about medication in RA patients might be 
worthwhile in improving medication adherence. However, strong evidence about 
effective interventions to increase necessity beliefs about medication is currently 
absent. Development of such interventions and research into the effectiveness of 
these interventions is needed. 
Although the strength of the association between having an indifferent attitude 
toward medication and medication non-adherence was considerable, targeting 
patients with such an indifferent attitude is not sensible in clinical practice because 
of the low prevalence (4%; 580 patients need to be screened to detect 25 
indifferent patients). 
4.2. Conclusion 
Weaker necessity beliefs about medication, a more unfavorable balance between 
necessity and concern beliefs about medication, and having an indifferent attitude 
toward medication are associated with medication non-adherence. Psychological 
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factors hardly confound those associations. Of the BMQ constructs associated with 
non-adherence, increasing necessity beliefs about medication in clinical practice 
might be most worthwhile to improve medication adherence in RA patients. 
------ - ---------· 
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SUPPLEMENTARY MATERIALS 
Calculation of non-adherence with the Compliance Questionnaire Rheumatology 
To obtain a dichotomous CQR non-adherence score, first a discriminant Z-score 
(which has been validated against a Medication Event Monitoring System [MEMS] 
taking compliance of ~80%) has to be calculated . 
The CQR has 19 items, which reflect statements about drug-taking behavior. 
Patients respond to a 4-point Likert scale ranging from 1, "don't agree at all", to 4, 
"agree very much"; items 4, 8, 9, 11, 12, and 19 have to be reversely recoded (4=1, 
3=2, etc). Missing items are substituted with the patient's average on all non-
missing items when the amount of missing items is smaller than four; otherwise, no 
score is calculated. The Z-score is calculated by means of the following function: 
Z-score = -3.4777- (0.4448.cqr1)- (0.9517.cqr2) + (1.6758.cqr3)- (0.2101.cqr4) + 
(0.0244.cqr5)- (0.5353.cqr6) + (0.003.cqr7) + (0.0135.cqr8)- (0.0106.cqr9) -
(0.2546.cqr10) + (0.1023.cqr11) + (0.1155.cqr12) + {0.0248.cqr13) + {0.1091.cqr14) 
+ (0.4475• cqr15) + (0.2284. cqr16) + (0.535. cqr17) - {0.4191. cqr18) + {0.6829. cqr19) 
Non-adherence is defined when subjects have a Z-score ~ -0.5849. For more 
information about the CQR, see de Klerk et al.19 
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Table Sl Details of used questionnaires (except beliefs and adherence) 
Secondary outcome 
measure 
Questionnaire ----·-· - ---·-----------, Description 
- - -- ·-....-....---....----:----:---- ·-- -·--,-~-,--
Rheumatoid arthritis Rheumatoid Arthrit'1s F1ve items, measurlng global d'1sease 
(RA) dlsease activity D1sease Activity Index act'1v1ty/paln, current duration of mornlng 
Patient's usual 
abilities in past week 
Pain severity 
Illness cognitions 
Self-efficacy 
Anxiety and 
depression 
. 
(RADAI)01 stiffness, and current tender joints. Score 
range: D-10, w1th higher scores indicatlng 
more d1sease activity 
Health Assessment 
Questionnaire D1sabihty 
Index (HAQ-DI)32 
HAQ vlsual analogue scale 
(VAS)'2.'' 
Illness Cognition 
Questionnaire (ICQ)35 
Arthritls Self-Efficacy Scale 
(UVR)3637 
Hospltal Anxiety and 
Depress·lon Scale (HADS)08 
Twenty items, measurlng elght dimensions of 
functlonlng (dressing and grooming, arls'mg, 
eatlng, walking, hygiene, reachlng, grlpplng, 
and common, dally activities) Greater than or 
equal to six dlmensions need a valid score to 
obtain the total score Score range: D-3, w'1th 
h1gher scores indicating more d'1sab'dity. Note 
that we took aids and devices lnto account ln 
calculating the HAQ-DI score 
Scale range 0 mm (no pain) to 100 mm 
(unbearable pain) 
Three subscales of six items each, measunng 
"helplessness" as a way of emphasizlng the 
aversive meaning of a disease, "acceptance" 
as a way to diminlsh this aversive mean1ng, 
and "perce1ved benef1ts" as a way of adding a 
positive meaning to a disease Score range : 6-
24, with higher scores indicating more 
helplessness, acceptance, and perceived 
benefitS 
Measures the patient's perceived ability to 
perform specific behaviors aimed at 
controlling disability The UVR has three 
subscales: self-eff1cacy related to physical 
function (eight items). to coping with pain 
(five Items), and to coping with other 
symptoms associated with arthnt1s (such as 
depression and fatigue, six items). 
Score range 1-5, w'1th higher scores indicating 
stronger self-efficacy 
Fourteen items. Total score range D-42, with 
h'1gher scores indicating a higher degree of 
anxiety/depression. 
The HADS has two subscales, one for anxiety 
and one for depress'1on, with seven ltems per 
scale . Subscale score range : D-21; subscale 
scores higher than 8 are indicative of anxiety 
or depression 
All items in a questionnaire need a valid answer to obtain a total score, unless mentloned otherwise 
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Table 52 The contribution of single, psychological factors to associations between beliefs about medication and CQR non-adherence (corrected for 
demographic and clinical factors) 
Basic, adjusted model (including 
demographic and clinical 
. 
variables) 
+ ICQ helplessness§ 
+ ICQ acceptance11 
+ ICQ perceived benefits 
+ UVR self-efficacy pain 
+ UVR self-efficacy physical 
functioning 
+ UVR self-efficacy symptoms 
+ HADS anxiety/depression 
Necessity 
beliefs 
0 .8 
{0.8- 0.9)t 
Concern 
beliefs 
1.0 
(0.9-1.1) 
CQR non-adherence, OR (95% Cl) 
NC 
differentia I 
0.9 
(0.9 -1.0)t 
Overuse 
bebefs 
1.1 
(1.0 -1.2)* 
Harm 
beliefs 
11 
(1.0 -1.2) 
Attitudinal profiles 
Skeptical Indifferent Ambivalent 
1.8 5 .0 0.8 
(0.5- 5.9) (1.3 -19.3)* (0.5 -1.4) 
0.9 
(0.5-1.6) 
0.6 
(0 .4-1.1) 
6 .9 0.7 
(1.5 -32.2)* (0.4-1.2) 
Accepting 
0.9 
(0.5 -1.5) 
0 .8 
(0.5 -1.3) 
1.1 
(0.6 -1.9) 
1.0 
(0.6-1.6) 
• Each ofthese models is adjusted for age, sex, living with others (yes/no), high education(yes/no), currently employed or studying (yes/no), disease duration, n 
DMARDs used, route of DMARD administration, disease activity (RADAI) and pain (VAS). t p:>0.01 * p:>0.05 §Basic, adjusted model (corrected for demographic and 
clinical variables) and ICQ helplessness. 11 Basic, adjusted model (corrected for demographic and clinical variables) and ICQ acceptance (etc). 
Abbreviations: CQR, Compliance Questionnaire Rheumatology; OR, odds ratio; NC, necessity concerns; ICQ. Illness Cognition Questionnaire; UVR, Arthritis Self-Efficacy 
Scale; HADS, Hospital Anxiety and Depression Scale; RADAI, Rheumatoid Arthritis Disease Activity Index; VAS, Visual Analog Scale; n DMARDs, number of disease-
modifying antirheumatic drugs. 
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ABSTRACT 
Introduction Studies suggest that both healthcare providers' and patients' beliefs 
about medication influence medication adherence. This study aims to describe and 
compare rheumatologists' and RA (rheumatoid arthritis) patients' beliefs about 
medication. 
Methods Data were collected in a specialized rheumatology clinic in the 
Netherlands. An adapted version of the Beliefs about Medicines Questionnaire 
(BMQ) was used to measure beliefs about medication in rheumatologists. 
(Dichotomized) scores on the BMQ of rheumatologists were compared to RA 
patients' scores on the BMQ using t-tests and two-group tests of proportions with 
95% confidence intervals. 
Results Twenty-seven (96% of the eligible) rheumatologists (mean age 42 years, 63% 
female) and 580 (71% of the eligible) RA patients (mean age 63 years, 68% female) 
were included. Generally, beliefs about medication did not differ between 
rheumatologists and patients. Both groups strongly perceived the need to take 
prescribed medication, but also had significant concerns about the long-term effects 
of the medication (63% of rheumatologists and 68% of patients expressed 
concerns). Some differences in beliefs were also present: Fewer rheumatologists 
worried about the fact that patients have to take medicines (15% versus 44%, 
respectively) and about the possibility that patients become too dependent on the 
medicines (15% versus 30%, respectively). 
Conclusion This study indicates that, generally, rheumatologists' beliefs about 
medication barely differ from those of patients. However, in some respects, patients 
do have stronger concerns about medication than rheumatologists. Future research 
should focus on the interplay between rheumatologists' and patients' beliefs about 
medication and its impact on medication adherence. 
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l.INTRODUCTION 
Medication adherence is not optimal in patients with rheumatoid arthritis (RA) and 
varies from 22% (underuse) to 107% (overuse) [1-5]. As medication non-adherence 
can result in more disease activity, radiological damage and a lower quality of life [6-
8], effective interventions to improve medication adherence are warranted. 
A useful target to improve medication adherence might be patients' beliefs 
about medication. In a meta-analysis, both stronger perceptions about the necessity 
of the medication and fewer concerns about the harmfulness of the treatment were 
associated with better medication adherence (ORnecessity = 1.7, ORconcerns = 0.5) [9]. In 
RA, necessity beliefs about medication were found to be among the most relevant, 
modifiable determinants of non-adherence [10]. 
While published studies tend to focus on the medication beliefs of patients only, 
emerging studies suggest that beliefs about medication of healthcare providers 
(HCPsj might influence medication adherence as weil. Some medication beliefs of 
doctors, nurses and pharmacists have been shown to be different from patients with 
a chronic disease (RA not included), and such differences might lead to 
misunderstandings and increased medication non-adherence [11-17]. However, 
sufficient evidence about this interplay is currently lacking in and outside the field of 
RA. As a first step toward gaining this knowledge, this study aims to describe 
rheumatologists' medication beliefs and to compare these with the medication 
beliefs of RA patients. 
2. METHODS 
This descriptive study has been approved by the local medical ethical board (CMO 
2013/190) and is reported according to the STROBE guidelines [18]. 
2.1. Design 
2.1.1. Rheumatologist data 
After signing informed consent forms, all rheumatologists, residents, and physician 
assistants (henceforth referred to as 'rheumatologists') working in June 2013 at the 
rheumatology department of the Sint Maartenskliniek (a clinic specialized in 
rheumatology in the Netherlands) were asked to complete questionnaires. 
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2.1.2. Patient data 
Patient data were obtained from a cross-sectional study conducted at the Sint 
Maartenskliniek between September 2009 and September 2010 on beliefs about 
medication [19]. Inclusion criteria were having RA for at least one year, being;;::: 18 
years old, and using;;::: 1 prescribed disease-modifying antirheumatic drug (DMARD). 
For further details, see Zwikker et al. [19]. 
2.2. Measures 
2.2.1. Rheumatologists 
The rheumatologist background variables assessed were age, sex, work-related 
function, and years of work experience within the field of RA. 
The original, validated Beliefs about Medicines Questionnaire (BMQ) measures 
beliefs about medication in patients with a chronic disease. It consists of the BMQ 
'specific' and the BMQ 'general'. The BMQ 'specific' has two scales, measuring 
patients' beliefs about the necessity of prescribed medication and their concerns 
about potential adverse consequences of taking the medication. Items within scales 
are scored from 1 (strongly disagree) to 5 (strongly agree) [20,21]. 
The BMQ 'general' assesses general beliefs about pharmaceuticals as a class of 
treatment [22] and also has two scales. The 'overuse' scale includes beliefs about 
the way in which medicines are endorsed by doctors. The 'harm' scale includes 
beliefs about the potential of medication to harm. To obtain scale scores, items 
within the scale were averaged; no missing items were allowed. Higher scores 
indicated stronger beliefs [20]. 
To make the original BMQ suitable for rheumatologists, all items were converted 
to the rheumatologists' perspective (see Table 3). The conversion was discussed 
between the researchers HZ, NL and the developer of the BMQ (Prof. Horne) and 
subsequently approved by all co-authors of this study. 
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2.2.2. Patients 
The patient background variables assessed were age, sex, living with others (yes/no), 
educational level (high/not high), employment/studying (yes/no), disease duration, 
and the type and number of DMARDs used. Beliefs about medication were measured 
using the original BMQ (see 2.2.1). 
The internal consistency of all BMQ scales was sufficient in the patient 
population: Cronbach's alpha varied from 0.69 to 0.84. However, the internal 
consistency of the scales was poor for the rheumatologist population, as alpha 
varied from 0.47 to 0.57 [23]. 
2.3. Data analyses 
Scores of the BMQ subscales were described using means and standard deviations. 
Scores on single BMQ items were described using medians and interquartile ranges 
(appendix). Differences in means between rheumatologists and patients were 
examined using t-tests. Subsequently, single items were dichotomized above the 
scale midpoint {>3, so '1' when scoring 'agree' or 'strongly agree' and '0' if not) to 
compare the strength of views about medication among rheumatologists and 
patients. Differences in percentages were examined using two-group tests of 
proportions. Confidence intervals were set at 95%, and analyses were based on 
complete cases and were performed in STATA10. 
3. RESULTS 
3.1. Participants 
Twenty-seven out of 28 rheumatologists employed at the Sint Maartenskliniek in 
June 2013 completed the questionnaires (Table 1). Patients' characteristics are 
shown in Table 2. 
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Table 1 Sample characteristics of the rheumatologists (n=27) 
Background variables 
Age in years (mean, SD) 
Female 
Work-related function Rheumatologists 
Residents 
Phys1c1an assistants 
Work expenence in years (med'1an, IQR) 
Descnptlves 
42.0 (9 7) 
17 (63%) 
21 (78%) 
4(15%) 
2 (7%) 
5.0 (3.G-10.0) 
.~----------------------------------------------------------------------
Data are means (SD), medians (interquartile range), or numbers(%) 
Table 2 Sample characteristics of the patients 
Background variables N of patients Descnptives 
providing data 
-... -... ·----· ·-··- ·--·---------------------Age in years (mean, SD) 
Female 
Livmg with others (yes) 
Higher education t 
Currently employed or studying (yes) 
Disease duration in years (median, IQR) 
Number of DMARDs used 
Route of DMARD administration 
1 DMARD 
2 DMARDs 
3 DMARDs 
± 
Oral· 
Parenteral§ 
580 62 8 (12 6) 
580 396 (68%) 
571 458(80%) 
571 106 (19%) 
552 216 (39%) 
556 14 (8-22) 
476 307 (65%) 
476 149 (31%) 
476 20(4%) 
476 272 (57%) 
476 296 (62%) 
~------------------------------------------~f------------------------
Data are means (SD), medians (interquartile range), or numbers(%). Higher education means having at 
least a bachelor or master's degree. *Azathioprine, hydroxychloroquine, leflunomide, methotrexate, 
predniso(lo)n, or sulfasalazine. § Abatacept, adalimumab, aurothiomalate, etanercept, methotrexate, 
methylprednisolon, infliximab, rituximab, or tocilizumab 
3.2. Results 
Table 3 shows the (dichotomized) BMQ scores, and the differences between 
rheumatologists and patients along with a 95% confidence interval. Medians and 
interquartile ranges for single items are displayed in Appendix Table I. 
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(J1 
_ Ta_b_Je_3 __ _,_(1?ifferences_~MQ scores between rheumatologis~s and patients --~~-
Mean (SO) (scale Jevel)/percent:age scoring above scale midpoint (Item level) • 
Rheumatologists {n=27) Patients (n .. 531-565) t Difference (95% Cl)* 
Necessity beliefs aboUI: medication 
Mean (SO) (scale level) 3.9 (0.4) 4.0 (0.7) -0.1 (-0.3 to 0.0) 
Percentage scormg above scale m1dpomt (Item level) 
My patient~' /my health, at present, depends on the medic~nes 96 81 16 (8 to 23)§ 
My patients' /my life would be 1m possible without the medicines 41 83 
-43 (-61 to -24)11 
Without the med1c1nes my patients/! would be very ill 78 67 11 (-5 to 27) 
My patients' /my future health w11l depend on the medicines 89 78 11 (-2 to 23) 
The medicines protect my patients/me from becom1ng worse 100 84 16 (13 to 19)§ 
Concern beliefs about medication 
Mean (SO) (scale level) 2./ (0.5) 2.9 {0.7) -0.2 (-0 4 to 0.0) 
Percentage scoring above scale m1dpomt (1tem level) 
It wornes me that my pat1ents/l have to take med1cmes 15 43 
-29 (-43 to -15)11 
I sometimes worry about long-term e>ffects ofthe/my medicines 63 68 -5 (-24 to 13) 
I have Insufficient knowledge about the effects ofthe med1c1nes 19 23 -4 (-19 to 11) 
These/my medicines disrupt my pat1ents'/my life 7 10 -2 (-13 to 8) 
I sometimes worry that my patients/! become too dependent on the 15 30 -15 (-29 to -1) 
medicines 
These medicines give my patients/me unpleasant side effects 44 30 14 (-5 to 33) 
- Table 3 continues -
- Table 3 continued -
Harm beliefs 
Mean {50} (scale level) 
Percentage scormg above scale midpoint (item level) 
People who take medicines should stop their treatment for a while every 
now and again 
Most medicines are add1ct1ve 
Natural remedies are safer than medicines 
Medicines do more harm than good 
All medicines are poisons 
Overuse beliefs 
Mean (SD) (scale level) 
Percentage scoring above scale midpoint (item level) 
Doctors prescribe too many medicines~ 
Doctors place too much trust on medicines 
If doctors had more t1me with patients they would prescribe fewer 
medicines 
Mean (SO) (scale level)/percentage scoring above scale midpoint (item Ievell* 
Rheumatologists (n=27) . t Pat1ents (n=S31-565} Difference (95% a)* 
1.7 (0.5) 2.6(0.6} 
-0.8 (-1.0 to -0.6)" 
7 17 -9 (-20 to 1} 
4 13 -9 (-17to-1) 
0 18 
-18 (-21 to -15} 11 
0 7 -7 (-9to-5) 
7 22 -14 (-25 to -4) 
2.5 (0.6} 2.6{0.7) -0.1 {-0.3 to 0.2) 
19 10 8 (-7 to 23) 
7 15 -8 {-18 to 2} 
19 15 4 (-11 to 19) 
- .. ~... .~.- -~-~..... . ... .. .. ·--·····-.. -.--· .. --...... t .-·- ·----·--·---- .... ---·----"-........ - ... ·--'·--·-· ---···-··- .. .. - ·----.. --~--
1= Strongly disagree, 2= Disagree, 3= Uncertain, 4= Agree, 5= Strongly agree. Of the 580 patients included in the cross-sectional study, between 531 
and 565 provided data on the BMQ items* Differences in means (scale level) or percentages {item level): rheumatologist score minus patient score. 
§p !> 0.05 11 p s 0.01 ~Adapted item: original item is 'Doctors use too many medicines.' 
3.2.1. Rheumatologists' beliefs about medication 
In general, rheumatologists had a strong perceived need for patients to take their 
medication (mean 3.9, SD 0.4). Their concern beliefs were not as strong as their 
necessity beliefs (mean 2.7, SD 0.5). Nevertheless, 63% of the rheumatologists were 
concerned about the long-term effects of the medication and 44% about unpleasant 
side effects. 
Looking at beliefs about 'medication in general,' rheumatologists generally did 
not believe that medicines have much potential to harm and that physicians overuse 
medication. Nevertheless, 19% of the rheumatologists (strongly) agreed with the 
statement 'Doctors prescribe too many medicines.' 
3.2.2. Comparison of medication beliefs between rheumatologists and patients 
Beliefs about medication of rheumatologists and patients did not differ on a scale 
level, except for general harm beliefs (the rheumatologists had a milder opinion 
than the patients about the potential of medicines to harm). 
Although both rheumatologists and patients had a strong perceived need for 
patients to take the prescribed medication, fewer rheumatologists agreed with the 
statement 'My patients'/my life would be impossible without the medicines' (41%, 
compared to 83% of patients) . Also, a lower percentage of rheumatologists worried 
(15% of rheumatologists versus 44% of patients) about the fact that patients have to 
take medicines in the first place, and about patients becoming too dependent on 
medicines (respectively, 15% versus 30%). 
4. DISCUSSION 
This study illustrates that rheumatologists' beliefs about medication barely differ 
from those of patients. Rheumatologists and patients had a stronger perceived need 
for patients to take prescribed medication than concerns about taking medication, 
although the majority of both groups had concerns about the long-term effects of 
medication. 
We found some differences in medication beliefs between both groups. 
Rheumatologists had a milder opinion about the potential of medicines to harm. 
Furthermore, patients had stronger thoughts that life without medicines would be 
impossible, and had stronger concerns about having to take medicines, and about 
being dependent on them. 
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The finding that rheumatologists' perceived medication beliefs 'in general' were 
less harmful than patients' beliefs is in line with the findings of two other studies 
assessing general medication beliefs using the BMQ among doctors, nurses and 
pharmacists [15,17] . The HCPs in these studies also perceived medication ' in 
general' to be less harmful than patients did . This difference in attitude between 
HCPs and patients might be explained by the fact that the patient has to deal with 
the burden of using medicines in daily life, not the HCP [24] . 
A strong feature of this study is that it is the first to describe rheumatologists' 
beliefs about medication and to describe specific beliefs about medication among 
physicians according to an adapted version of the Beliefs about Medicines 
Questionnaire. 
A limitation of this study was the poor internal consistency of the BMQ scales for the 
rheumatologist sample. Two other studies assessing medication beliefs in HCPs also 
reported low to moderate alpha values [14,17] . Because of their knowledge about 
RA medication, the rheumatologists might have more subtle or other thoughts 
about the medication, and thus might have more/other factors underlying the 
current BMQ statements. Thus, our current version of the BMQ for rheumatologists 
might not be specific enough. 
Another limitation of this study is the three-year time period between 
measurements of the patient data set and the rheumatologist data set. Medication 
beliefs might change over time [25,26], so our results might have been different if 
we had used a synchronous cross-sectional study design. However, given that 
general medication beliefs have been found to be stable over a four-year period 
irrespective of changes in health [27], it is uncertain whether this time lag has biased 
our results. 
Finally, a sign ificant limitation of this study is that we compared medication 
beliefs on a group level between rheumatologists and patients. Using this approach, 
true differences in beliefs between pairs of rheumatologists and patients could not 
be detected. Furthermore, medication adherence was not assessed. Future research 
should obviate these deficiencies, making it possible to examine the effect of 
rheumatologists' medication beliefs (and the interplay with patients' beliefs) on 
patients' medication adherence to further explore rheumatologists' medication 
beliefs as a possible target for improving patients' adherence. 
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Appendix Table 1 Outcome scores on t he BMQ items: medians and interquartile ranges 
--------------------------------:----~ Rheumatologists (n=27) 
Necessity beliefs about medication 
My pat1ents' /my health, at present, depends on the medicines 
My pat1ents'/my life would be impossible Without the medicines 
Without the medicines my pat1ents/l would be very ill 
My pat1ents'/my future health Will depend on the medicines 
The medicines protect my patients/me from becoming worse 
Concern beliefs about medication 
It worries me that my patients/! have to take medicines 
I sometimes worry about long-term effects of the/my medicines 
I have insufficient knowledge about the effects of the medicines 
These/my medicines disrupt my pat1ents' /my life 
I sometimes worry that my patients/! become too dependent on the medicines 
These medic1nes give my patients/me unpleasant side effects 
t 
Median (IQR) 
4(4--4) 
3(2--4) 
4(4-4) 
4(4--4) 
4(4-5) 
2(2-3) 
4(3--4) 
2(1-2) 
2 (2-3) 
2(2-3) 
3 (3-4) 
Patients (n=S31-565)·--
Median (lOR) t 
4(4-5) 
4(4-5) 
4(3-5) 
4(4-4) 
4 (4-5) 
3(2--4) 
4(3'--4) 
2(2-3) 
2(2-2) 
3(2--4) 
3(2--4) 
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-Appendix Table 1 continued-
Harm beliefs 
People who take medicines should stop their treatment for a while every now and again 
Most medicines are addictive 
Natural remedies are safer than medicines 
Med1c1nes do more harm than good 
All medicines are poisons 
Overuse beliefs 
Doctors pre~cribe too many medicines* 
Doctors place too much trust on medicmes 
If doctors had more time with patients they would prescribe fewer medicines 
Rheumatologists (n=:27) 
Median (IQR) t 
2 (1-2) 
2(1-2) 
2 (1-2) 
1 (1-2) 
1 (1-2) 
3 (2-3) 
2 (2-2) 
3 (2-3) 
Med1an (IQR) t 
2 (2-3) 
2(2-3) 
3 (2-3) 
2 (2-3) 
3 (2-3) 
2 (2-3) 
3 (2-3) 
3 (2-3) 
~- - ... ·--··~ t-·-~···· -·---·~····- .. - -·---·- ····---------···---
~ Of the 580 patients included in the cross-sectional study, between 531 and 565 provided data on the BMQ items. Data shown are medians with their interquartile 
G( range (IQR.) . 1 = Strongly disagree, 2 = Disagree, 3 = Uncertain, 4 =Agree, 5 = Strongly agree. * Adapted item: original item is 'Doctors use too many medicines.' 
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Chapter 8 
Sumn1ary and general discussion 
8.1 . Summary 

Medication adherence is suboptimal in patients with rheumatoid arthritis (RA). As 
medication non-adherence can have serious consequences for patients' health and 
societal costs, effective interventions to improve adherence are warranted. 
Therefore, in part one of this thesis, we identified relevant targets for improving 
medication adherence in RA patients in a narrative review (chapter 2). As addressing 
beliefs about medication was considered to be a promising strategy to improve 
adherence, we developed and tested an intervention for its effectiveness in 
changing medication beliefs and improving adherence in RA patients (chapters 3 and 
4). 
In part two of the thesis, we further explored beliefs about medication as 
possible intervention target. We examined longitudinal associations between beliefs 
about medication, other psychosocial factors and medication non-adherence 
(chapter 5). In addition, we examined whether beliefs about medication are 
independent associates of non-adherence to disease-modifying antirheumatic drugs 
(DMARDs, chapter 6), and compared rheumatologists' and patients' beliefs about 
medication (chapter 7). This chapter summarizes the main findings of the studies 
within this thesis. 
Chapter 2 comprises a narrative review of adherence literature about aspects of 
medication adherence to DMARDs in RA patients. 
We concluded that adherence to DMARDs in RA patients is suboptimal, varying 
from 22% (underuse) to 107% (overuse), and that time-efficient interventions are 
needed to improve adherence. These interventions should be tailored to the 
patient's causes of non-adherence. These causes can be unintentional due to 
practical barriers like forgetfulness, or intentional. Intentional non-adherence is 
driven by a decision not to take medicines as prescribed. It is assumed that patients 
make these decisions by a cost-benefit assessment, in which personal beliefs about 
the necessity of taking medication is balanced against perceived concerns about 
taking the medication. Because these medication beliefs influence adherence in RA 
patients, it is important that adherence improving interventions take these beliefs 
into account next to practical barriers. 
Chapter 3 describes the development of a short, group-based intervention to 
improve adherence to DMARDs in adult, non-adherent RA patients. The Intervention 
Mapping (IM) framework was used to systematically integrate theories, empirical 
evidence, and practice perspectives during the development of the intervention. 
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Following the IM framework, we first conducted a thorough needs assessment 
(amongst others, comprising the results of the narrative review and focus groups 
with non-adherent RA patients). This assessment demonstrated that beliefs about 
medication are a promising target to improve adherence in RA patients, but also 
that most interventions do not systematically target such beliefs. Hence, our 
intervention aimed to change the balance between necessity and concern beliefs 
about medication in a systematic way, and aimed to resolve practical barriers in 
taking medication to improve adherence. 
In short, the intervention consists of two group sessions moderated by a 
pharmacist. During these sessions, patients' self-perceived needs to take medication 
('necessity beliefs'), concerns about taking medication ('concern beliefs'), and 
practical barriers are discussed. The first session focuses on an inventory of a 
patient's personal beliefs and barriers, whereas the second focuses on discussing 
these individual beliefs and barriers in the group. Hereby, the pharmacist and other 
patients being present provide non-judgmental feedback and solutions. To explore a 
patient's individual ambivalence regarding his/her beliefs and barriers, the 
pharmacist uses motivational interviewing techniques. In between the sessions, 
participants make a homework assignment about their own beliefs and barriers, and 
eight weeks after the second session, a follow-up call to the individual patients is 
made by the pharmacist. 
Chapter 4 describes the effectiveness of the group based intervention, tested in a 
randomized clinical trial. A total of 123 adult, non-adherent RA patients using 
DMARDs were randomized into the intervention arm (group sessions + brochure 
about DMARDs) or control arm (brochures only). The main outcome measures were 
beliefs about medication assessed with the Beliefs about Medicines Questionnaire 
(BMQ), and medication adherence assessed with the Compliance Questionnaire 
Rheumatology (CQR). Patients were assessed up to 12 months follow-up. No 
differences were found in these outcomes between the intervention - and control 
arm. 
Chapter 5 comprises a systematic review about longitudinal associations between 
psychosocial predictors (e.g., beliefs about medication/ treatment) and non-
adherence to chronic, preventive maintenance medication (CPMM). Knowing 
whether such factors predict non-adherence in the long term could be helpful in 
designing adherence improving interventions. 
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In this systematic review, results of 30 studies were summarized using a qualitative 
best evidence synthesis. All studies appeared to be of low quality. Limited evidence 
was found for the absence of longitudinal associations between psychosocial 
predictors and CPMM non-adherence. Thus, it is possible that psychosocial factors 
are only associates of non-adherence when measured cross-sectionally, but do not 
predict non-adherence longitudinally. 
Chapter 6 reports a cross-sectional study, assessing whether beliefs about 
medication are independent associates of non-adherence to DMARDs when 
controlling for potentially important demographical, clinical, and psychological 
confounders (anxiety/depression, self-efficacy and illness cognitions). 
Five hundred eighty patients filled in questionnaires. The logistic regression 
model, corrected for all confounders, demonstrated that (weaker) necessity beliefs, 
a more unfavorable balance between necessity- and concern beliefs, and having an 
iridifferent attitude towards medication were associated with CQR non-adherence. 
Psychological, demographical, and clinical factors hardly influenced associations 
found. We concluded that the beliefs as mentioned above are, thus, independent 
associates of medication non-adherence in RA patients. 
Chapter 7 describes rheumatologists' beliefs about medication and compares them 
with patients' medication beliefs. Current research into beliefs about medication is 
mainly focusing on the patient, while beliefs about medication of healthcare 
providers might also influence adherence of patients. 
Twenty seven rheumatologists filled in an adapted version of the BMQ. 
Generally, beliefs about medication did not differ between rheumatologists and 
patients. Both groups had a strong perceived need for taking prescribed medication, 
but also had significant concerns about long-term effects of the medication (e.g., 
63% of the rheumatologists and 68% of the patients expressed concerns). Some 
differences in beliefs were also present, as patients seemed to have stronger 
concerns about taking medication in general and about being dependent of 
medication, for example. Future research should study the effect of the interplay 
between beliefs about medication of healthcare providers and patients on patients' 
medication adherence to further explore healthcare providers' medication beliefs as 
possible target to improve patients' adherence. 
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In chapter 8.2, the results presented in this thesis are discussed within a broader 
perspective. Recommendations for future research and clinical practice will also be 
provided. 
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Chapter 8 
Summary and generol discussion 
8.2. General discussion 

Beliefs about medication: what was unknown, what did we do 
(Recent) Cochrane reviews about the effectiveness of interventions for enhancing 
medication adherence conclude that these interventions are mostly complex and of 
limited effect [1,2]. Moreover, the only slightly effective intervention in improving 
medication adherence in patients with rheumatoid arthritis (RA) is intensive and 
time-inefficient (seven individual education sessions of 30 minutes), as it is not 
group-based and intends for both adherent and non-adherent patients [3]. So, short 
and effective interventions to improve adherence in RA patients are needed in 
clinical practice. 
Many studies included in our narrative review and needs assessment (chapters 2 
and 3) underline the importance of addressing medication beliefs to improve 
adherence in- and outside the field of RA [4-19]. Despite the possible central role of 
beliefs about medication, most published interventions fail to systematically target 
beliefs about medication. 
Therefore, part one of this thesis focuses on developing and testing a short, 
group-based intervention to change medication beliefs and to improve medication 
adherence in non-adherent RA patients. In developing the intervention, the 
Intervention Mapping (IM) framework was used [20]. This framework enabled the 
systematic use of theory, empirical evidence, and practical perspectives in 
developing our intervention (Figure 1: elaborated in chapter 3). Each of the six 1M-
steps were conducted by members of a multidisciplinary task group, consisting of 
pharmacists, researchers, psychologists, rheumatologists, experts on motivational 
interviewing, and RA patients. This led to a well-founded and promising 
intervention, consisting of two group sessions led by a pharmacist, a homework 
assignment, and a follow-up call aiming to improve the balance between necessity 
and concern beliefs about medication and to resolve practical barriers in taking 
medication. The central communication method used is motivational interviewing 
[22,23]. Intervention effects were examined by means of a randomized clinical trial 
(chapter 4). 
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Step 1: Needs assessment- analysis of determinants 
Literature study, cross-sectional study and focus group 
study about determinants of medication non-adherence 
Step 2: Intervention objectives 
Formulation of specific mtervention objectives, based on 
information of the needs assessment 
Step 3: Health behavior change methods and 
techniques 
Literature study to select appropriate health behavior 
change methods and techniques in accomplishing the 
specifiC intervention ObJectives 
l 
Step 4: Intervention content and pilot 
Determination of intervention content (created by combining 
health behavior methods and techmques) and pilot of 
intervention and matenals 
Step 5: Implementation of intervention 
! 
' Step 6· Evaluation of intervention 
Figure 1 Intervention Mapping framework (derived from Brug et al. [21]) 
We further explored beliefs about medication as possible intervention target in part 
two of this thesis. Evidence regarding beliefs about medication and other 
psychosocial factors being associated with medication non-adherence is mainly 
based on studies with cross-sectional designs [24]. Therefore, we studied 
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longitudinal associations (with follow-up of adherence measurements ~ 3 months 
after baseline) between psychosocial predictors and medication non-adherence in a 
systematic review (chapter 5). Also, we examined if beliefs about medication are 
truly independent associates of non-adherence by taking potential important 
confounders like anxiety/depression, self-efficacy, and illness cognitions into 
account in data-analyses (chapter 6). No single study had accomplished that before. 
Last, a novel area of interest explored in this thesis are beliefs about medication of 
healthcare providers, as they might also influence adherence of patients [25-31]. 
Therefore, we described rheumatologists' beliefs about medication and compared 
them with patients' medication beliefs (chapter 7). The yielded knowledge in this 
thesis provides new leverage points for future research and the design of effective 
interventions aiming to improve medication adherence in chronically ill patients. 
Study results: meaning and lessons learned 
In sum, our narrative review and needs assessment stated that beliefs about 
medication could be a potentially useful target to improve adherence among (RA) 
patients. Our cross-sectional study demonstrated that certain medication beliefs (as 
measured with the BMQ) were indeed obvious and independent associates of 
medication non-adherence in RA patients when controlling for psychological, 
demographical and clinical factors. However, the results of our randomized 
controlled trial indicated that our intervention was not superior to the control arm 
in changing medication beliefs or in improving medication adherence. Moreover, we 
found no evidence for longitudinal associations (~ 3 months) between psychosocial 
factors and non-adherence in our systematic review. We will discuss these study 
results and lessons learned within a broader perspective in the following section. 
Lessons learned from the randomized controlled trial (part one thesis) 
Lessons learned stem from the participants included, implicit trial effects, the 
measurement of adherence and design, preparation, and execution of the 
intervention. 
Trial participants 
The results of the RCT might be explained by the characteristics of the patients 
included in the trial, amongst others. Although clinical trials provide the best 
possible level of evidence, it is generally known that trials are prone to bias [32-34]. 
Bias can also occur before trials are carried out [34]. This seemed to apply to our 
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RCT, because patients with a relatively long disease duration (mean: 14.8 years) 
participated in the trial. As a consequence, a change in beliefs about medication and 
adherence might have been harder to establish. In fact, modifying existing beliefs 
and adherence behaviors in patients with a long disease duration is harder to 
establish than forming new beliefs and behavior in recently diagnosed RA patients 
who are, essentially, in the process of adopting a new lifestyle [35]. There is, indeed, 
some evidence that medication beliefs can be changed in newly diagnosed patients 
to improve adherence [4,36]. Our inclusion criterion for patients having RA at least 
one year was based, however, on the fact that it takes time for patients to develop 
specific beliefs about their own medication. These beliefs are shaped by an 
individual's experience using medication (37] and develop later on when patients 
become more familiar with treatment [16]. From this perspective, attempts to 
change specific medication beliefs in newly diagnosed RA patients would have been 
less useful. Disease duration of trial participants is, either way, a point to consider 
when testing effects of interventions to change beliefs about medication. 
Implicit trial effects 
A second explanation for the results of the trial could be that there was insufficient 
room for additional change in beliefs about medication and adherence in the 
intervention participants. In fact, beliefs and adherence had already favorably 
changed before the actual intervention took place according to our data [38]. This 
might have been due to phenomenon's like 'regression to the mean' [39] but also to 
implicit trial effects. 
Examples of implicit trial effects are Hawthorne effects (i.e., trial participants 
benefit through their own improved behavior and improved behavior of healthcare 
professionals due to increased awareness of observation in a trial setting), and care 
effects [40]. McNicholas et al. [40] explain that 'inherent to trial participation, the 
obligation is to proceed through certain steps, all of which could affect interpersonal 
care', and that 'obtaining informed consent is mostly a positive experience for 
patients who agree to participate'. In our trial, care effects might have occurred 
during the intake meetings between the researcher and the individual patients. 
These effects were avoided as much as possible, by using a standardized protocol 
which instructed the involved researchers to discuss technical trial information and 
to obtain informed consent only. However, patients also asked questions about their 
medication intake behavior. The researchers indicated that it was sometimes 
impossible to avoid answering this type of questions, thereby implicitly and 
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unintentionally providing care to patients. Whenever possible, implicit trial effects 
should be anticipated on when conducting a trial. 
Measurement of adherence 
Other lessons learned concern measurements of adherence. Although medication 
adherence is widely examined in the literature, there is no consensus on the best 
(direct or indirect) method of measuring adherence to therapy [41]. Direct, objective 
measures like biomarkers might prove that the medication has been taken by the 
patient, but are less suitable to use in clinical practice because they are expensive 
and inconvenient to patients [18]. So, adherence measures used in practice will 
mostly be proxies of adherence rather than absolute measures of adherence [42]. 
In our trial, we also used proxy measures of adherence by using self-report 
questionnaires (the Compliance Questionnaire Rheumatology (CQR) and the 
Medication Adherence Report Scale (MARS)), and pharmacy refill data. It is possible 
that true changes in medication adherence, and the differences herein between the 
intervention arm and control arm were not detected by our measures. To our 
knowledge, the sensitivity to change of both questionnaires is still unknown and 
moreover, self-report measures are prone to social desirable answers of patients. 
Thereby, these measures tend to overestimate adherence [41,43] making it more 
difficult to detect differences in the levels of adherence between participants of the 
intervention arm and control arm. However, no method is free of bias. Biomarkers 
or electronic monitoring devices can also overestimate adherence, for example, 
because patients are aware that their medication intake behavior is continuously 
and directly monitored [18]. Garfield et al. [43] therefore point out that 'rather than 
there being a 'gold standard', the choice of adherence measures will depend on the 
specific situation'. 
In our case, the measures chosen were the most valid, feasible and cost-efficient 
measures available at the time for testing intervention effects on adherence in a 
clinical setting. Regarding the CQR, however, we did learn from personal 
communication with patients that administration of some items was cumbersome. 
For some patients, a couple of items were 'inapplicable', but this was not a response 
option within the CQR. Patients handled this situation in various ways. Some left the 
concerning item open, some filled in 'don't agree at all' (because: 'not applicable'), 
and others, in contrast, filled in 'agree very much' (because they answered the 
statement from the perspective of patients in general). This might have 
contaminated CQR scores. To compensate for possible disadvantages of single 
Summary and general discussion I 257 
measures, it is, thus, important to combine different adherence measures when 
examining intervention effects [44]. 
Design, preparation, and execution of the intervention 
Finally, the results of the trial might be explained by aspects regarding the design, 
preparation, and execution of the intervention. 
In designing the intervention, a group format was chosen with motivational 
interviewing (MI) as central intervention style (a non-judgmental, patient-centered 
approach that facilitates behavior change [22,23]). Group counseling has certain 
advantages over individual counseling as it is time efficient by helping more patients 
in a certain time span [23,45,46]. Also, within groups, participants hear and consider 
new ideas and perspectives from their 'peers' [23], thereby enabling us to make use 
of 'social influence' in changing beliefs about medication and resolving practical 
barriers in taking medication (see chapter 3). Concerning Ml, there is a large body of 
literature of well-designed clinical trials supporting its efficacy when treating 
individual patients [23,47-50], and although evidence for Ml in groups is still limited, 
available studies suggest promising results [23]. Therefore, we deemed Ml to be a 
main working element of the intervention. 
A disadvantage, however, is that Ml is difficult to apply, [51] especially in groups. 
One must assist many patients at the same time, which requires facilitating focused 
and productive interactions between patients with different histories, beliefs, 
values, and communication styles [23]. Although our intervention leaders followed a 
three-day Ml-course at a renowned Ml center in The Netherlands, this training 
might not have been sufficient for a sustained application of Ml-skills in a group 
setting. 
Another lesson learned regarding the intervention concerns the number of 
group sessions. We decided on two group sessions because brief interventions 
might be as effective as intensive treatments [52] and to keep the intervention time 
efficient. However, group cohesiveness is considered crucial for positive outcomes 
[23]. Group cohesiveness develops over time [23], so from this perspective, two 
group sessions might not have been sufficient. 
Lessons learned from the further exploration of medication beliefs (part two thesis) 
The fact that no differences were found in beliefs about medication and medication 
adherence between the intervention arm and control arm, does not mean that 
beliefs about medication are not potentially useful targets to improve adherence. As 
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stated in the previous paragraph, several explanations can be given for the trial 
results. Also, most new studies about the effects of (educational) interventions on 
changing beliefs about medication and improving adherence [36,53-55] showed that 
beliefs are changeable, and in one case, this led to obvious improvements in 
adherence [53]. The further exploration of associations between medication beliefs 
and non-adherence in part two of this thesis, moreover, has provided new 
knowledge and thoughts about the role of medication beliefs in improving 
adherence. 
To start with, our cross-sectional study (chapter 6) demonstrated that certain 
medication beliefs as measured with the BMQ were independent associates of 
medication non-adherence in RA patients when controlling for psychological, 
demographical and clinical factors. Recent publications also confirmed the 
association between beliefs about medication and medication non-adherence in and 
outside the field of RA [9,14]. Medication beliefs, thus, might still be a potential 
target to improve medication adherence from this point of view. Our systematic 
review into longitudinal associations between psychosocial factors (including 
medication beliefs) and non-adherence, however, did not demonstrate longitudinal 
associations (chapter 5). This means that the association between medication beliefs 
and (non-)adherence might be time-dependent and thus, might change over time. If 
that is true, than this might have implications for the timing and design of 
interventions. 
Maybe, associations between beliefs about medication and adherence are 
simply cross-sectional in nature. They might be 'snapshots'. A logical thought, 
because (specific) medication beliefs and adherence are dynamic features which are 
not stable over time [18,37,56-61]. Beliefs about the necessity of taking medication 
might fluctuate over the course of a disease depending on disease severity, for 
example, and might correlate well with adherent behavior at that same time. 
However, those beliefs might just not be predictive of adherent behavior in the 
future. Haynes et al. furthermore state that adherence cannot be 'cured' [1]. So 
perhaps, patients might rather benefit from continuous 'booster intervention 
sessions', creating a cumulative effect on improving adherence over time. 
These thoughts need further exploration within the wider field of adherence 
research, however, because evidence about (the absence of) longitudinal 
associations between beliefs about medication and adherence is still scarce [9,24]. 
Moreover, the longitudinal studies which are currently available show conflicting 
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results [9,24,58-60,62]. In contrast to the results of our systematic review, a recent 
meta-analysis of Horne et al. [9] demonstrated the presence of longitudinal 
associations between beliefs about medication and adherence, for instance. The 
latter meta-analysis also included studies with short term follow-up duration (< 3 
months), while our systematic review only included studies with a longer follow-up 
duration (~ 3 months), possibly meaning that beliefs are associated with adherence 
at the same point of time or in the short term only. Either way, more research into 
this topic is needed to gain new leverage points for the design of effective 
interventions which aim to change beliefs about medication and to improve 
adherence. 
Our exploration of beliefs about medication revealed another gap in literature. 
Current research into beliefs about medication is mainly focusing on the patient, 
while beliefs about medication of healthcare providers might also influence patients' 
adherence. Some medication beliefs of healthcare providers have shown to be 
different from those of patients with a chronic disease, and such differences might 
lead to misunderstandings and increased medication non-adherence [25-31]. 
However, sufficient evidence about this interplay is currently lacking. As a first step 
in gaining this knowledge, we compared rheumatologists' medication beliefs with 
RA patients' beliefs about medication (chapter 7). Although most beliefs about 
medication did not differ between rheumatologists and patients, some differences 
were identified too. Patients seemed to have stronger concerns about taking 
medication in general and about being dependent of medication, amongst others. 
Future research should now examine the effect of the interplay between the 
medication beliefs of both healthcare providers and patients on patients' 
medication adherence, to further examine healthcare providers' beliefs as possible 
target to improve patients' adherence. 
Recommendations for future research and practice implications 
In sum, given the lessons learned about our work and the fact that much about 
medication beliefs is yet unknown, we have the following recommendations for 
future research: 
Research into associations 
o Explore the effect of the interplay between the medication beliefs of both 
healthcare providers and patients on patients' medication adherence, to further 
examine healthcare providers' beliefs as possible target to improve patients' 
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adherence. We have shown that medication beliefs can differ between 
rheumatologists and patients, and such differences might lead to 
misunderstandings and increased medication non-adherence [25-31]. However, 
sufficient evidence about this interplay is currently lacking. 
o Focus research upon associations between (changes in) beliefs about medication 
and (changes in) medication non-adherence over time. Studies about this topic 
are still scarce. However, if associations between medication beliefs and non-
adherence are, in fact, time-dependent, this might have implications for the 
timing/design of interventions. 
Design of interventions 
o When associations between medication beliefs and adherence appear to be 
mainly cross-sectional in nature, one could experiment with offering continuous 
'booster intervention sessions' to patients to see if cumulative effects can be 
created in changing medication beliefs and adherence over time. When working 
with groups, this also offers possibilities for developing good group cohesiveness 
over time (which is considered to be crucial for positive outcomes) [23]. 
Motivational interviewing in groups 
o Although recent studies suggest that applying Ml in groups is promising, 
additional research into the effectiveness of Ml group interventions is needed. 
Evaluation of intervention effects 
o The disease duration of patients is an important factor to take into account 
when developing and offering interventions to improve non-adherence. 
Modifying existing beliefs and adherence behaviors in patients with a long 
disease duration might be harder to establish than forming new beliefs and 
behavior in recently diagnosed (RA) patients [35]. In contrast, patients start to 
develop specific beliefs about their medication later on, when they become 
more familiar with treatment [16]. Thus, the disease duration of patients should 
neither be too long or too short. 
o Take into account implicit trial effects. Gamble et al. provide an example in doing 
this [63]. They tested effects of an adherence improving intervention in patients 
with difficulty to control asthma by means of a two-phased, randomized clinical 
trial. In phase 1, when non-adherence was identified, a short, physician-led 
concordance conversation was arranged with the patient. During this meeting, 
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non-adherence was discussed and a treatment plan was agreed upon to address 
poor adherence. The aim of phase 1 was to examine the effect of the 
communication with the patient, the fact that the treating healthcare team was 
aware of the patient's non-adherence, and the effect of the concordance 
conversation. After this phase, 31 of 83 patients (37%) became adherent to 
medication and 90% of these 31 patients remained adherent 15 months 
thereafter. Participants who remained non-adherent after phase 1 were 
approached to enter phase 2. Herein, the actual intervention was tested. This 
was an individualized, psycho-educational, nurse-led intervention which was 
effective in improving medication adherence. 
o Until a gold standard for adherence measurement is found, triangulate multiple 
adherence measures to compensate for disadvantages of single adherence 
measures [44]. 
o When selecting the CQR for measuring adherence in RA patients, consider using 
the CQR-5. This is a short version of the CQR recently developed by Hughes et al. 
[64]. In this version, only one of the cumbersome items of the Dutch version is 
retained (item no. 5, for which we recommend to replace the word 'pills' with 
'medicines'). Use of the CQR-5 increases the clinical utility by reducing the 
patient burden whilst maintaining a good level of reliability and validity [64]. 
Lastly, we recommend to examine the sensitivity to change of the CQR. 
Practice implications 
As a patient's beliefs about medication are associated with his/her medication 
adherence, it is important that healthcare providers act on this topic. Until a clearly 
effective and feasible intervention is found, healthcare providers are advised to 
incorporate feedback about adherence behavior into routine daily care. A short, 
concordance-based conversation can, in fact, lead to improved adherence [63]. We 
also recommend that healthcare providers take into account the medication beliefs 
of their patients during these conversations: they should discuss the patients' 
perception about the need for the treatment and consider the patient's concerns 
about taking the medication throughout the course of therapy [18]. The BMQ and 
CQR-5 can might be considered as input for the short conversations. 
Conclusion 
Several studies show that beliefs about medication are relevant and modifiable 
determinants of non-adherence in (RA) patients. Our intervention was ineffective, 
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however, in changing beliefs about medication and in improving adherence. Yet, 
given the lessons learned from our work and the fact that much about medication 
beliefs is still unknown, we advocate for more research into this topic. With the 
recommendations and reflections on beliefs about medication in this thesis, we 
hope to provide new stimuli for this further exploration. 
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ReumatoYde artritis (RA) is een auto-immuunziekte met als belangrijkste kenmerk 
'ontstekingen in de gewrichten'. Een dergelijke ontsteking ontstaat doordat het 
eigen afweersysteem de gewrichten aanvalt. Medicatie vormt de basis van de 
behandeling van RA. 
Ondanks de belangrijke rol van medicatie neemt een deel van de patienten hun 
medicatie niet altijd in volgens het schema dat zij met hun reumatoloog hebben 
afgesproken. Dit noemen we 'medicatie-therapieontrouw'. Therapieontrouw kan de 
gezondheid van patienten beYnvloeden, aangezien het kan leiden tot meer 
ziekteactiviteit, meer gewrichtsschade en tot een lagere kwaliteit van Ieven. Met het 
verbeteren van medicatie-therapietrouw in Nederland kan bovendien jaarlijks tot 
vier miljard euro worden bespaard (bij diverse ziektebeelden). Het verbeteren van 
medicatie-therapietrouw is dus essentieel. 
Patienten kunnen veel verschillende redenen hebben voor het niet (goed) 
gebruiken van hun medicatie. Een vaak gebruikt onderscheid is 1) niet-intentionele 
redenen van therapieontrouw, zoals het vergeten om medicatie in te nemen, het 
niet begrijpen van de bijsluiter of andere praktische barrieres, en 2) intentionele 
redenen van therapieontrouw. Daarbij neemt de patient min of meer een besluit om 
de medicatie niet in te nemen. Het wordt verondersteld dat patienten dan een soort 
'kosten-baten afweging' maken: de patient weegt zijn/haar opvattingen over de 
noodzaak voor het nemen van medicatie af ten opzichte van zijn/haar zorgen over 
potentiele bijwerkingen of andere nadelen van medicatie. Hoe ongunstiger de 
balans is tussen deze medicatie-opvattingen (dus hoe minder sterk de 
waargenomen noodzaak om medicatie te nemen en hoe sterker de zorgen over 
medicatie), hoe groter de kans zal zijn dat patienten hun medicatie niet goed 
gebruiken. 
Veel wetenschappelijke studies wijzen erop dat medicatie-therapietrouw van 
patienten met RA of andere, chronische aandoeningen verbeterd kan worden door 
het veranderen van medicatie-opvattingen. Bestaande interventies voor het 
verbeteren van medicatie-therapietrouw benutten deze opvattingen echter niet, of 
niet op een systematische wijze. Bovendien zijn de interventies vaak complex, 
tijdrovend en weinig effectief. Het doe I van dit proefschrift is dan ook om medicatie-
opvattingen van RA-patienten te exploreren en te beYnvloeden ter verbetering van 
medicatie-therapietrouw. 
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Deel 1 
In deel 1 van dit proefschrift (hoofdstukken 2, 3 en 4) wordt een overzicht gegeven 
van mogelijke aangrijpingspunten om medicatie-therapietrouw te verbeteren bij 
patienten met RA. Ook is een interventie ontwikkeld en getest op effectiviteit 
aangaande het veranderen van medicatie-opvattingen en het verbeteren van 
thera pietrouw. 
Hoofdstuk 2 bevat een literatuuroverzicht van diverse aspecten van 
therapieontrouw aan disease-modifying antirheumatic drugs (DMARDs). DMARDs 
be'invloeden het ziektebeloop bij RA en zijn daarmee belangrijk voor de behandeling 
van de ziekte. In dit hoofdstuk Iaten we zien dat therapietrouw aan DMARDs niet 
optimaal is en varieert van 22% (ondergebruik: 22% van de voorgeschreven 
medicatie wordt daadwerkelijk ingenomen) tot 107% (overmatig gebruik). Effectieve 
interventies zijn dus nodig om therapietrouw aan DMARDs te verbeteren. Omdat 
therapieontrouw van intentionele en niet-intentionele aard kan zijn, is het 
essentieel dat met beide aspecten rekening wordt gehouden. Dat kan door het 
adresseren van zowel medicatie-opvattingen als het adresseren van ervaren, 
praktische barrieres in het nemen van medicatie. 
Hoofdstuk 3 beschrijft de ontwikkeling van een korte groepsinterventie om DMARD-
therapietrouw te verbeteren bij volwassen, therapieontrouwe RA-patienten. Deze 
interventie beoogt dit te doen door de balans tussen de waargenomen noodzaak 
voor, en zorgen over het nemen van medicatie op systematische wijze te 
veranderen en door het verhelpen van praktische barrieres in het nemen van 
medicatie. Het 'intervention mapping' raamwerk is tijdens het ontwikkelingsproces 
gebruikt om theorie, empirisch bewijs en perspectieven uit de beroepspraktijk te 
integreren. 
De interventie bestaat uit twee groepssessies geleid door een 
ziekenhuisapotheker. Tijdens de eerste sessie worden de persoonlijke medicatie-
opvattingen en praktische barrieres van de individuele patienten ge'inventariseerd. 
Hierna maken de deelnemers een huiswerkopdracht over hun eigen 
opvattingen/barrieres en na een week volgt de tweede sessie. Daarin worden de 
opvattingen en barrieres plenair besproken en geven de apotheker en de andere 
patienten niet-veroordelende feedback en oplossingen. Om tegenstrijdigheden te 
verkennen in de opvattingen/barrieres van een patient, maakt de apotheker gebruik 
van motivational interviewing-technieken. Acht weken na de tweede sessie voert de 
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apotheker nog een kort, telefonisch gesprek met individuele patienten om de 
sessies te evalueren. 
Hoofdstuk 4 beschrijft de effectiviteit van de groepsinterventie. De effectiviteit is 
gemeten op basis van een gerandomiseerde, klinische trial. Totaal zijn 123 
volwassen, therapieontrouwe RA-patienten die DMARDs gebruiken ingeloot voor de 
interventie (de groepssessies + een brochure over de DMARDs) of de controlegroep 
(aileen de brochures). De belangrijkste uitkomstmaten zijn medicatie-opvattingen, 
gemeten met de Beliefs about Medicines Questionnaire (BMQ) en medicatie-
therapietrouw gemeten met de Compliance Questionnaire Reumatology (CQR). 
Metingen zijn verricht tot 12 maanden na de interventie. Er zijn geen verschillen 
gevonden in de uitkomstmaten tussen de interventie- en controlegroep en dus is de 
groepsinterventie niet effectief bevonden. 
Deel2 
In deel 2 van dit proefschrift (hoofdstukken 5, 6 en 7) zijn medicatie-opvattingen op 
diverse manieren geexploreerd in relatie tot therapieontrouw. Daarmee willen we 
meer inzicht krijgen in de wijze waarop deze opvattingen benut kunnen worden 
voor het verbeteren van medicatie-therapietrouw bij RA-patienten. 
Hoofdstuk 5 bevat een systematische literatuurreview over lange termijnverbanden 
tussen psychosociale factoren, waaronder medicatie-opvattingen, en 
therapieontrouw aan chronisch te gebruiken medicatie. Onderzoeken of 
psychosociale factoren voorspellend zijn voor therapieontrouw gedrag op de lange 
termijn is nuttig voor het ontwerpen van therapietrouw-interventies. 
In de review zijn de resultaten van 30 studies over eventuele lange 
termijnverbanden samengevat op basis van een kwalitatief beoordelingssysteem: de 
'best evidence synthese'. Aile ge·includeerd studies waren van I age kwaliteit. Er is 
beperkte bewijskracht gevonden voor het niet bestaan van lange termijnverbanden 
tussen psychosociale factoren en medicatie-therapieontrouw. Wellicht hangen 
psychosociale factoren aileen samen met therapieontrouw gedrag op datzelfde 
tijdstip (dus als een patient op dat moment ernstige zorgen heeft over medicatie 
dan zal hij de medicatie op dat moment niet nemen), maar niet met 
therapieontrouw gedrag op de lange termijn. 
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Hoofdstuk 6 is een dwarsdoorsnede-onderzoek (voorspelt 'X' op hetzelfde tijdstip 
'Y'?). Daarin kijken we of medicatie-opvattingen nag steeds samenhangen met 
DMARD-therapieontrouw als we rekening houden met eventueel vertekenende 
invloeden van demografische, klinische en psychologische factoren 
(angst/depressie, eigen-effectiviteit en opvattingen over de ziekte). 
Vijfhonderdtachtig patienten vulden een vragenlijst in. Medicatie-opvattingen 
zijn gemeten met de BMQ en therapietontrouw is gemeten met de CQR. Met een 
logistisch regressiemodel tonen we aan dat een minder sterke, waargenomen 
noodzaak om medicatie te nemen, een ongunstigere balans tussen noodzaak en 
zorgen aangaande het nemen van medicatie en een onverschillige houding ten 
opzichte van medicatie samenhangen met therapieontrouw. Psychologische, 
demografische en klinische factoren zijn nauwelijks van invloed op deze verbanden. 
De conclusie is daarmee dat bovengenoemde medicatie-opvattingen onafhankelijke 
voorspellers zijn van medicatie-therapieontrouw bij RA-patienten. 
Hoofdstuk 7 beschrijf medicatie-opvattingen van reumatologen en vergelijkt ze met 
de medicatie-opvattingen van RA-patienten die in hoofdstuk 6 in kaart zijn gebracht. 
Bestaand onderzoek naar medicatie-opvattingen richt zich vooral op patienten, 
terwijl die van zorgverleners oak van invloed kunnen zijn op medicatie-
thera pietrouw. 
Zevenentwintig reumatologen hebben een aangepaste versie ingevuld van de 
BMQ. In het algemeen verschillen hun medicatie-opvattingen niet van die van de 
patienten. Zowel reumatologen als patienten voelen een sterke noodzaak voor het 
(moeten) nemen van de voorschreven medicatie. Tegelijkertijd heeft 63% van de 
reumatologen en 68% van de patienten oak zorgen over de lange termijneffecten 
van de medicatie. Voor enkele opvattingen zijn wei verschillen aanwezig: patienten 
lijken bijvoorbeeld grotere zorgen te hebben over het moeten nemen van medicatie 
op zich en over het feit dat men zich afhankelijk voelt van de medicatie. We bevelen 
aan om de wisselwerking tussen medicatie-opvattingen van zorgverleners en 
patienten en het effect daarvan op therapietrouw nader te verkennen. Daarmee 
wordt het inzicht in medicatie-opvattingen als aangrijpingspunt voor het verbeteren 
van therapietrouw verder vergroot. 
De betekenis van de resultaten van de studies in dit proefschrift is besproken in 
hoofdstuk 8.2. (general discussion). Oat onze groepsinterventie niet effectief is in 
het veranderen van medicatie-opvattingen en het verbeteren van therapietrouw, 
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betekent niet dat deze opvattingen dan geen zinnig aangrijpingspunt meer zijn om 
therapietrouw te verbeteren. Er zijn namelijk diverse, mogelijke verklaringen voor 
het uitblijven van effecten. Zo hebben vooral patienten met een relatief lange 
ziekteduur aan onze trial deelgenomen, terwijl het veranderen van medicatie-
opvattingen die al lang 'verankerd' zijn lastiger is dan het veranderen van recent 
gevormde opvattingen van recent gediagnosticeerde patienten. We hebben tevens 
geleerd van het ontwerp van de groepsinterventie, zoals dat twee groepssessies 
wei Iicht onvoldoende zijn geweest om medicatie-opvattingen te veranderen. 
De gedachte over medicatie-opvattingen als zinnig aangrijpingspunt om 
therapietrouw te verbeteren wordt ondersteund door de resultaten van ons 
dwarsdoorsnede-onderzoek. Daaruit blijkt dat medicatie-opvattingen onafhankelijke 
voorspellers zijn van medicatie-therapieontrouw bij RA-patienten. Hiernaast is sinds 
de aanvang van onze studies nieuw bewijs gekomen dat veranderen van medicatie-
opvattingen leidt tot een verbeterde therapietrouw. Echter, onze verdere exploratie 
naar medicatie-opvattingen laat invalshoeken zien waar nog weinig over bekend is 
(zoals de mate waarin verbanden tussen medicatie-opvattingen en therapietrouw 
tijdsafhankelijk zijn). Gezien de geleerde lessen pleiten we daarom voor meer 
onderzoek naar dit onderwerp. De aanbevelingen in dit proefschrift bieden 
handvatten voor deze verdere exploratie. 
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Hiernaast het recept wat dit promotietraject tot een geslaagd einde heeft gebracht. 
Een hoge mate van therapietrouw aan je werkschema is daarbij geen overbodige 
luxe! Vele mensen hebben de totstandkoming van dit proefschrift mogelijk gemaakt. 
Aan hen een woord van dank. 
Te beginnen met het team (co)promotoren. The dreamteam! Bart, Elsen Sandra, ik 
heb geluk gehad met jullie. In onze overleggen gingen stevige, inhoudelijke 
discussies altijd gepaard met veel plezier. Beste Bart, of beter, Bart Spring in 't Veld, 
mijn 1e copromoter; zeker in het begin vulden wij elkaar goed aan. Jij meer 
pragmatisch, ik meer theoretisch: volgens mij hebben we nu allebei een goede 
balans gevonden in het midden. Een mooi proces, ik heb een hoop van je geleerd! 
Veel dank voor je waardevolle input, meedenken, humor en aanstekelijke 
enthousiasme. En niet vergeten je schoenveters vast te knopen terwijl je die 
honderdduizend ballen in de Iucht houdt. 
Beste Els, als 2e copromoter heb je mij met raad en daad bijgestaan. Je bent een 
wetenschapper in hart en nieren en daar heb ik dankbaar gebruik van mogen 
maken. Soms werd ik wei eens gek van onze almaar voortschrijdende inzichten, 
maar die waren er niet voor niets. lk ben blij met het resultaatl Vee I dank voor jouw 
grate betrokkenheid en a lies wat je voor me hebt gedaan. 
Beste Sandra, wat ben ik blij dat jij mijn promotor was. lk kan mij werkelijk geen 
fijnere indenken. Naast oog voor inhoud heb je tevens oog voor het emotionele 
aspect van een promotietraject, dus oak op mijn mindere momenten voelde ik me 
vrij om bij je binnen te wandelen. Trouwens, ik wandel sowieso graag bij je binnen. 
Om na te praten over leuke congressen bijvoorbeeld ;-). Heel fijn nu je collega te 
zijn, dank je wei voor a lies! 
De leden van de leescommissie (prof. dr. Burger, prof. dr. Hazes en prof. dr. De 
Smet) en de andere leden van de corona wil ik danken voor de tijd die zij in de 
beoordeling van het proefschrift en de verdediging hebben gestoken. Prof. dr. Rob 
Horne, thank you for your willingness to attend the defense. It is a privilege to 
exchange thoughts with you about medication beliefs, especially on December 2"d! 
Dr. Liset van Dijk, beste Liset, jou wil ik in het bijzonder bedanken voor de afgelopen 
twee jaar. De ruimte die jij samen met het NIVEL hebt gecreeerd bood mij de kans 
om een eindsprint in het promotietraject te trekken. Bovendien ben ik via jou bij de 
Sint Maartenskliniek en het NIVEL terechtgekomen. Veel dank voor alles! 
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Uiteraard wil ik de Sint Maartenskliniek en het NlVEL bedanken voor hun bijdragen 
aan de totstandkoming van dit proefschrift. 
Een groot gedeelte van het promotietraject stond in het teken van de randomized 
controlled trial (RCT). Veel mensen hebben de uitvoering daarvan mogelijk gemaakt. 
Birgit, ik begin bij jou. Jij bent mede de ontwikkelaar geweest van de interventie en 
hebt de RCT opgestart. Dank daarvoor! Uiteraard wil ik ook de andere mensen 
bedanken die hebben bijgedragen aan de ontwikkeling van de interventie en de 
opzet van de RCT. 
Voor de administratieve ondersteuning wil ik Dicky, Estella en Sonja bedanken. 
Jullie waren de steunpilaren van de RCT en bovendien heel gezellige collega's. 
Cheers! Ook wil ik de medewerkers van de afdelingen Farmacie en Reumatologie 
bedanken voor hun bijdragen aan het logistieke proces. Tevens onmisbaar was de 
inzet van de reumatologen en arts-assistenten die de patienten hebben 
ge"includeerd en die talloze formulieren hebben ingevuld voor het onderzoek. Dank 
jullie wei! ln het bijzonder gaat mijn dank uit naar dr. Alfons den Broeder, dr. Hans 
Cats en prof. dr. Frank van den Hoogen, die veel tijd hebben gestoken in de 
ontwikkeling en/of uitvoering van de interventie . 
Zander welwillende patienten geen onderzoek. Graag wil ik de heer Henk van 
Duijn en mevrouw Alma Peters (het patientenpanel) bedanken voor hun adviezen en 
betrokkenheid tijdens dit traject. De patienten die hebben deelgenomen aan de 
voormeting en/of de trial zelf wil ik dan ken voor hun tijd en moeite. 
Graag wil ik aile co-auteurs van de artikelen in dit proefschrift bedanken voor hun 
bijdragen, waaronder dr. Wim van Lankveld voor zijn input aan de start van dit 
traject. Nienke (Lesuis), jou wil ik bedanken voor de constructieve samenwerking en 
je gevoel voor humor. Voor ons toch jammer dat Menken van Grieken bananenvla 
niet meer op de markt is ... 
De afgelopen jaren heb ik met veel leuke collega's mijn promotietijd doorgebracht. 
Mijn directe collega's van research, waaronder Agnes, Aniek, Anke, Joke, de Linda's, 
Lotte, Michie!, Mirelle, Nienke, Sarah en Thomas, wil ik bedanken voor de vele 
gezellige en nuttige momenten. Jullie zijn aangenaam gezelschap! Lieve Nienke, 
gelukkig had je jouw token net niet meer nodig toen de mijne verliep tijdens het 
indienen van mijn proefschrift. Dank voor deze redding! lk wens jou en Linda 
(Willems) veel succes met de nieuwe banen. Lieve Agnes, Joke, Aniek, Sarah en 
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Lotte, bedankt voor de mooie tijd op de kamer en voor het 'Kerstman-schieten'. Dat 
is tach wei de ultieme onderbreking als je vastzit in denkprocessen. Lieve Aniek, te 
gek dat je de knoop hebt doorgehakt om aan een promotietraject te beginnen! lk 
weet zeker dat je dit tot een goed einde gaat brengen. Zet hem op. 
lk wil ook Brenda, Miranda, Petra, Cheriel, Lise, Elien, Aatke, Victor, Karin 
(Lancee), Elke, Jan, lise en de leden van de SMK-hardloopgroep bedanken voor de 
fijne tijd. Natuurlijk ook de heren van de ICT. Een PC is best leuk, maar hij moet 
uiteraard wei werken. Jullie hebben me regelmatig uit de brand geholpen! 
Joke en Agnes, mijn paranimfen. Lieve Joke, ik began bij jou op de kamer aan mijn 
traject terwijl jij de jouwe net aan het afronden was. Dat die laatste loodjes zwaar 
wegen kreeg ik wei mee, ("Aan het einde ben je er he-le-maal klaar mee!") evenals 
de tips & tricks aangaande het uitvoeren van wetenschappelijk onderzoek. Eigenlijk 
was je voor mij een soort van onderzoeksmoeder die me regelmatig op het juiste 
spoor heeft gezet. Dank je wei! En dat wij tach wei vals zingen heeft niemand 
gehoord. Lieve Agnes, wij hebben elkaar zo'n beetje door onze laatste fase 
heengesleept op de Maartenskliniek. Wat hebben we vaak tot in de late uurtjes 
doorgewerkt in een uitgestorven gebouw. Dat we daarna die berg konden affietsen 
was wei mooi meegenomen. Zeker te bedenken dat jouw werkdagen wei heel vroeg 
begonnen (6.00 je bed uit om hard te lopen?!?) Je bent een topper. lk ben blij dat 
jullie achter mij staan tijdens de verdediging! 
Het combineren van mijn promotietraject met mijn baan bij het NIVEL was pittig. 
Gelukkig kon ik rekenen op morele steun: een aantal collega's wil ik in het bijzonder 
noemen. Lieve Christel, lnge (van Bruinessen) en Janneke, op een of andere manier 
wisten jullie mij altijd de juiste, mentale oppeppers te geven. Metals mooie afsluiter 
het etentje bij SmaaQt. Bedankt voor jullie support! lnge, jou wil ik ook bedanken 
voor de opmaak van het receptbriefje en voor de fotografie tijdens de promotie, 
echt heel fijn. Lieve Nikki, wat ben ik blij dat ik jou heb getroffen. lk geloof dat we 30 
jaar hebben in te halen of zoiets. Komend jaar beginnen we aan de inhaalrace! Dank 
ook voor je input op de general discussion. Lieve lnge's (Spronk en Van der Lee) en 
Mara, jullie hebben de slingers letterlijk en figuurlijk opgehangen. Bedankt voor jullie 
steun en spontane verassingsacties, dat doet wonderen! lnge Spronk wil ik ook 
bedanken voor het nalezen van een hoofdstuk uit dit proefschrift. Marcia, Karin, 
Dominique, Linda, Daphne, Elsbeth, Willemijn, Tessa, Liesbeth, Jeanine, Romy en 
Marijn wil ik bedanken voor het aanhoren van mijn proefschriftverhalen, lunches 
Dankwoord (Acknowledgments) I 281 
en/of samenwerking. Doortje Saya wil ik bedanken voor de opmaak van mijn 
proefschrift. Je hebt me veel werk uit handen genomen! Oat was erg prettig. 
De leden van het Wetenschappelijk Platform Therapietrouw Nederland wil ik 
bedanken voor de inspirerende bijeenkomsten. Wat een bevlogen club mensen! 
Lieve Marcia en Annemiek, dan eindelijk aile drie dr .. De tijd is omgevlogen. Leuk om 
jullie (bijna) moederschap te volgen en bedankt voor jullie support door de jaren 
heen. Marcia, ook dank voor het nalezen van de general introduction! Hiernaast wil 
ik graag Hans, Marcel, Edwin, Christel, Danielle, Jacqueline, Ellen en Helga bedanken 
voor de leuke samenwerking en/of congresbezoeken. 
Het thuisfront. Of beter gezegd, thuisfronten. Lieve Wiel en Elma, toen ik rap moest 
verhuizen naar de andere kant van het land hebben jullie mij drie jaar lang een 
woonplek geboden. Daarbij was tot-in-de-puntjes geregelde zorg inbegrepen, 
inclusief warme maaltijden, een boodschapje hier en daar en zelfs het strijken van 
mijn karatepakl Het was niet altijd makkelijk om weg te zijn van mijn eigen thuis, 
maar dankzij jullie kon ik volop doen waarvoor ik was gekomen: werken aan mijn 
proefschrift. Dank jullie well Annemieke en Mariet wil ik bedanken voor de gezellige 
momenten die we hebben doorgebracht. 
Nijmegen voelde aan als een warm bad dankzij een aantal mensen die ik heb 
leren kennen . Van t .c. Malden zijn dat Paul, Junus, Christiane, Michel en Tanja. 
Junus, jij was degene die mij nader kennis heeft Iaten maken met de vereniging. 
Dank je well Blijft vooral menig 30-plusser van de baan meppen of drijf ze tot 
wanhoop met jouw dropshots. Paul, jij gaat de zorg voor Alzheimerpatienten weer 
een stukje beter maken, bien sOr! Bedankt voor je steun tijdens mijn 
promotietraject, dat was erg waardevol voor mij. Christiane, Michel en Tanja, jullie 
wil ik ook bedanken voor de support en ontspannen avonden. 
Bij Dojo Chikara heb ik kennisgemaakt met het Goju-Ryu karate. Wat een intense 
ervaring. Sensei Mark, Colette, John, Julia, Niek, Bram, Jeroen, Maarten, Sander en 
natuurlijk de andere leden: trainen met jullie is een feest. Op stap met jullie is 
trouwens ook feest! In het bijzonder wil ik sensei Mark Bicknell danken voor zijn 
engelengeduld en wijze lessen. Lieve Colette, ik ben nog steeds onder de indruk van 
jouw woman power. Bedankt voor het sparren en de loll lk train graag weer eens 
een Gasshuku mee. 
282 I Dankwoord (Acknowledgments) 
Onderwijl blonk ik uit in afwezigheid bij thuisfront Noord-Holland. Gelukkig ben ik 
toch regelmatig uit mijn 'werkgrot' gehaald om even met iets anders dan werk bezig 
te zijn. Lieve Fanny, Leontine, Mirjam, Marjolijn en Sanne, elk van jullie ken ik al 
minstens 20 jaar. We zijn nog steeds verbonden in elkaars Ievens en groeien nog 
steeds met elkaar mee, bijzonder! Lieve Gabrielle, Marit, Vanessa, Martine, Roos, 
Marieke, Natalie, Cynthia, Sabine, Yuni en Ingrid, stiekem kennen wij elkaar toch ook 
al best wei heel lang. lk wil iedereen bedanken voor de support, saunabezoekjes, 
high tea's/lunches, fietstochten of elke andere vorm van ontspanning. Lieve 
Maayke, Carolien en Hajo, jullie brengen letterlijk en figuurlijk muziek in mijn Ieven. 
En een cognacje hier en daar. Dank jullie wei! Stuart, many thanks voor de controle 
op Engelse taal van mijn general introduction en general discussion. En natuurlijk wil 
ik mijn maatjes van Sportschool van den Nieuwendijk en t.v. De Gouw ook danken 
voor hun interesse de afgelopen jaren. Het is fijn weer terug te zijn en zie ernaar uit 
om weer vaker met elkaar te trainen. 
Graag wil ik mijn (schoon)familie bedanken voor hun interesse en aanmoedigingen 
(onder wie Ada en George!) Jawel, het boekje is nu echt af. Mijn lieve nicht 
Marianne en tante Mar wil ik bedanken voor de uitstapjes naar de masseur of 't 
Twiske. Heerlijk was dat. Lieve Jolanda, Vivian, Marco, Rens en Bart, ik ben blij dat 
we intussen officieel familie zijn geworden. En wat groeien de jongens als kool. 
Afspreken gaat nu een stuk makkelijker worden. lk wil jullie bedanken voor jullie 
steun en Jolanda ook specifiek voor de gezellige etentjes ! Het smaakt elke week 
naar meer. 
Lieve pap en mam, een goed begin is het halve werk. Wat heb ik een geluk dat mijn 
bed bij jullie heeft gestaan! Jullie hebben mij alles geboden wat nodig was om hier 
te komen. Ook de hulp tijdens mijn promotietraject is memorabel. Van 
gerepareerde laptop tot een nieuwe PC, van porties warme maaltijden tot zinnige 
reflecties op het Ieven. Heel veel dank voor a lies wat jullie voor me hebben gedaan 
en nog steeds doen! Ralph, lief broertje, Zwolle is inderdaad een te gekke stad. lk 
ben blij dat jij en Joyce je draai gevonden hebben. En afstand speelt geen rol. Wat 
goed zit, zit goed. Kus! 
Lieve Arnold, je bent niet aileen mijn man, mijn grote liefde, maar ook mijn 
allerbeste maatje. En oh ja, de beste grappenmaker die er bestaat. Althans, vind ik. 
lk weet dat ik de laatste jaren veel van je heb gevraagd. Toen al eens verhuisd voor 
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een studie en de afgelopen drie jaar voor mijn promotie. In die zin had je beter 
afgeweest met een vrouw die 's avonds je sloffen klaarzet, maar helaas heb je een 
ander exemplaar aan de haak geslagen ;-). Ondanks dat je niet de makkelijkste jaren 
achter de rug hebt, heb je er werkelijk alles aan gedaan om mij te ontlasten . Heel 
vee I dank voor a lies wat je voor me hebt gedaan en voor wie je bent. Nu is het jouw 
tijd, ik hou van je! 
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